CN106986938A - With IL 4 and/or IL 13 antibody combined and application thereof - Google Patents

With IL 4 and/or IL 13 antibody combined and application thereof Download PDF

Info

Publication number
CN106986938A
CN106986938A CN201710131539.4A CN201710131539A CN106986938A CN 106986938 A CN106986938 A CN 106986938A CN 201710131539 A CN201710131539 A CN 201710131539A CN 106986938 A CN106986938 A CN 106986938A
Authority
CN
China
Prior art keywords
antibody
seq
cell
mammal
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201710131539.4A
Other languages
Chinese (zh)
Other versions
CN106986938B (en
Inventor
E·劳
V·米科尔
D·李
J·克鲁伊普
M·戴维森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Sanofi Aventis SpA
Original Assignee
Sanofi Aventis SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39313041&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN106986938(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis SpA filed Critical Sanofi Aventis SpA
Publication of CN106986938A publication Critical patent/CN106986938A/en
Application granted granted Critical
Publication of CN106986938B publication Critical patent/CN106986938B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Plant Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention relates to IL 4 and/or IL 13 antibody combined and application thereof.Specifically, the present invention relates to the novel anti-IL 4 of humanization and the antibody of IL 13 and its fragment, and IL 4 and IL 13 novel bispecific antibody and its fragment are which can specifically bind to.Present invention additionally comprises disease or the obstacle that IL 4 and/or IL 13 is mediated, including allergic asthma and dermatitis are treated or prevented using the antibody.

Description

With IL-4 and/or the IL-13 antibody combined and application thereof
The application is the applying date on October 14th, 2008, Chinese Application No. 200880111668.6, entitled The divisional application of the patent application of " with IL-4 and/or the IL-13 antibody combined and application thereof ".
Invention field
The present invention relates to novel anti-IL-4 antibody, anti-il-13 antibody and double special anti-IL-4/ anti-il-13 antibodies and Its because improperly IL-4 and/or IL-13 activity or metabolism and caused by mammal include the disease of people or the improvement of obstacle, Purposes in terms for the treatment of and prevention.Antibody interested may block part such as IL-4 or IL-13 and acceptor or receptor complex Such as IL-4R α, IL-13R α 1 and IL-13R α 2 combination and/or signal transduction.Invention further discloses contain antibody interested Prevention, immunization therapy and diagnosis composition and their use in the method for preventing or treating the disease that mammal includes people On the way, these diseases are that, by lymphoid cell and non-lymphoid cell, including monocyte, fibroblast and endothelial cell are not Caused by appropriate metabolism and/or activity.These diseases include autoimmune disorder and caused by inflammation or using inflammation to be special The disease levied, such as allergic asthma and dermatitis.
Background of invention
Interleukin-4 (IL-4) is a kind of thin for lymph B and T cell and many non-lymphoid cells, including monokaryon Born of the same parents, endothelial cell and fibroblast have the pleiotropic cytokines of broad-spectrum biological effect.For example, IL-4 stimulates several rely on In the propagation of IL-2 and IL-3 cell line, expression of the II class major histocompatibility complexs on resting B cells is induced, and Strengthen IgG4 and the IgE secretion of human B cell.IL-4 is relevant with the immune response of Th2- types, is produced by Th2 cells, and promote Enter the differentiation of Th2 cells.Various disorders all involve IL-4, such as allergy and asthma.
IL-13 be find recently by activated T lymphocytes, bone-marrow-derived lymphocyte and activation after mast cell secrete Cell factor (Minty, A. et al., Nature, 1993,362,248-250, and McKenzie, A.N. etc. of 112 amino acid People, Proc.Natl.Acad.Sci.U.S.A, 1993,90,3735-3739).
Due to having many common biological natures with IL-4, IL-13 is described as the cell factor of an IL-4 sample. B cell (Defrance, T. et al., J.Exp.Med., 1994,179,135-143, Punnonen, J. et al., (USA), Proc.Natl.Acad.Sci. 1993,90,3730-3734, Fior, R. et al., Eur.Cytokine Network, 1994,5,593-600), monocyte (Muzio, M.R.F. et al., Blood, 1994,83,1738-1743, De Waal Malefyt, R. et al., J.Immunol, 1993,151,6370-6381, Doyle, A. et al., Eur.J.Immunol.1994, 24,1441-1445, Montaner, L.J. et al., J.Exp.Med., 1993,178,743-747, Sozzani, P. et al., J.Biol.Chem., 1995,270,5084-5088) and other non-hematopoietic cells (Herbert, J.M. et al., Febs Lett., 1993,328,268-270, and Derocq, J.M. et al., Febs Lett.1994,343,32-36) on, its activity is really The real activity for being similar to IL-4.On the other hand, with IL-4 on the contrary, it does not have specific response to tranquillization or the T cell of activation (Zurawuki, G. et al., Immunol.Today, 1994,15,19-26).
A.J.Minty and comment on IL-13 describe in detail IL-13 monocyte/macrophage, Multiple biological activities on bone-marrow-derived lymphocyte and some hemopoietic precursors.In addition, also several parts as shown by data, this cell factor There is multiple-effect effect on other cell types.These non-hematopoietic cells directly influenceed by IL-13 are endothelial cell, small glue Cell plastid, keratinocyte and kidney and colon cancer.
One of analysis phase of intracellular biological molecule institute transmission signal is to recognize its membrane receptor.For IL-13 acceptors Research shows that IL-13 and IL-4 have common acceptor, or at least have some components of coreceptor compound, and altogether Same signal transduction element (Zurawski S.M. et al., Embo Journal, 1993,12,2663-2670, Aversa, G. etc. People, J.Exp.Med., 1993,178,2213-2218, Vita, N. et al., Biol.Chem., 1995,270,3512-3517, Lefort, S. et al., Febs Lett., 1995,366,122-126).This acceptor is present in the surface of polytype cell, Its number is changed with considered cell type difference.A.J.Minty indicates the suitable distribution of IL-13 and IL-4 acceptors (the Interleukin-13for Cytokines in Health and Disease (cytokine interleukins in health and disease Plain -13) writes D.G.Remick and J.S.Frie, Marcel Decker, N.Y.1996).
Cell surface receptor and receptor complex are combined with different affinity with IL-4 and/or IL-13.With IL-4 and/ Or the acceptor of IL-13 combinations and the key component of receptor complex are IL-4R α, IL-13R α 1 and IL-13R α 2.These chain conducts IL-4R α/IL-13R α l (II type IL-4R) or IL-4R α/γ c (I type IL-4R) monomer or heterodimer is expressed in cell On surface.IL-4R α monomers and IL-4R α/γ c heterodimers are combined with IL-4 but not combined with IL-13.The Hes of IL-13R α 1 The monomers of IL-13R α 2 are combined with IL-13 but not combined with IL-4.IL-4R α/heterodimers of IL-13R α 1 are both combined with IL-4, Also combined with IL-13 (Murata et al., Int.J.Hematol., 1999,69,13-20).
Th2- types immune response promotes antibody tormation and humoral immunity, and is used for resisting extracellular pathogen by well-designed Body.Th2 cells are to produce Ig mediator (humoral immunity) and produce IL-4, IL-5, IL-6, IL-9, IL-10 and IL-13 (Tanaka, et al., Cytokine Regulation of Humoral Immunity, 251-272, Snapper, editor, John Wiley and Sons, New York (1996)).Th2- type immune responses are characterized in produce certain form of cell factor (such as IL-4, IL-13) and certain types of antibody (IgE, IgG4), belongs to typical allergic reaction, is likely to result in tears in one's eyes The contraction of airway muscle cell in eye and SOA, such as airway inflammation and lung.
According to its biological function, IL-4 and IL-13 are the cell factors with critical treatment meaning, in many diseases In, including asthma, play the effect (Curr Opin Allergy Clin Immunol 2005, Vo.5,161-166) of key. IL-4 has been demonstrated to suppress autoimmune disease, and IL-4 and IL-13 are proved with the latent of enhancing antineoplastic immune response Power.Because the two cell factors are directed to the pathogenesis of allergic disease, therefore, the inhibitor of these cell factors should This can provide the benefit in treatment.
Accordingly, it is desirable to which IL-4, IL-13 improved activating agent (agent) can be suppressed, and IL-4 can be suppressed IL-13 single-activity agent can be suppressed.
Summary of the invention
The present invention provide can specifically binding to IL-4 and/or IL-13 Humanized monoclonal and double special novel antibodies and Its fragment and derivative.Some anti-single or double specific antibodies of IL-4 and/or IL-13 and its fragment can change, and be formed with preventing Intrachain disulfide bond, is being prepared and molecule stable during internal use so as to be formed.The antibody of the present invention is described here Biologicall test in neutralize IL-4 and/or IL-13 activity.
The amino acid sequence and its corresponding nucleotide sequence of variable heavy chain and light chain of the present invention including the antibody.
Another embodiment of the present invention includes the cell line and carrier for carrying antibody sequence of the present invention.
Another embodiment of the present invention is that the antibody is being prepared for treating and IL-4 and/or IL-13 functions and generation Thank to the purposes in the pharmaceutical composition of relevant disease and obstacle.Especially, the present invention with cancer, autoimmune disorder and by The disease that inflammation is caused or is characterized with inflammation, such as allergic asthma are relevant with the treatment of dermatitis.
The application further relates to following items：
1. specific bond IL-4 humanized antibody.
2. 1 antibody, it is included by SEQ ID NO:The variable light chain domain of 3 compositions.
3. 1 antibody, it, which is included, is selected from SEQ ID NO:4 and SEQ ID NO:5 variable heavy chain domain.
4. an any one of 1-3 optional antibody, wherein the antibody is antibody fragment.
5. 1 antibody, it includes the C of constant regionH1、CH2And CH3Domain.
6. such as the polypeptide of item 5, IgG antibody therein is IgG4 antibody.
7. the nucleic acid of the coding such as polypeptide of item 1.
8. the carrier containing the nucleic acid such as item 7.
9. the cell containing the carrier such as item 8.
10. specific bond IL-13 humanized antibody.
11. 10 antibody, it is included by SEQ ID NO:The variable light chain domain of 1 composition.
12. 11 antibody, it is included by SEQ ID NO:The variable heavy chain domain of 2 compositions.
13. any one of item 10-12 optional antibody, wherein the antibody is antibody fragment.
14. any one of 10-12 antibody, it includes the C of constant regionH1、CH2And CH3Domain.
15. such as the polypeptide of item 14, wherein IgG antibody is IgG4 antibody.
16. the nucleic acid of the coding such as polypeptide of item 15.
17. the carrier containing the nucleic acid such as item 16.
18. the cell containing the carrier such as item 17.
19. specific bond IL-13 and IL-4 bispecific antibody or bispecific antibody fragment.
20. 19 bispecific antibody or antibody fragment, it further includes variable light chain and variable heavy chain.
21. 20 bispecific antibody or antibody fragment, wherein the variable light includes amino acid sequence SEQ ID NO:1 and SEQ ID NO:3.
22. 20 bispecific antibody or antibody fragment, wherein the variable heavy chain includes amino acid sequence SEQ ID NO:2 and SEQ ID NO:5.
23. 20 bispecific antibody or antibody fragment, wherein the variable heavy chain includes amino acid sequence SEQ ID NO:2 and SEQ ID NO:4.
24. 20 bispecific antibody or antibody fragment, wherein the variable light includes amino acid sequence SEQ ID NO:1 and SEQ ID NO:3, and the variable heavy chain includes amino acid sequence SEQ ID NO:2 and SEQ ID NO:4.
25. 24 bispecific antibody or antibody fragment, wherein the SEQ ID NO:1 and SEQ ID NO:3 are connected by peptide Junctor links together, the SEQ ID NO:2 and SEQ ID NO:4 are linked together by peptide connector.
26. 25 bispecific antibody or antibody fragment, wherein the peptide connector is by SEQ ID NO:6 compositions.
27. IL-13 and IL-13 bispecific antibody is specifically combined, wherein variable light chain includes SEQ ID NO:1 He SEQ ID NO:3, variable heavy chain includes SEQ ID NO:2 and SEQ ID NO:4, and also include constant region domain.
28. 27 bispecific antibody, wherein the constant region domain is made up of CH1, CH2, CH3 and CL.
29. humanized antibody and the pharmaceutical composition of pharmaceutical acceptable carrier comprising item 1 or item 8.
30. included in the optional bispecific antibody or the drug regimen of antibody fragment and pharmaceutically useful carrier of item 19-28 Thing.
31. 1 or the humanized antibody of item 10, it is further conjugated with effector molecule.
32. 31 humanized antibody, wherein the effector molecule is selected from：Heterologous polypeptide, medicine, radioactive nucleotides and Toxin.
33. any one of 19-28 optional bispecific antibody or antibody fragment, it further sews with effector molecule Close.
34. 33 bispecific antibody or fragment, wherein the effector molecule is selected from：Heterologous polypeptide, medicine, radioactive nucleus Thuja acid and toxin.
35. treating the method for allergic disease in mammal, it comprises the steps：Apply and control to the mammal Treat the optional bispecific antibody or antibody fragment according to item 19-28 of effective dose.
36. treating the method for allergic disease in mammal, it comprises the steps：Apply and control to the mammal Treat the humanized antibody according to item 1 or 10 of effective dose.
37. the method for the treatment of cancer, it comprises the steps：To the mammal using therapeutically effective amount according to item 19-28 optional bispecific antibody or antibody fragment.
38. the method for the treatment of cancer, it comprises the steps：To the mammal using therapeutically effective amount according to item 1 or 10 humanized antibody.
39. treating the method for asthma in mammal, it comprises the steps：It is effective that treatment is applied to the mammal The optional bispecific antibody or antibody fragment according to item 19-28 of amount.
40. treating the method for asthma in mammal, it comprises the steps：It is effective that treatment is applied to the mammal The humanized antibody according to item 1 or 10 of amount.
41. treating the method for disease relevant with the abnormal generations of IL-4 and/or IL-13 in mammal, it includes following Step：The optional bispecific antibody or antibody fragment according to item 19-28 of therapeutically effective amount are applied to the mammal.
42. treating the method for disease relevant with the abnormal generations of IL-4 and/or IL-13 in mammal, it includes following Step：The humanized antibody according to item 1 or 10 of therapeutically effective amount is applied to the mammal.
43. suppressing the method for the reaction that TH-2 is mediated in mammal, it comprises the steps：Applied to the mammal With the optional bispecific antibody or antibody fragment according to item 19-28 of therapeutically effective amount.
44. suppressing the method for the reaction that TH-2 is mediated in mammal, it comprises the steps：Applied to the mammal With the humanized antibody according to item 1 or 10 of therapeutically effective amount.
45. the nucleic acid of the coding such as bispecific antibody of item 27.
46. the carrier containing such as nucleic acid of item 45.
47. the cell containing the carrier such as item 46.
Other features and advantage are also described herein, will be illustrated in following detailed description and accompanying drawing.
Brief description
Fig. 1 is the schematic diagram of double special anti-IL-4/IL-13 antibody molecules containing 4 polypeptide chains.Two lighter chains by N-VLhB-B13- connector-VLh8D4-8- CL-C (CL, constant region of light chain) is constituted, and two heavier chains are by N-VHhB-B13- connector- VHh8D4-8- CH1-CH2-CH3-C is constituted.Connector sequence (G4S)2For GGGGSGGGGS (SEQ ID NO:6).
Fig. 2 shows B-B13 anti-il-13 antibodies (the SEQ ID NO of humanization:1 and the amino acid sequence of variable domains 2) The anti-IL-4 antibody of 8D4-8 (the SEQ ID NO of row and humanization:3,4 and the amino acid sequence of variable domains 5).Lower stroke Line represents the amino acid change to being done.Runic represents CDR.
The detailed description of the present invention
The present invention is not limited to specific method as described herein, scheme, cell line, carrier or reagent, because it Can change, without departing from the spirit and scope of the present invention.Moreover, term as used herein is specific real merely for illustrating The purpose of scheme is applied, the scope of the present invention is not intended to limit.Unless otherwise defined, all technologies and science used herein The implication of term and any acronym is identical with the implication that field those of ordinary skill of the present invention is generally understood that.Implement this It can be used any similar or equivalent to method described herein and material during invention, exemplary methods, equipment only described herein And material.
The albumen reported that may be used together and may use in the present invention with the present invention for narration and disclosure Matter, enzyme, carrier, the purpose of host cell and methodology, the mode of the equal nationality reference of all patents and publication mentioned by this paper It is integrally incorporated herein.But, this paper any parts are not to be construed as being to recognize that the reason because formerly inventing, and the present invention haves no right sound Claim earlier than these disclosures.
There is provided some terms before the teaching preparation method related to using IL-4 and/or IL-13 and target product With the following non-limiting definition of phrase, with guidance technology personnel.
" interleukin-4 ＂ (IL-4) is related to natural appearance or endogenous mammal IL-4 albumen or occurred or interior with natural The corresponding mammal IL-4 albumen in source has albumen (such as recombinant protein, synthetic proteins (i.e. use synthesis of same amino acid sequence Protein prepared by organic chemistry procedures)).Correspondingly, as defined here, the term include ripe IL-4 albumen, it is many State or allelic variant, IL-4 other isotypes, and above-mentioned modification or unmodified form (such as esterified (lipidate) Or glycosylation).It is natural occur or endogenous IL-4 include wild-type protein as ripe IL-4, polymorphic or allelic variant and Other isotypes and mutant forms naturally occurred in mammal (such as people, non-human primate).These albumen can Reclaim or separate from such as naturally-produced IL-4 source.These protein and occur or endogenous corresponding IL-4 to natural The protein for having same amino acid sequence is the name nominating by corresponding mammal.For example, when corresponding mammal When being people, the protein is then referred to as people IL-4.Several mutation IL-4 protein known in the art, as draped over one's shoulders in WO 03/038041 Dew.
" interleukin-13 ＂ (IL-13) refers to natural appearance or endogenous mammal IL-13 albumen or occurred with natural Or endogenous corresponding mammal IL-13 albumen has the albumen of same amino acid sequence (such as recombinant protein, synthetic proteins is (i.e. The protein prepared with synthetic organic chemistry method)).Correspondingly, as defined here, the term includes ripe IL-13 Albumen, polymorphic or allelic variant, IL-13 other isotypes (as produced by by optional montage or other cell processes), And above-mentioned modification or unmodified form (such as esterified or glycosylation).Natural appearance or endogenous IL-13 include wild Type protein such as ripe IL-13, polymorphic or allelic variant and other isotypes naturally occurred in mammal and prominent Deformation type (such as people, non-human primate).For example, IL-13 used herein includes huIL-13 variant, wherein positioned at maturation The Arg of 110 positions of huIL-13 replaced that (ripe IL-13 110 positions are equivalent to the 130 of precursor protein by Gin Position), Gin is relevant with asthma (atopy and non-specific responding asthma) and other IL-13 variant. (Heinzmann et al., Hum MoI Genet 9:549-559(2000)).These albumen can coming from such as naturally-produced IL-13 Reclaim or separate in source.These protein and occur or endogenous corresponding IL-13 has same amino acid sequence to natural Protein is the name nominating by corresponding mammal.For example, when corresponding mammal is people, the protein then claims For huIL-13.Several mutation IL-13 protein are known in the art, as disclosed in WO 03/035847.
For antibody chain peptide sequence, phrase " essentially identical " can be regarded as showing with reference to peptide sequence at least 70%th, the antibody chain of 80%, 90%, 95% or more sequence identity.For nucleotide sequence, the term can be regarded as table Reveal the nucleotide sequence with the sequence identity with reference to nucleotide sequence at least above 85%, 90%, 95% or 97% or higher.
Term " homogeneity " or " homology " can refer in candidate sequence with corresponding sequence residue identical nucleotide base or The percentage of amino acid residue, the candidate sequence is is compared with corresponding sequence, through aligned sequences and introducing room (if having It is necessary) to realize the maximum homogeneity percentage of whole section of sequence and any conservative replaces be not considered as sequence identity part Afterwards.No matter N-terminal or C-side extension or insertion should not be construed as reduction homogeneity or homology.Method and calculating for comparison Machine program is easily obtained, and is known in the art.Sequence analysis software measurement sequence identity can be used.
" function fragment, variant, the derivative or the like " of antibody or antigen etc. and their diversified forms etc. are short Language and term refer to the compound or molecule with total length purpose antibody or antigen identical bioactivity in nature.Example Such as, function fragment of anti-IL-4 antibody or the like is can to combine fragment of IL-4 molecules or the like, or can be prevented or base Part or excitement or antagonistic antibodies combination the IL-4 fragment of ability or the like are reduced in sheet.
" substituted type " variant is that at least one amino acid residue is removed and inserted by different amino acid in native sequences Enter the variant of its same position.The substitution can be single, only have an amino acid wherein in the molecule and be substituted；Or can To be multiple, wherein the identical molecule has two or more amino acid to be substituted.Multiple substitutions can be located at continuous site.Together Sample a, amino acid can be replaced by multiple residues, wherein such variant includes both substitution and insertion." insert type " makes a variation Body is the variant that one or more amino acid are inserted into the amino acid close to one section of native sequences some specific location.Tightly Adjacent amino acid means to be connected with α-carboxyl of the amino acid or alpha-amido functional group." deletion form " variant is natural amino acid sequence The variant that one or more amino acid are removed in row.Under normal circumstances, deletion form variant is in the specific region of its molecule Inside there is one or two amino acid to be lacked.
Term " antibody " is used for broadest implication, specifically cover monoclonal antibody (including full length monoclonal antibodies), Polyclonal antibody, multi-specificity antibody (such as bispecific antibody), the one or more CDR of carrying or anti-from CDR sequence Body fragment or synthesis polypeptide, as long as these polypeptides exhibits go out required bioactivity.Antibody (Abs) and immunoglobulin (Igs) It is the glycoprotein with identical architectural feature.Generally, antibody, which is considered to have, determines or generally acknowledged specific Ig. Therefore, although antibody shows the binding specificity with specific target, immunoglobulin includes antibody and other shortage targets are special The antibody sample molecule of property.Antibody of the present invention can be any species (such as IgG, IgE, IgM, IgD, IgA) or subclass (such as IgG1、IgG2、IgG2a、IgG3、IgG4、IgA1、IgA2Deng) antibody (" type " and " species " and " hypotype " and " sub- Class " is used interchangeably herein).Natural or wild type (i.e. derived from not manned group member) antibody and immune globulin The heterotetrameric glycoproteins of white typically about 150,000 dalton, it is by two identical light chains (L) and two identical heavy chains (H) constitute.One end of every heavy chain has variable domains (VH), it is followed by multiple constant domains.One end of every light chain With variable domains (VL), the other end has constant domain.So-called " inartificial to manipulate " means without being intended to contain it Or the processing of expression exotic antigen binding molecule.Wild type can refer to the most common allele found in a colony or species Or refer to derived from the antibody for not manipulating animal, allele or multiformity are compared to, or derived from manipulation with some form for example Mutagenesis, using recombination method etc. change the antigen binding molecules amino acid variant or derivative.
As used herein, " anti-IL-4 antibody " mean can specific bond IL-4 defined herein antibody or be derived from The polypeptide (derivative) of these antibody, it includes but is not limited to suppress or essence reduces IL-4 and the combination or suppression of its acceptor The molecule of IL-4 activity.
As used herein, " anti-il-13 antibody " mean can specific bond IL-13 defined herein antibody or source From the polypeptide (derivative) of these antibody, it includes but is not limited to suppress or essence reduces IL-13 and the combination or suppression of its acceptor The molecule of IL-13 activity processed.
For the variable domains of antibody, term " variable " means the correlation molecule for having extensive sequence difference between antibody Some parts, and be used for for its specific target specific antibodies specific recognition and combination.But, changeability is in antibody It is not equally distributed in whole variable domains.Changeability, which is concentrated on, is referred to as complementarity determining region (CDRs；I.e. CDR1, CDR2 and CDR3) or hypervariable region three sections, they are respectively positioned in the variable domains of light chain and heavy chain.In variable domains The higher part of conservative is referred to as framework (FR) area or frame sequence.Each variable domains of native heavy and light chain are equal Including four FR areas, it mainly uses beta sheet configuration, and three CDRs of their nationalitys are connected, and CDRs formation rings, the ring connects Connect beta sheet structure and form the beta sheet structure of part in some cases.The CDRs of every chain is generally connected by FR areas neighbouring Pick up and, and by means of the CDR from other chains, contribute to the formation (ginseng of antibody target binding site (epitope or determinant) See Kabat et al. Sequences of Proteins of Immunological Interest, National Institute of Health,Bethesda,MD(1987)).As used herein, the numbering of immunoglobulin amino acid residue is foundation Kabat et al. immunoglobulin amino acid residue numbering system and carry out, unless otherwise indicated.One CDR can have spy Different combination associates the ability of epitope.
Term used herein " hinge " or " hinge region " mean the first and second constant domains comprising antibody it Between amino acid flexible polypeptide.
Term " antibody fragment " means a part for complete or total length chain or antibody, usually target calmodulin binding domain CaM or variable region Domain.The example of antibody fragment includes but is not limited to Fab、Fab'、F(ab')2And FvFragment." function fragment " or " anti-IL-4 and/or IL- 13 antibody analog " be can prevent or the essence reduction receptor-binding ligands or the ability of enabling signal transduction fragment or Analog.As used herein, function fragment is typically identical with " antibody fragment " implication, and in antibody, can refer to prevent Only or substantially reduce the fragment of the ability of the receptor-binding ligands or enabling signal transduction, such as Fv、Fab、F(ab')2Etc.." Fv" fragment is two as formed by the variable domains of heavy chain and the variable domains nationality Non-covalent binding mode of a light chain Aggressiveness (VH-VLDimer) composition.In the configuration, three CDRs interactions of each variable domains, to determine VH-VL Target binding site on dimer interface, as the situation of complete antibody.Six CDRs assign complete antibody jointly Target binding specificity.But, even single variable domains (or only include the special CDRs of 3 targets FvHalf), still There can be the ability for recognizing and combining target.
" single-stranded Fv"、"sFv" or " scAb " antibody fragments include the V of antibodyHAnd VLDomain, wherein these domains position In on wall scroll polypeptide chain.In general, the FvPolypeptide also includes one section and is located at VHAnd VLPolypeptide linker between region, its Usually flexible molecule, can make sFv formation be suitable for the required structure of target combination.
Term " double antibody (diabody) " means the antibody fragment with two antigen binding sites, and these fragments can be wrapped Include the light variable domains (V with same polypeptide chainL) connected heavy-chain variable domains (VH).By using too short connection Body causes two variable domains on same chain not match, the dual anti-binding domains be forced and another chain combination Domain is matched, and generates two antigen binding sites.
FabFragment contains the variable domains and constant domain of light chain and the variable of heavy chain and first constant structure Domain (CH1)。Fab'Fragment and FabThe difference of fragment is the former in CH1The c-terminus of domain adds several residues, to wrap Include one or more cysteines from antibody hinge region.F is located at by cracking(ab')2The hinge of pepsin digestion product Disulfide bond at cysteine, can generate Fab'Fragment.Ferment treatment and chemical treatment are additionally carried out to antibody can generate other purposes Function fragment.
Term " linear Fab " means tetravalent antibody (Miller et al. (2003), J described in Miller etc. Immunol.170:4854-4861)." linear Fab " is made up of a succession of identical CH1-VH domains, at each Matched with identical light chain CH1-VH positions.Have developed these molecules is the potency and transmission affinity stress effect in order to increase antibody To strengthen its functional affinity, still, they are monospecifics.
Term " bispecific antibody (BsAbs) " means the antigen binding site that two antibody is combined with same molecule Molecule.Therefore, bispecific antibody can be in combination with two different antigens.In addition to the application of diagnostic purpose, double spies Xenoantibody is by the way that strength effect system is turned in affected areas, or increase antibody and/or stimulating activity, so that new for exploitation Treatment method paved road.
The different conjugate molecules using chemical fusion are initial attempted to by for the knot of the two of different target antigens complete antibodies Close specificity coupling (Staerz et al. (1985), Nature 314:628-631).
Have been transmitted through different hybridoma technology and bispecific antibody is prepared for from hybrids knurl, show that it has and sight in vitro Similar property (Milstein＆Cuello (1983) Nature 305 of the different conjugate that observes:537-540).
Although having obtained making us being hopeful using the different conjugate or bispecific antibody prepared from cell fusion as described above Result, but several factors but make their extensive treatment use become unactual.These factors include：It is different greatly in vivo to sew The quick removing of compound, the technology for producing high labor intensity required for any kind molecule, need deeply purifying different will be conjugated Thing is separated from monoconjugate or single specific antibody, and normal yield is very low.
Genetic engineering is increasingly being used for designing, changes, produces with one group of desired binding characteristic and effector The antibody or antibody derivatives of function.
It has developed a variety of recombinant techniques effectively to produce bispecific antibody, can not only be used for antibody fragment (Carter Et al. (1995), J.Hematotherapy 4:463-470；Pluckthun et al. (1997) Immunotechology 3:83- 105；Todorovska et al. (2001) J.Immunol.Methods 248:47-66), total length IgG forms can be also used as (Carter(2001)J.Immunol.Methods 248:7-15)。
Two different scFvs combinations are produced and are referred to as the double special of sc-BsAbs or Ta-scFvs with minimum molecular weight Xenoantibody form (Mack et al. (1995), Proc.Acad.Sci.USA.92:7021-7025；Mallender et al. (1994) J.Biol.Chem.269:199-206).In genetic engineering, nationality is by dimerization functional group such as two scFvs of leucine zipper fusion So as to build bispecific antibody (Kostelny et al. (1992) J.Immunol.148:1547-53；De Kruif et al. (1996) J.Biol.Chem.271:7630-4)。
As described above, double antibody is the divalence bispecific antibody fragment of very little.These fragments are on same peptide chain comprising logical The VH that VL is attached to using connector is crossed, the connector too short (less than 12 amino acid) causes two structures on same chain It can not be matched between domain.These domains are forced to carry out intermolecular pairing with domain complementary on another chain, so as to produce Two antigen binding sites.These diabodies fragments, or " double antibody ＂ is divalence and has bispecific.(Holliger etc. People (1993), Proc.Natl.Acad.Sci.USA.90:6444-6448).The size of double antibody is similar with Fab fragments.Arrived with 3 The polypeptide chain of the VH and VL domains of the connector connection of 12 amino acid primarily forms dimer (double antibody), and by 0 to 2 What the connector of amino acid residue was connected then advantageously forms tripolymer (three antibody (triabody)) and the tetramer (four antibody (tetrabody)).Except the length of connector is outside one's consideration, the definite pattern of oligomerization seems to depend on the composition of V- domains and taken To (Hudson et al. (1999), J Immunol Methods 231:177-189).Double antibody molecule end-results it is predictable Property is very poor.
Although the construct based on sc-BsAbs and double antibody shows very interesting clinical potentials, however, it has proven that, this The molecule of the Non-covalent binding of sample is but not sufficiently stable in physiological conditions.The general stability of scFv fragments depends on VL and VH and tied The stability in structure domain itself and the stability of domain interfaces.It has been shown that the stability at scFv fragment VH-VL interfaces is inadequate It is the main cause of irreversible scFv inactivations, can makes to be conducive to dredging for aggregation because the interface transient state that peptide connector is allowed is opened Pool block (patch) exposes to the open air, thus cause unstable and low-yield (With Pl ü ckthun (2001), J.Mol.Biol.305:989-1010)。
The optional side that double special bivalent antigen-binding proteins are prepared from VH and VL domains is disclosed in US5,989,830 Method.Such double end antibody fragment is the bi-cistronic vectors acquisition that nationality encodes two polypeptide chains by expressing, and one of them is more Peptide chain has two VH connected by peptide connector (VH1- connectors-VH2), and another polypeptide chain is by complementary VL domain groups Into the VL domains are connected in series (VL1- connectors-VL2) by peptide connector.US5,989,830 descriptions, each connector At least ten amino acid residue should be included.
US2005/0003403 A1 describe the increased multivalent protein compound (PPC) of valence state.Multivalent protein compound bag Containing two polypeptide chains, their generally lateral arrangements each other.Each polypeptide chain generally comprises 3 or 4 " v for including amino acid sequence Area ＂, when v areas corresponding with relative polypeptide chain are matched, these amino acid sequences can form antigen binding site.Often Up to about 6 " v areas ＂ can be used on individual polypeptide chain.V areas on each polypeptide chain are linearly coupled to each other, can be by the bonding pad scattered Connection.When being arranged in PPC forms, the v areas on each polypeptide chain form single antigen binding site.Compound may be included One or more of binding specificities.
But, show aggregation, unstability and very poor expression productivity (Wu et al. (2001) using such molecule Prot.Eng.14:1025-1033).These are to express the Typical stability problem being likely to occur during based on single-stranded antibody.(With Pl ü ckthun (2001), J.Mol.Biol.305:989-1010).
Therefore, present invention aim to provide double special multivalent antibodies, aggregation can be avoided the formation of using it.This Outside, it should have stability, be allowed to can be used for treatment use.
Term as used herein " monoclonal antibody " means the antibody derived from basic homologous antibody group, that is, constitutes the colony Single antibody in addition to may be with the presence of the mutation that naturally occur of minority, be identical.
This paper monoclonal antibody specifically includes " chimeric " antibody, and a portion heavy chain and/or light chain are special with being derived from certain Earnest kind belongs to certain specific antibodies species or the corresponding sequence of subclass (type or hypotype) is identical or homologous, wherein the chain Remainder is to being derived from another species or belonging to the antibody and the corresponding sequence of the antibody fragment of another antibody type or subclass Row are identical or homologous, as long as these antibody fragments show to combine IL-4 and/or IL-13 or influence IL-4 and/or IL-13 activity Or required bioactivity (the US patent No.s 4,816,567 of metabolism；With Morrison et al., Proc Natl Acad Sci USA 81:6851(1984)).Therefore, the CDR from same category antibody may migrate to the FR of variety classes or Subclass Antibodies.
Monoclonal antibody is the antibody of high degree of specificity, for single target site, epitope or determinant.Moreover, with it is usual Unlike routine (polyclonal) antibody preparation including the different antibodies for the different determinants (epitope) of antigen, each Dan Ke Grand antibody is for the single determinant on target.In addition to its specificity, synthesis of the monoclonal antibody in host cell is favourable , do not polluted by other immunoglobulins, and the related gene and mRNA for encoding its antibody chain are provided for clone.Modification Language " monoclonal " prompting derives from the property of the antibody of basic homologous antibody group, and it should not be construed as needing any ad hoc approach production of nationality The raw antibody.For example, the monoclonal antibody for the present invention can be from phage antibody library through using widely-known technique point From or from polyclonal product purification.The parent monoclonal antibodies used according to the present invention can be by Kohler et al. in Nature 256:Prepared by the hybridoma method described in 495 (1975), or prepared by recombination method well known in the art.
Term " multivalent antibody " used in the present invention means comprising two or more antigen binding sites thus can tied Close the antibody of two or more antigens with identical or different structure.Term " divalence " represents that antibody includes two antigen bindings Site.Term " tetravalence " represents that antibody includes four antigen binding sites.
Term " antigen binding site " used in the present invention means such part in antibody, and it is comprising specifically with resisting Former combines partially or in whole, and with antigen partially or in whole into complementary region.When antigen is very big, antibody is possible can only A specific part of antigen is attached to, this is partly referred to as epitope.Antigen-binding domains can be by one or more antibody Variable domains are provided.Preferably, antigen-binding domains be can by antibody light chain variable domains (VL) and heavy chain of antibody (VH) is combined to form in structure changes domain.
Term " antigen " used in the present invention means one of the molecule that can be combined by the antibody of the present invention or molecule Partly.Antigen can have one or more than one epitope.The example of the recognizable antigen of antibody of the present invention includes but is not limited to serum Albumen such as cell factor, such as IL-4, IL5, IL9 and IL-13, biologically active peptide, cell surface molecule such as acceptor, transhipment egg In vain, ion channel, virus and bacterioprotein.
Term used in the present invention " single special " means that the multivalent antibody of the present invention only may recognize that an antigen, institute Some antigen binding sites are all identicals.
Term used in the present invention " double special " means that the multivalent antibody of the present invention can be different with one or two Two different epitopes are identified on antigen.
Term used in the present invention " how special " mean that the multivalent antibody of the present invention can be different with one or more Multiple different epitopes are identified on antigen.
Term " connector " used in the present invention means that is adjusted a connection antibody structure varistructure of the present invention The peptide in domain.Peptide connector can include any amino acid, preferably glycine (G) and serine (S).In heavy chain polypeptide and light chain Between polypeptide or internal, connector can be identical or different each other.In addition, the length of connector can be 1,2,3,4,5,6,7,8, 9,10,11,12,13,14,15,16,17,18,19 or 20 amino acid.The preferred peptide of heavy domain and light chain domain Connection body unit is GGGGS.The number of the connection body unit of heavy chain and light chain can be identical (symmetrical order), can also It is (asymmetrical order) different from each other.
Peptide connector, which is preferably of sufficient length that, can provide enough flexible degrees to prevent antibody moiety for example by position The mutual activity of resistance interference, so as to allow protein suitably to fold, if it is necessary, can also allow antibody molecule with same cell Two or more acceptor interactions that may be very open；However, it is preferable that it is short enough with allow antibody part in cell It is middle to keep stable.
Therefore, the length of peptide connector, composition and/or conformation can be selected easily by those skilled in the art, so as to Optimize the property required for multivalent antibody.
" humanization " form of inhuman (such as mouse) antibody be chimeric immunoglobulin, immunoglobulin chain or they Fragment (the F of such as antibodyv、Fab、Fab'、F(ab')2Or other target combination subsequences), compared with human antibody, it contains from inhuman The sequence of immunoglobulin.In general, the humanized antibody substantially includes one, is typically the variable knot of two altogether Structure domain, wherein all or substantially all CDR region domains correspond to the CDR region domain of non-human immunoglobulin, and it is all or basic Upper all FR regions are the FR regions of human immunoglobulin(HIg) template sequence.The humanized antibody may also include at least a portion and exempt from Epidemic disease immunoglobulin constant area (Fc), the constant region of typically selected human immunoglobulin(HIg) template.In general, it is therefore an objective to possess In the antibody molecule that people's vivo immunogenicity is minimum.Therefore, it is possible to one or more of one or more CDRs amino acid Also it can be replaced with the lower amino acid of human host's vivo immunogenicity, not minimize one or more of CDRs substantially but To IL-4 and/or IL-13 specific bond function.Or, FR can be to be inhuman, but immunogenicity most strong those amino acid quilts Replace with the relatively low amino acid of immunogenicity.But, CDR transplanting as discussed above is not the unique of acquisition humanized antibody Approach.May not enough fully, because framework region residue participates in determining the three-dimensional structure of CDR rings and resisted for example, only modifying CDR region domain Body and the phenomenon of total affinity of its part are not uncommon.Therefore, any method can be implemented, so that inhuman parent antibody molecule quilt The antibody molecule lower to people's immunogenicity is modified to, and simultaneously not always needs global sequence's homogeneity with human antibody (global sequence identity).Therefore, also can especially it be taken for example, by only replacing several residues to realize humanization In generation, is exposed on antibody molecule and is not embedded in the intramolecule therefore the residue of not accessible host immune system.Herein This method is taught in terms of " activity " or " flexibility " residue on substitution antibody molecule, its target is to reduce or slow down to be formed The immunogenicity of molecule, does not destroy the antibody but to its epitope or the specificity of determinant.For example, see Studnicka etc. People, Prot Eng 7 (6) 805-814,1994；Mol Imm 44:1986-1988,2007；Sims et al., J Immunol 151:2296(1993)；Chothia et al., J Mol Biol 196:901(1987)；Carter et al., Proc Natl Acad Sci USA 89:4285(1992)；Presta et al., J Immunol 151:2623 (1993), WO 2006/042333 and U.S. State's patent No. 5,869,619.
The molecular flexibility of humanization approach interested based on antibody during Immune discrimination and its when influence.Protein It is flexible relevant with the molecular motion of protein molecular.Protein flexibility is that whole albumen, Partial Protein or single amino acids residue are adopted Constellation sets (ensemble) ability is taken, wherein the conformation is each dramatically different.Information about protein flexibility can lead to The experiment of carry out protein X-ray crystallography is crossed (see, for example, Kundu et al., 2002, Biophys J 83:723-732.), core Magnetic resonance experiments are (see, for example, Freedberg et al., J Am Chem Soc 1998,120 (31):7916-7923) or carry out Molecular dynamics (MD) is simulated and obtained.The MD simulations of protein are carried out on computers, can be by calculating the thing between atom Reason interacts and allows to determine motion of all proteins atom within a period of time.The output of MD simulations is studied albumen Track in simulated time section.The track is the set of protein conformation, also referred to as snapshot (snapshot), the protein Conformation for example every 1 psec (ps) periodic samples during simulating.The set of analysis snapshot is exactly based on, people can quantify egg The flexibility of white matter amino acid residue.Therefore, for the polypeptide containing flexible residue, flexible residue is to take different constellation sets Residue.MD methods are well known in the art, see, for example, Brooks et al., Proteins:A Theoretical Perspective of Dynamics,Structure and Thermodynamics(Wiley,New York,1988).Number MD simulations can be carried out by planting software, and such as Amber is (referring to Case et al. (2005) J Comp Chem 26:1668-1688), Charmm is (referring to Brooks et al. (1983) J Comp Chem 4:187-217；With MacKerell et al. (1998) The Encyclopedia of Computational Chemistry vol.1:271-177, Schleyer et al. eds.Chichester:John Wiley＆Sons) or Impact (referring to Rizzo et al., J Am Chem Soc；2000；122 (51):12898-12900)。
Most protein compound enjoys the relatively large and more flat surface that is embedded, it has been shown that binding partners albumen Flexibility provide its elastic source so that they conforma-tional can be mutually adapted (Structure (2000) 8, R137- R142).Therefore, it has been shown that the example of " induced-fit " has played main function in the interface of protein-protein.In addition, The data volume of steady growth shows that protein actually combines part (the Protein Science of various shapes, size and composition (2002)11:184-187), and conformational diversity seemingly recognizes the key component (Science of different chaperone abilities (2003)299,1362-1367).Flexible residue take part in the combination (Structure of protein-protein chaperone (2006)14,683-693)。
Flexible residue can take many conformations, and they provide the set of interaction zone, and it is possible to be remembered B thin Born of the same parents recognize and trigger immunogenic response.Therefore, antibody humanization can be made by modifying many residues from framework region so that Constellation sets and the identification region set that is shown by modified antibodies be similar to as far as possible the constellation sets that human antibody taken and Identification region set.
This point can be achieved by modifying a limited number of residue in following method：(1) the homologous of parental generation mAb is built Model, carries out MD simulations；(2) analysis flexible residue and identification nonhuman antibody molecule most flexible residue, and identification are possible to It is the residue or motif in heterogeneous or degradation reaction source；(3) identification shows the identification region collection most like with parental generation antibody The human antibody of conjunction；(4) flexible residue to be mutated is determined, may also be dashed forward for the residue or motif in heterogeneous and degraded source Become；(5) known T cell or B cell epitope are checked for.Calculated using MD teaching herein through using implicit solvent mould Type can find flexible residue, and the solvent model describes the original of the aqueous solvent interaction interior during simulating with protein atomic Cause.Once identifying one group of flexible residue in variable light and heavy chain, that is, identify highly similar one group with purpose antibody People's heavy chain and light chain variable region framework.It for example can be used blast search in the database of antibody human germ line sequences at one group Carried out on flexible residue.It can also be carried out by comparing parental generation mAb dynamics with the dynamics in germline norm structure storehouse.Retrieval When exclude CDR residues and neighbouring residue, to ensure that the high affinity for antigen is retained.
It is later substituted for flexible residue.When several personal residues show similar homology, also by the way that humanization may be influenceed The residue property of the solution behavior of antibody drives the selection.For example, preferably polar residues, rather than hydrophobic in the flexible ring of exposure Residue.Residue for unstability and heterogeneous potential source is also undergone mutation, even if they are found on CDRs.These are residual Base includes the methionine of exposure, because sulfoxide formation is probably due to the key such as Asp-Pro dipeptides of epoxide, acid labile Proteolysis cutting (the Drug Dev Res (2004) 61 of key:137-154)；Positioned at exposed asparagine residue and then Deamidation sites (J Chromatog (2006) 837 at p1 amino acid such as Gly, Ser, Ala, His, Asn or Cys: 35-43) with N- glycosylation sites such as Asn-X-Ser/Thr sites.Generally, exposed methionine can be by Leu institutes Substitution, exposed asparagine can be replaced by glutamine or aspartic acid, or its subsequent residue can be replaced.For sugar For base site (Asn-X-Ser/Thr), replaceable Asn or Ser/Thr residues.
Check that the multiplexed sequence formed whether there is known B cell or linear T cell epitopes.For example, using the public Available IEDB is retrieved.If finding known epitope in the multiplexed sequence, retrieve and replace another group of human sequence.
With unlike the surface remodeling procedures of the US patent No.s 5,639,641, this method has inquired into B cell mediation and T is thin The immunogenic response of born of the same parents' mediation.This method, which also avoid, transplants observable active loss problem using CDR sometimes (US is special Profit number is 5,530,101).In addition, the problem of also contemplating stability and solubility in design and selection course, so as to produce pair The antibody optimized in low immunogenicity, high antigen affinity and improvement bio-physical property.
Such as US patent No.s 5,639,641 are disclosed to exist for the strategy and method and reduction antibody of surface reshaping antibody Other methods of different hosts vivo immunogenicity.In brief, in a method for optimizing, (1) generation heavy chain of antibody and light chain The position in Variable Area storehouse is compared, to produce the position of heavy chain and the exposure of light chain variable region framework surface, wherein all variable The comparison position in region at least about 98% is identical；(2) define one group of heavy chain and light chain variable region framework surface exposure Amino acid residue, for inhuman such as rodent antibodies (or its antibody fragment)；(3) one group and the rodent are identified The amino acid residue the most consistent heavy chain of animal surface exposure and the amino acid residue of light chain variable region framework surface exposure； And (4) are except any atom of any residue in the rodent antibodies CDRWithin amino acid residue outside, The exposure amino acid substitution on one group of heavy chain and light chain variable region framework surface determined by step (2) is reflected by step (3) One group of fixed heavy chain and the exposure amino acid residue on light chain variable region framework surface, to generate the people source for retaining binding specificity Change such as rodent antibodies.
Antibody can include CDR using many other technologies and transplant (EPO 0 239 400；WO 91/09967 and the US patent No.s 5,530,101 and 5,585,089), veneer (veneering) or surface remodeling (EPO 0 592 106；EPO 0 519 596；Padlan,1991,Molec Imm 28(4/5):489-498；Studnicka et al., 1994, Prot Eng 7 (6): 805-814 and Roguska et al., 1994, PNAS 91:969-973) reorganize (the US patent No.s 5,565,332) with chain and enter pedestrian source Change.Human antibody can the method that knows of many this areas of nationality prepared, including but not limited to phage display method is (special referring to US Profit number 4,444,887,4,716,111,5,545,806 and 5,814,318 and WO 98/46645, WO 98/50433, WO 98/ 24893, WO 98/16654, WO 96/34096, WO 96/33735 and WO 91/10741), for example nibbled using transgenic animals Tooth class animal, uses chimeric cell etc..
" antibody homologue " or " homologue " mean any point for clicking here instructed specific bond IL-4 and/or IL-13 Son.Therefore, no matter antibody homologue includes natural or recombinant antibodies, whether modified, remain purpose biological property and (for example tie Close IL-4 or IL-13) antibody moiety, such as FabOr FvMolecule, single-chain antibody and carry many of one or more CDR region domains Peptide etc..The amino acid sequence of the homologue need not be identical with naturally occurring antibody amino acids sequence, but can be varied or repair Be decorated with carry substituted amino acid, insertion amino acid, missing amino acid, on isolating protein beyond 20 amino acid of normal presence Amino acid etc., to obtain the polypeptide with enhancing or other favorable properties.
Antibody with homologous sequence is its amino acid sequence and the IL-4, the special IL-4/IL- of IL-13 or double of the present invention The amino acid sequence of 13 antibody has the antibody of sequence homology.Preferably, homology is located at the Variable Area of antibody of the present invention Amino acid sequence." sequence homology " applied to this paper amino acid sequences is defined as through for example according to Pearson＆ Lipman, Proc Natl Acad Sci USA 85,2444-2448 (1988) FASTA search methods are determined and other amino Acid sequence have at least about 90%, 91%, 92%, 93%, 94% or more sequence homology, more preferably at least about 95%th, 96%, 97%, 98% or 99% sequence homology.
Chimeric antibody is the antibody with different antibodies part, and it is derived from separate sources such as different antibodies, variety classes Antibody, different animals species, for example matched with the variable region from mouse monoclonal antibody and human immunoglobulin(HIg) constant region Antibody etc..Therefore, humanized antibody is a kind of chimeric antibody.Method dawn known in the art for producing chimeric antibody, See, for example, Morrison, 1985, Science 229:1202；Oi et al., 1986, BioTechniques 4:214； Gillies et al., 1989, J Immunol Methods 125:The He of the 191-202 and US patent No.s 5,807,715,4,816,567 4,816,397。
Artificial antibody includes scFv fragments, chimeric antibody, double antibody, three antibody, four antibody and mru (referring to Winter＆ Milstein summary, 1991, Nature 349:293-299；And Hudson, 1999, Curr Opin Imm 11:548- 557), wherein every kind of be respectively provided with antigen binding or epitope-binding ability.In single-stranded FvFragment (scFv) in, the V of antibodyHAnd VLKnot Structure domain nationality flexibility victory peptide is connected.Generally, the connector is about the peptide of 15 amino acid.If connector is small Much, for example, 5 amino acid, then can form double antibody.The minimum combining unit of antibody is CDR, usually with enough spies Different identification and the heavy chain CDR2 of binding ability.This fragment is referred to as molecular recognition unit or mru.Such several mrus can nationality it is short Connector peptide connect together so that formed with higher than single mru affinities made binding proteins.
The functional equivalent of purpose antibody is also included within the scope of the present invention.Term " functional equivalent " includes carrying Antibody, antibody homologue, chimeric antibody, artificial antibody and the antibody of modification of homologous sequence, for example, wherein each function equivalent Thing is to combine IL-4 and/or IL-13 according to it, suppress IL-4 and/or IL-13 signal transductions ability or function, or suppresses IL-4 And/or IL-13 is attached to what the ability of its acceptor was defined.Technical staff can understand one group of molecule and name of entitled " antibody fragment " One group for " functional equivalent " has overlapping.Prepare and retain the methods of functional equivalent of IL-4 and/or IL-13 binding abilities and be Those skilled in the art know, and are such as WO 93/21319, EPO Ser.No.239,400, WO 89/09622, EPO Disclosed by Ser.No.338,745 and EPO Ser.No.332,424.
The functional equivalent of the application also includes modified antibodies, such as by any kind of molecule through being covalently attached to antibody And the antibody modified.For example, modified antibodies include passing through such as glycosylation, acetylation by known protection/blocking group already, gathered PEGylation, desamidization, phosphorylation, amidatioon, derivatization, proteolysis cut, are connected to cell ligand, are connected to toxin Or the antibody of the modification such as cytotoxic moieties or other albumen.It is covalently attached without such antibody, the antibody mediated immunity is in life Into anti-idiotype reaction.The modification can realize that it includes but is not limited to specified chemical cutting, acetyl by known technology Change, formylated, metabolism synthesis etc..In addition, one or more atypical amino acid can be contained by being modified antibody.
Those skilled in the art can realize the optimization of binding affinity using many technologies.Generally, these skills Art includes several amino acids residue, the subsequent knot for screening analysis mutant polypeptide to associated antigen or epitope at substitution purpose site Close affinity.
Once antibody is identified and separates, generation antibody variants or mutant or mutein are generally used for, wherein One or more amino acid residues of one or more hypervariable regions of such as described antibody are changed.Alternately or additionally, may be used One or more variations (for example replacing) of framework region residue are introduced to antibody, wherein these variations cause antibody mutants pair IL-4 and/or IL-13 binding affinity rise.Can the example through the framework region residue of modification include it is non-covalent directly in conjunction with anti- Former residue (Amit et al., Science 233:747-753(1986))；Influence CDR conformations or the residue interacted therewith (Chothia et al., J Mol Biol 196:901-917(1987))；And/or participate in VL-VHResidue (the EP 239 at interface 400).In certain embodiments, the modification of one or more this kind of framework region residues causes the combination of antibody and associated antigen Affinity increase.For example, about 1 to about 5 framework region residue can be changed in the embodiment of the present invention.Sometimes, this foot To produce the antibody mutants for being suitable for preclinical test, even if any residue of wherein hypervariable region does not all change.But just Antibody mutants may include that one or more hypervariable regions change in the case of often.Also constant region can be changed to obtain preferable or more manage The effector property thought.
The some hypervariable region residues changed can change at random, especially when the initial binding affinity of parental generation antibody can make at random The antibody mutants of generation are easily screened in measure teaching herein with regard to the combination changed.
A kind of method for obtaining antibody mutants such as CDR mutant is " alanine scanning mutagenesis " (Cunningham＆ Wells,Science 244:1081-1085 (1989) and Cunningham＆Wells, Proc Nat Acad Sci USA 84: 6434-6437(1991)).One or more some hypervariable region residues are replaced by alanine or polyalanine residue.To the substitution table Reveal function sensitive these some hypervariable region residues then by or just substitution site introduce it is further or it is other mutation and it is smart Repair.Therefore, the site that amino acid sequence changes is introduced although being determined in advance, the property of mutation itself need not be determined in advance. According to the required property of scanned residue, it can attempt to carry out similar substitution using other amino acid.
Identifying the method for amino acid residue to be finished more system includes the height that identification participates in combining IL-4 and/or IL-13 Become some hypervariable region residues that area's residue and little or no participation IL-4 and/or IL-13 are combined.Carry out non-binding some hypervariable region residues Alanine-scanning, wherein detecting enhancing of each ala mutant to IL-4 and/or IL-13 combination.In another embodiment In, these residues that selection substantially participates in IL-4 and/or IL-13 combinations are modified.Modification may include deleting residues or in mesh Residue neighbouring insert one or more residues.But, modification under normal circumstances is included with another 49-Phe ,82-Ser,115-Arg,144-Met,145-Asn ,161-Arg,169-Met Human Connective tissue growth factor residue.Protect The substitution of keeping property can be the first substitution.If the substitution causes bioactivity to change (such as binding affinity), then can Another conservative replacement is carried out to determine whether to obtain more substantial variations.
By selecting amino acid of its property with being located under normal circumstances at certain site to have the amino acid of more essence differences, More substantial modification can be carried out to the presentation of antibody scope and biological property.Therefore, it can be carried out in the case where maintaining following situations The substitution：(a) polypeptide backbone structure in region, such as lamella or helical conformation are replaced；(b) electric charge of the molecule at target site Or hydrophobicity, or (c) side chain size.
For example, according to common side chain properties, naturally occurring amino acid can be divided into following groups：
(1) it is hydrophobic：Methionine (M or met), alanine (A or ala), valine (V or val), leucine (L or leu) With isoleucine (I or ile)；
(2) it is neutral, hydrophilic：Cysteine (C or cys), serine (S or ser), threonine (T or thr), asparagine (N or asn) and glutamine (Q or gln)；
(3) it is acid：Aspartic acid (D or asp) and glutamic acid (E or glu)；
(4) it is alkaline：Histidine (H or his), lysine (K or lys) and arginine (R or arg)；
(5) residue of chain orientation is influenceed：Glycine (G or gly) and proline (P or pro), and
(6) it is fragrant：Tryptophan (W or trp), tyrosine (Y or tyr) phenylalanine (F or phe).
Non-conservative substitutions needs to exchange amino acid from another group of amino acid.Conservative replaces are needed monoamino-acid Exchange interior another amino acid in groups.
It is preferred that 49-Phe ,82-Ser,115-Arg,144-Met,145-Asn ,161-Arg,169-Met Human Connective tissue growth factor include following 49-Phe ,82-Ser,115-Arg,144-Met,145-Asn ,161-Arg,169-Met Human Connective tissue growth factor, its：(1) reduction is to the sensitiveness of proteolysis, (2) drop The low sensitiveness to oxidation, (3) change binding affinity and (4) assign or modified other physico-chemicals of these analogs Or functional character.Analog may include the various mutations protein of the sequence in addition to naturally occurring peptide sequence.For example, can be to day The sequence (preferably forming the polypeptide portion beyond the region of intermolecular contacts) so existed carries out single or multiple amino acid Substitution (being preferably conservative amino acid substitution).In addition to the change of R bases or the size or conformation of side chain, conservative amino acid takes (such as amino acid substitution should not be tended to interrupt in parental sequences to exist the architectural feature of Dai Buying material alterations parental sequences Spiral, or destruction characterize parental sequences other types of secondary structure (Proteins, Structures and Molecular Principles, Creighton, editor, W.H.Freeman and Company, New York (1984))； Introduction to Protein Structure(Branden&Tooze,eds.,Garland Publishing,New York,N.Y.(1991))；With Thornton et al. Nature 354:105(1991).
Under normal circumstances, the antibody mutants that biological property improves have and the anti-human IL-4 and/or IL-13 antibody of parental generation Heavy chain or light variable domains amino acid sequence at least 75% amino acid sequence identity or similitude, at least 80%th, the amino acid sequence of at least 85%, at least 90% and generally at least 95% homogeneity.With regard to parental generation antibody sequence Speech, homogeneity or similitude are defined herein as through aligned sequences and introducing room (if being necessary) realizing the percentage of maximum After sequence identity, candidate sequence it is (i.e. identical residue) identical with parental generation antibody residue or similar (i.e. based on identical side chain Property and from same group of amino acid residue, see above) amino acid residue percentage.
Or, resisted by the FR and CDR region domain or anti-IL-4 of heavy chain and light chain, anti-il-13 or double special IL-4/IL-13 The F of bodycThe system sudden change in region, can generate antibody mutants.Another method of antibody mutants is generated including the use of phagocytosis Body display carries out affinity maturation (Hawkins et al., J Mol Biol 254:889-896 (1992) and Lowman et al., Biochemistry 30(45):10832-10838(1991)).Known bacteriophage coat protein merges (Smith, Science 228:1315(1985)；Scott&Smith,Science 249:386(1990)；Cwirla et al., Proc Natl Acad Sci USA 8:309(1990)；Devlin et al., Science 249:404(1990)；Wells&Lowman,Curr Opin Struct Biol 2:597 (1992) and US5,223,409) can be used for will the albumen or the phenotype of peptide that be shown with encoding them The genotype of phage particle link together.The F of antibodyabDomain has also been illustrated on bacteriophage (McCafferty Et al., Nature 348:552(1990)；Barbas et al., Proc Natl Acad Sci USA 88:7978(1991)；With Garrard et al., Biotechnol 9:1373(1991)).
Monovalent phage display is consisting of the following：Body display is merged using a histone qualitative change body as bacteriophage coat protein In (Bass et al., Proteins 8 on phage particle:309(1990).Bitten already by continuous application mutagenesis, unit price in the past Phage display and functional analysis (Lowman＆Wells, J Mol Biol 234:564 578(1993)；The US patent No.s 5,534, 617) CDR region domain (Barbas et al., Proc Natl Acad the Sci USA 91 such as by concentrating on antibody:3809 (1994)；With Yang et al., JMol Biol 254:392 (1995)) realize affinity maturation or multiple protein balance combination The raising of affinity.
Many (such as 10 can be built on phage particle6Or more) discrepant albumen becomes on its sequence ad-hoc location The storehouse of allosome, wherein each phage particle contains the DNA of coding specific protein variant.It is many through being carried out using immobilized antigen Take turns affinity after purification, separate single phage clone, and deduce out from DNA the amino acid sequence of institute's display protein.
Produce after antibody mutants, bioactivity of the molecule relative to parental generation antibody can be determined according to teaching herein.Just As noted above, this is related to the binding affinity and/or other bioactivity or physical property that determine antibody.The one of the present invention In individual preferred embodiment, one group of antibody mutants is prepared, its binding affinity to antigen is screened.Optionally can be to selected from sieve One or more antibody mutants of choosing carry out one or many other biological activity determinations, to determine that antibody mutants have New or improved property.In a preferred embodiment, the antibody mutants remain similar or more with parental generation antibody Good/higher binding affinity combination IL-4 and/or IL-13 ability.
The antibody mutants selected according to this can be modified further by the purposes wanted generally according to antibody.It is this kind of to repair Decorations may include further to change amino acid sequence, with merging and/or covalent modification for heterologous polypeptide.For example, silk typically can be used Propylhomoserin substitution have neither part nor lot in maintain antibody mutants appropriate configuration cysteine residues, with improve the molecule oxidation stability and Prevent abnormal crosslinking.On the contrary, can add cysteine to improve stability (especially when antibody is antibody fragment such as F to antibodyv During fragment).
Another type of antibody mutants have the glycosylation pattern changed.Can by found on deleted antibodies one or The glycosylation site not having on multiple carbohydrate fractions and/or the one or more antibody of addition realizes this point.The glycosylation of antibody Generally N is connected to Asn or O is connected to Ser or Thr.Tripeptide sequence, asparagine-X-serine and asparagine-X- Soviet Unions ammonia Acid is the common recognition sequence that carbohydrate fraction is connected to asparagine side chain through enzymatic, and wherein X is appointing in addition to proline What amino acid.For example N- acetylgalactosamines, galactolipin, fucose or xylose are connected to hydroxy-amino-acid, and most of is silk ammonia Acid or threonine, although 5-OxoPro or 5- hydroxylysines can also be used.To original antibody sequence add or substitution one or Multiple serines or threonine residues can increase the glycosylated probability of O- connections.
The effector function of antibody of the present invention can be ideally modified, to strengthen the effectiveness of antibody.For example, can be FcArea introduces cysteine residues, so as to form interchain disulfide bond in the region.The homodimeric antibody generated according to this can have The cytotoxicity (ADCC) of improved internalization capability and/or the cell killing of increased complement-mediation and antibody-dependant, referring to Caron et al., J Exp Med 176:1191-1195 (1992) and Shopes, Immunol 148:2918-2922(1993). Or, it can transform with two FcThe antibody in area, thus the antibody can have enhanced complement lysis and ADCC abilities, referring to Stevenson et al., Anti-Cancer Drug Design 3:219 230(1989).
The covalent modification of antibody is covered within the scope of the invention.Cleavage that can be by chemical synthesis or by antibody or Chemical cleavage (if feasible) realizes this point.Being reacted by the targeting amino acid residue of antibody and organic derivatizing agents can be to anti- Body molecule introduce antibody other type covalent modifications, wherein organic derivatizing agents can with selected side chain or with N-terminal or C-terminal residue Reaction.
Cysteinyl residue can occur anti-with alpha-halogen acetic acid esters (and corresponding amine) such as monoxone or chloroacetamide Should, generation carboxymethyl or carboxylic acid amides methyl (carboxyamidomethyl) derivative.Can also for example, by with bromine trifluoroacetone, α-bromo- β-(5- imidazole radicals) propionic acid, chloracetyl phosphate, N- alkyl maleimides, 3- nitro -2- disulfides, first Base 2- disulfides, p-chloromercuribenzoate, 2-chloromercura-4- nitrophenol or chloro- 7- nitre Base benzo -2- oxa- -1,3- diazole reacts, and derivation obtains cysteinyl residue.
Histidyl residues can be obtained by reacting derivation under pH 5.5-7.0 with pyrocarbonic acid diethyl ester.It it is also possible to use to bromine Phenacyl bromide, the reaction is carried out preferably in pH 6.0 0.1M sodium cacodylates.
Lysyl (lysinyl) and α terminal residues can react with butanedioic acid or other carboxylic acid anhydrides, to reverse residue Electric charge.Obtaining other Suitable agents containing alpha-amido residue for derivation includes imino-ester such as methyl Picolinimidate, phosphopyridoxal pyridoxal phosphate, pyridoxal, chlorine boron hydride, TNB, O- methyl-isoureas and 2,4- penta 2 Ketone, amino acid can be transaminase-catalyzed with glyoxalic acid.
Can by with one or more conventional reagents such as phenylglyoxal, 2,3- diacetyl, 1,2- cyclohexanediones and indenes Three reactive ketones modify Arginyl residues.The derivation of arginine residues usually requires basic reaction conditions.Moreover, these reagents can Reacted with lysine and arginic epsilon-amino.
Aromatic diazo compound or tetranitromethane can be used to carry out the special modification of tyrosinyl residues.For example, using N- acetyl imidazoles and tetranitromethane form O- acetyl tyrosyl species and 3- nitro-derivatives respectively.Use125I or131I can Iodate tyrosinyl residues are to prepare the labelled protein for radiommunoassay.
By being reacted with carbodiimide (R-N=C=C-R'), Carboxyl side groups (asparagyl or glutamyl) can quilt Modification, wherein R and R' can be different alkyl, such as 1- cyclohexyl -3- (2- morpholinyl -4- ethyls) carbodiimides or 1- second Base -3- (4- nitrogen -4,4- pendimethalin bases) carbodiimide.Moreover, pass through can with ammonium ion reaction for aspartoyl and glutamyl It is converted into asparaginyl- and glutaminyl residues.
Glutaminyl and asparaginyl residues are often divested acylamino- under neutral or basic conditions, give birth to respectively Into corresponding glutamy and aspartyl resi dues.The form that these residues slough acid amides is fallen within the scope of the invention.
Other modifications include the di of hydroxylation, seryl or the threonyl residues of proline and lysine, rely ammonia Acid, arginine and alpha-amino (Creighton, the Proteins of methylating of histidine side chains:Structure and Molecular Properties, W.H.Freeman＆Co., San Francisco, pp.79-86 (1983)), the second of N-terminal amine The amidatioon of acylated and any C-terminal carboxyl.
Another type of covalent modification, which is related to, is coupled to glucosides on antibody by chemical mode or enzyme mode.These methods The antibody of the glycosylation capabilities with N- connections or O- connections need not be produced in host cell.According to used coupling side Method, sugar can be connected to：(a) arginine and histidine；(b) free carboxy；(c) sulphur of free sulphur hydrogen-based, such as cysteine Hydrogen-based；(d) hydroxyl of free hydroxyl group, such as serine, threonine or hydroxyproline；(e) aromatic residues such as phenylalanine, junket The aromatic residues of propylhomoserin or tryptophan；Or the acyl ammonia of (f) glutamine.WO 87/05330 and Aplin＆Wriston, CRC Crit Rev Biochem, pp.259-306 (1981) describe this kind of method.
Any carbohydrate fraction on antibody can be removed by chemistry or enzyme mode.For example Chemical deglycosylation needs antibody sudden and violent Compound trifluoromethanesulfonic acid or suitable compound are exposed to, so as to cause except connection sugared (N- acetyl glucosamines or N- acetyl group Galactosamine) beyond most of or all sugar cuttings, while keeping the integrality of antibody.Such as Hakimuddin et al., Arch Biochem Biophys 259:52 (1987) and Edge et al., Anal Biochem 118:131 (1981) are described Chemical deglycosylation.Can be for example, by Thotakura et al., Meth Enzymol 138:Many inscribes described in 350 (1987) Any cleavage for realizing carbohydrate fraction on antibody in glycosidase and exoglycosidase.
Another type of antibody covalent modification include according to the US patent No.s 4,640,835,4,496,689,4,301,144, 4,670,417th, the antibody is connected to many charged non-protein polymers and for example gathered by mode described in 4,791,192 or 4,179,337 One kind of ethylene glycol, polypropylene glycol or polyoxygenated alkenes (polyoxylalkylene).
Another optimization technique for obtaining mutant or mutein is that nationality phage display carries out affinity maturation (Hawkins et al., J Mol Biol 254:889-896 (1992) and Lowman et al., Biochemistry 30 (45): 10832-10838(1991)).In brief, several hypervariable region sites (such as 6-7 site) are mutated to produce each site All possible 49-Phe ,82-Ser,115-Arg,144-Met,145-Asn ,161-Arg,169-Met Human Connective tissue growth factor.The antibody mutants obtained according to this are merged with unit price as with albumen on phage particle Form is showed on phage particle.The bacteriophage of performance various mutations body can pass through following circulation：Many wheels combine selection, with Separated and be sequenced to showing the mutant of high-affinity afterwards.
Select the method for new Binding peptide that the storehouse of structure related polypeptide can be used.Produced by mutagenesis external with such as phagocytosis The storehouse of the structure related polypeptide of glutelin fusion, and it is illustrated in particle surface.These subsequent particles are contacted with target molecule, will The particle and the particle with low-affinity to target with highest affinity are separated.Then by infecting suitable bacterium place The conjugate of main amplification high-affinity, and repeat competitive binding step.The process is repeated, until affinity needed for obtaining is more Peptide.
Or, it is also possible to use polyvalent phage (McCafferty et al. (1990) Nature 348:552-554 and Clackson et al. (1991) Nature 352:624-628) to express random point mutation, (for example nationality uses fallibility archaeal dna polymerase Generation), to generate the storehouse of phage antibody fragment, and then screen affinity (Hawkins of the storehouse to IL-4 and/or IL-13 Et al. (1992) J Mol Biol 254:889-896).
Under preferable case, during affinity maturation, reproducible expression vector is in the tight of transcription regulatory element Under regulation and control, regulation condition of culture causes the amount or number that show the particle of more than one fusion protein copy to be less than about 1%.Equally In the preferred case, show that the amount of the particle of more than one fusion protein copy is less than the particle for showing single fusion protein copy The 10% of amount.The amount is less than 20% under preferable case.
By exchanging the different CDR of different antibodies chain in framework region or compound FR from multiple antibody, function can be produced Equivalent.Thus, for example, for one group of given CDRs, the different heavy chains such as IgG by replacing1-4,、IgM、 IgA1-2Or IgD, different types of antibody is possible to generate different IL-4 and/or IL-13 Antibody types and isotype.Therewith It is similar, by the way that one group of given CDRs is embedded into the framework region entirely synthesized, it can produce artificial in the scope of the invention Antibody.
The degree that the antibody fragment and functional equivalent of the present invention includes its specific bond IL-4 and/or IL-13 can be detected The molecule of survey.With reference to detectable degree including purpose antibody binding capacity at least 10-100% in the range of all values, it is excellent Elect at least 50%, 60% or 70%, more preferably at least 75%, 80%, 85%, 90%, 95% or 99% as.With more than mesh The affinity of antibody 100% equivalent be also included within.
General CDRs is important for epitope identification and antibody binding.But, the residue comprising CDRs can be become It is dynamic, without disturbing antibody identification and combining the ability for associating epitope.For example, epitope can not be influenceed to recognize but increase antibody Variation to the binding affinity of epitope.Based on the understanding to main antibody sequence, several research are more to antibody sequence Individual site introduces the effect to antibody characteristic after one or more amino acid change, for example with reference to expression (Yang et al., 1995,J Mol Biol 254:392-403；Rader et al., 1998, Proc Natl Acad Sci USA 95:8910- 8915；With Vaughan et al., 1998, Nature Biotechnology 16,535-539).
Therefore, use such as oligonucleotide mediated direct mutagenesis, box mutagenesis, fallibility PCR, DNA reorganization or Escherichia coli The method such as mutant strain change CDR1, CDR2 or CDR3 or heavy chain and the sequence of light chain gene in framework region, purpose can be generated Equivalent (Vaughan et al., 1998, Nat Biotech 16 of antibody:535-539；With Adey et al., 1996, Chap.16, Pp.277-291, in Phage Display of Peptides and Proteins, eds.Kay et al., Academic Press).Changing the method for primary antibody nucleotide sequence can cause the affinity of antibody to improve (Gram et al., 1992, Proc Natl Acad Sci USA 89:3576-3580；Boder et al., 2000, Proc Natl Acad Sci USA 97: 10701-10705；Davies&Riechmann,1996,Immunotech 2:169-179；Thompson et al., 1996, J Mol Biol 256:77-88；Short et al., 2002, J Biol Chem 277:16365-16370；With Furukawa et al., 2001,J Biol Chem 276:27622-27628)。
For example, by the multiple amino acid change for selecting to select after many wheel selections, " the polypeptide of repeat number wheel can be used Select " to select higher and higher affinity to combine.After first round selection it can be carried out to other regions of part or amino acid The selection that it takes turns, wherein first round selection are related to the first region of the amino acid selection of part or antibody polypeptides.Repeat many pollings Select, until the affinity property needed for realization.
Improveing antibody also includes the antibody with improved characteristics, and their nationality animal immunes, hybridization neoplasia and selection have The standard technique of the antibody of special features and prepare.
" antagonist ", which is meant, can suppress one or more bioactivity (such as nationality IL-4 and/or IL-13 letters of target molecule Number transduction) molecule.Antagonist is by inactivating or killing by the cell of ligand activation and/or interference acceptor or ligand activation (example Such as tyrosine kinase activation) or ligand binding to acceptor after signal transduction, may interfere with that acceptor is attached to part and vice versa. The antagonist can block the interaction of receptor-ligand, or this interaction of essence reduction completely.
" activator " mean the protein including the one or more bioactivity of activation IL-4 and/or IL-13, polypeptide, peptide, Antibody, antibody fragment, conjugate, macromolecular, the compound of small molecule.Activator can be by as by the cell of ligand activation Mitogen is acted on and/or by the interference cell inactivation after ligand binding to acceptor or signal transduction suppression, so that and acceptor To the binding interactions of part, vice versa.For purposes of the present invention, all such interference positions of activator by regarding To be suitable.
Term " cell ", " cell line " and " cell culture " include their offspring.It should also be understood that due to intentional or nothing The mutation of meaning, all the progeny is not necessarily accurate identical, such as on DNA content.Including with identical purpose function or biology The variant offspring of property, wherein purpose function or biological property are to be screened for initial cell.
Term " carrier " means nucleic acid construct body, carrier, and it contains nucleic acid, transgenosis, foreign gene or target gene, it Be effectively connected to suitable regulating and controlling sequence with suitable host carry out transgenosis expression.This kind of regulating and controlling sequence bag Include the promoter for for example influenceing transcription, the optional operon sequence of control transcription, encode suitable mRNA ribosome bind sites The sequence of sequence and regulatory transcription and translation termination.Carrier can be plasmid, phage particle or only potential genome Insert.Once being transformed into suitable host, carrier can be replicated and function independently of the genome of host, Or can be incorporated into some cases on the genome of host cell.In this manual, " plasmid " and " carrier " is interchangeable makes With because plasmid is the common type of service of carrier.But, it is contemplated that including playing the such other of equivalent function vector The carrier of form, they are or dawn just known in the art, such as virus, the synthetic molecules for carrying nucleic acid, liposome.
" mammal ", which means, for therapeutic purposes can be classified as any animal of mammal, and it includes people, family Poultry and farm-animals, non-human primate and zoo animal, sport animals or pet, such as dog, horse, cat, ox.
It can be screened or application target antibody in the measure that described herein or this area knows.It is this kind of to determine it is generally necessary to Detection such as labeled reagent.Word " mark " used herein means and can directly or indirectly be conjugated to molecule or albumen for example Detectable compounds or composition on antibody.Mark can this as it is detectable (such as labelled with radioisotope, particle or Fluorescence labeling), or can be catalyzed the chemical modification of the substrate compounds or composition that can be detected for enzyme mark.
As used herein, " solid phase " means adhesive thereon non-aqueous of entity or molecule antibody for example of the present invention Matrix.Solid phase example included by this paper is included partly or entirely by glass (such as controlled pore glass), polysaccharide (such as agar Sugar), polyacrylamide, polystyrene, polyvinyl alcohol and polysiloxanes formation solid phase.In some embodiments, according to upper Hereafter, the solid phase may include the hole of assay plate；It can be used for purification column (such as affinity chromatographic column) in other cases.Cause This, the solid phase can be paper, pearl, plastics, chip etc., can be from many materials such as nitrocellulose, agarose, polyphenyl second Prepared by alkene, polypropylene, silicon etc., can also take many conformations.
According to for method well known to those skilled in the art and for example, see hereafter, this area have already learned of the matter coding IL-4 and IL-13 gene or cDNA, they can be cloned into plasmid or other expression vectors, and numerous expression systems any one It is middle to be expressed.
It is prepared by the method that the nucleotide sequence of encoding amino acid sequence mutant can be known by many this areas.These Oligonucleotides-mediation that method includes but is not limited to the mutant or non-mutant form of the molecules of interest previously prepared is (or fixed Point) mutagenesis, PCR mutagenesis and box mutagenesis be (see, for example, Kunkel, Proc Natl Acad Sci USA 82:488(1985)).
Antibody of the present invention or its fragment, derivative or the like (such as heavy chain or light chain of antibody of the present invention, the present invention The antibody mutation protein of single-chain antibody or the present invention) recombination expression include building containing encoding antibody as described herein or anti- The expression vector of the polynucleotides of body fragment.Once obtaining the polynucleotides of encoding antibody molecule, it can be known by this area Recombinant DNA technology produces the carrier for producing the antibody.Build and adjusted containing antibody coding sequence and suitable transcription and translation Control the expression vector of signal.These methods include such as recombinant DNA technology in vi, synthetic technology and internal genetic recombination.
Expression vector is transferred in host cell body by routine techniques, is then transfected by routine techniques culture Cell, to produce the antibody or fragment of the present invention.In one aspect of the invention, the carrier of encoding heavy chain and light chain can be in host Intracellular coexpression, to express whole immunoglobulin molecules detailed in this article.
Many hosts/expression vector system can be used to express the antibody molecule of the present invention.These expression systems not only generation Table can produce and then purify the carrier (vehicle) of purpose coded sequence, can further represent with Suitable nucleotide coded sequence Can the cell in situ that express antibody molecule of the present invention when conversion or transfection.Bacterial cell such as Escherichia coli and eukaryotic are commonly used In the expression of recombinant antibody molecule, in particular for the expression of full length recombinant antibody molecule.For example, mammalian cell is for example The load of carrier of the Chinese hamster ovary celI with for example carrying the main intermediate immediate-early genes promoter element from human cytomegalovirus Body combine be antibody effective expression system (Foecking et al., Gene 45:101(1986)；With Cockett et al., Bio/ Technology 8:2(1990)).As the art is well aware, plant and plant cell cultures, insect cell be it is also possible to use Etc. producing destination protein.
In addition, the adjustable insetion sequence of selection is expressed or with required specific fashion modification and the host of processed gene product Cell.These modifications (for example glycosylating) and processing (for example cutting) of protein product are probably important for protein function. Different host cells has the property and special mechanism of protein and gene outcome post translational processing and modification.It is suitable to may be selected Cell line or host system, to ensure the correct modification and processing of expressed purpose antibody.Therefore, can be used to possess is used for Major transcript is suitably processed, gene outcome is glycosylated and the eukaryotic host cell of the cell mechanism of phosphorylation.These lactations are moved Thing host cell includes but is not limited to CHO, COS, 293,3T3 or myeloma cell.
Stable expression is preferred for long-term high-yield production recombinant protein.Stable expression antibody can for example be transformed The cell line of molecule.The expression vector containing virus origin of replication is used with it, not as using by suitable expression regulation element (example Such as promoter, enhancer, sequence, transcription terminator, polyadenylation site) regulation and control DNA and selected marker conversion host Cell.Introduce after foreign DNA, engineered cells can be allowed to be grown 1 to 2 day on enriched medium, selectivity is then transferred to On culture medium.The selected marker of recombinant plasmid assigns the resistance to selection so that plasmid stabilisation is incorporated into chromosome by cell On, and it is extended to cell line.These transformation cell lines cannot be only used for Antibody preparation, it may also be used for screening and assess directly or The compound interacted indirectly with antibody molecule.
Many selective systems can be used, its respectively include but is not limited to herpes simplex virus thymidine kinase (Wigler et al., Cell 11:223 (1977)), hypoxanthine-guanine phosphoribosyl transferase (Szybalska et al., Proc Natl Acad Sci USA 48:202 (1992)), glutamate synthetase (Adv Drug Del are selected in the presence of methionine sulphoximine Rev 58,671,2006 and the website referring to Lonza Group Ltd. or document) and tk, hgprt or aprt cell in Adenine phosphoribosyl transferase gene (Lowy et al., Cell 22:817(1980)).Equally, antimetabolite resistance can be used The alternatively basis of following gene：Dhfr, it assigns MTX resistance (Wigler et al., Proc Natl Acad Sci USA 77:357(1980)；O'Hare et al., Proc Natl Acad Sci USA 78:1527(1981))；Gpt, it is assigned Mycophenolic acid (Mulligan et al., Proc Natl Acad Sci USA 78:2072(1981))；Neo, it assigns amino Glucosides G-418 resistances (Wu et al., Biotherapy 3:87(1991))；And hygro, it assigns hygromycin resistance (Santerre et al., Gene 30:147(1984)).Can be routinely using the method for recombinant DNA technology art known to select The recombinant clone needed, the description of these methods sees such as Ausubel et al., eds., Current Protocols in Molecular Biology,John Wiley&Sons(1993)；Kriegler,Gene Transfer and Expression,A Laboratory Manual,Stockton Press(1990)；Dracopoli et al., eds., Current Protocols in Human Genetics,John Wiley&Sons(1994)；And Colberre-Garapin Et al., J Mol Biol 150:1(1981).
The expression of antibody molecule can be increased (for example, see Bebbington et al., DNA by vector amplification Cloning,Vol.3.Academic Press(1987)).When the label in the carrier system for expressing antibody is amplifiable, training The copy number of marker gene can be increased by supporting the rise of inhibitor level in thing.It is relevant with antibody gene due to being amplified region Connection, the generation of antibody can also rise (Crouse et al., Mol Cell Biol 3:257(1983)).
Two or more expression vectors of the present invention can be used to carry out cotransfection to host cell, such as first vector is encoded Polypeptide from heavy chain, and polypeptide of the Second support coding from light chain.The two carriers can contain identical selectable marker, These labels can make heavy chain identical with the expression of light chain polypeptide.Or, it can be used and encode and can express heavy chain and light chain polypeptide Single carrier.In this case, light chain should be placed in before heavy chain, to avoid producing the excessive heavy chain for being free of toxicity (Proudfoot,Nature 322:52(1986)；And Kohler, Proc Natl Acad Sci USA 77:2197 (1980)).The coded sequence of heavy chain and light chain may include cDNA or genomic DNA.
Once producing the antibody molecule of the present invention by animal, chemical synthesis or recombination expression, it can be known by this area Any purifying immunoglobulin molecule method such as chromatographing (such as ion exchange, affinity chromatography, especially through protein To IL-4 and/or IL-13 affinity chromatography after A and size exclusion chromatography), centrifugation, differential solubility or pass through protein purification Any other standard technique purified antibody molecule.In addition, antibody of the present invention or antibody fragment can be fused to it is described herein Allogeneic polypeptide sequence or other peptide sequences for knowing of this area, in order to purify.
Any proper method that can be known by this area generates antibody of the present invention.Antibody of the present invention may include Polyclonal antibody, although due to antibody modification to optimize its use of use and optimization antibody in human body in itself, it is single Clonal antibody is still preferred, and this is because of its production and manipulates specific protein conveniently.The method for preparing polyclonal antibody is ability Field technique personnel know (Harlow et al., Antibodies:a Laboratory Manual,Cold Spring Harbor Laboratory Press,2nd ed.(1988))。
Antibody of the present invention preferably includes monoclonal antibody.Usable hybridoma technology for example by Kohler et al., Nature 256:495(1975)；The US patent No.s 4,376,110；Harlow et al., Antibodies:A Laboratory Manual, Cold Spring Harbor Laboratory Press, 2nd ed. (1988) and Hammerling et al., Monoclonal Antibodies and T-Cell Hybridomas, Elsevier (1981) description, recombinant DNA method For example prepare and the method using transfectoma or other methods for knowing for technical staff prepare monoclonal antibody.Available for producing Other examples of the method for monoclonal antibody include but is not limited to human B-lymphocyte hybridoma technology (Kosbor et al., Immunology Today 4:72(1983)；With Cole et al., Proc Natl Acad Sci USA 80:2026 (1983)) and EBV- hybridomas Technology (Cole et al., Monoclonal Antibodies and Cancer Therapy, pp.77-96, Alan R.Liss (1985)).These antibody can be to include IgG, IgM, IgE, IgA and IgD any immunoglobulin class and its any subclass Antibody.The hybridoma for producing mAb of the present invention can be cultivated in vitro or in vivo.
In hybridoma model, to host for example mouse, humanization mouse, carrier's immune system genes transgenosis it is small Mouse, hamster, rabbit, rat, camel or other any suitable host animals are immunized, and are produced or can be produced special to trigger With reference to the lymphocyte of IL-4 or IL-13 antibody.Alternatively, hedge cell is immunized in vitro.Use suitable fusion agent example As polyethylene glycol makes lymphocyte then be merged with myeloma cell, hybridoma (Goding, Monoclonal are formed Antibodies:Principles and Practice,Academic Press,pp.59-103(1986))。
In general, when preparing the hybridoma for producing antibody, can be used periphery hemolymph thin during if desired for people source cell Born of the same parents (" PBL "), or splenocyte or lymph node cells then can be used during if desired for non-human mammalian sources.Immortal cell line is usual It is the myeloma cell of the mammalian cell, especially rodent, ox or people source of conversion.General use rat or mouse Myeloma cell line.Hybridoma can be cultivated on suitable culture medium, the culture medium, which is preferably comprised, can suppress what is do not merged One or more materials of growth or the existence of immortality cell.If for example, parental cell lacks enzyme hypoxanthine guanine phosphoric acid Phosphoribosynltransferase (HGPRT or HPRT), the culture medium for hybridoma can typically contain hypoxanthine, aminopterin and thymidine (" HAT culture mediums "), they are the materials for preventing from lacking HGPRT cell growth.
It is preferred that immortal cell line be effective integration and support it is selected generation antibody cytotostatic high level produce The cell line of antibody, they are sensitive to culture medium such as HAT culture mediums.There are rat bone marrow tumour system, example in these myeloma cell lines As being derived from the MOPC- that can be obtained from Salk Institute Cell Distribution Center, San Diego, Calif 21 and MPC-11 mouse tumors and can be from American type culture collection (American Type Culture ), Collection the cell line for SP2/0, FO or X63-Ag8-653 cell that Manassas, VA are obtained.
Also describing human myeloma and mouse-human heteromyeloma (heteromyeloma) cell line is used to produce people Dan Ke Grand antibody (Kozbor, J Immunol 133:3001(1984)；With Brodeur et al., Monoclonal Antibody Production Techniques and Applications,Marcel Dekker,Inc,pp.51-63(1987))。51- 63(1987)).It is also possible to use mouse myeloma cell line NSO (European Collection of Cell Cultures, Salisbury,Wilshire,UK)。
Another option is to form hybridoma using electro' asion rather than chemical fusion.Without using fusion, but use Such as Epstein Barr are viral or other transformed genes carry out immortalised B-cell, for example, see Zurawaki et al., Monoclonal Antibodies, editor, Kennett et al., Plenum Press, pp.19-33. (1980).19-33. (1980).The severe combined immunization that the transgenic mice and transplanting that it is also possible to use expression immunoglobulin have human B lymphocyte lacks Fall into (severe combined immunodeficient, SCID) mouse.
Determining growth has the generation of the monoclonal antibody for IL-4 and/or IL-13 in the culture medium of hybridoma. It can be analyzed by immunoprecipitation or by external combination mensuration such as radiommunoassay (RIA), fluorecyte measurement (flluorocytometric analysis, FACS) or enzyme-linked immunosorbent assay (ELISA) determine hybridoma institute The binding specificity of the monoclonal antibody of generation.These technologies know for this area, and within the scope of the skill of technical staff. (Munson et al., Anal Biochem 107 can be analyzed for example, by Scatchard:220 (1980)) determine monoclonal antibody To IL-4 and/or IL-13 binding affinity.
After the hybridoma of the antibody of specificity, affinity and/or activity needed for identification is produced, these clones can pass through Limited dilution method is subcloned, and by standard method (Goding, Monoclonal Antibodies:Principles And Practice, Academic Press, pp.59-103 (1986) are cultivated.Suitable culture medium is included for example The Eagle culture mediums (D-MEM) or RPMI-1640 culture mediums of Dulbecco improvement.In addition, hybridoma can be swollen as ascites Knurl grows in animal body.
Pass through conventional immune globulins purification process such as a-protein-Sepharose, protein G-Sepharose, hydroxyl Apatite chromatography, gel exclusion chromatography, gel electrophoresis, dialysis or affinity chromatography are suitable from culture medium, ascites fluid or serum Separate or isolate the monoclonal antibody through subclone secretion.
There are many methods for being used to produce monoclonal antibody in this area, therefore the present invention is not limited to them only in hybridization Preparation in knurl.For example, monoclonal antibody can be prepared by the recombinant DNA method such as methods described of the US patent No.s 4,816,567. In this case, term " monoclonal antibody " means the antibody cloned from single eucaryote, bacteriophage or prokaryotes.
Using conventional method (for example using can specific bond encode mouse heavy chain and light chain or from people, humanization or The oligonucleotide probe of the gene of such chain in other sources) can delamination and sequencing coding monoclonal antibody of the present invention DNA (Innis et al., PCR Protocols.A Guide to Methods and Applications, Academic And Sanger et al., Proc Natl Acad Sci 74 (1990):5463(1977)).Hybridoma is used as this kind of DNA's Source.Once separation, the DNA can be placed in expression vector, the subsequent expression vector be transfected do not produce originally it is immune The host cell of globulin such as Bacillus coli cells, NSO cells, COS cells, Chinese hamster ovary (CHO) cell or marrow In oncocyte, to obtain the synthesis of monoclonal antibody in the host cell body of restructuring.Can also be for example, by employment heavy chain and light Coded sequence substitution homologous murine sequences (the US patent No.s 4,816,567 of chain constant domain；With Morrison et al., Proc Natl Acad Sci USA 81:6851 (1984)) or by by all or part of coded sequence of NIg polypeptide Immunoglobulin coding sequence is covalently bound to, so as to modify the DNA.These NIg polypeptides can by for It is changed to the constant domain of antibody of the present invention, or an IL-4 or IL-13 binding site of antibody of the present invention can be replaced by Variable domains, to form chimeric bivalent antibody.
These antibody can be univalent antibody.Method for preparing univalent antibody is known in the art.For example, one kind side Method is related to the recombination expression of light chain immunoglobulin and modification heavy chain.Heavy chain is general in FcThe optional position in area is truncated, to prevent Only heavy chain is crosslinked.Or, relevant cysteines residue can be replaced or be lacked by another amino acid residue, to prevent crosslinking.
The antibody fragment for recognizing specific epitopes can be generated by known technology.Conventionally by the proteolysis of complete antibody Digestion obtains these fragments (for example, see Morimoto et al., J Biochem Biophys Methods 24:107(1992)； With Brennan et al., Science 229:81(1985)).For example (F is produced using enzyme such as papainabFragment) or pepsin (produce F(ab')2Fragment) proteolysis cutting is carried out to immunoglobulin molecules, the F of the present invention can be producedabAnd F(ab')2Fragment. F(ab')2Fragment contains the C of variable region, constant region of light chain and heavy chainH1Domain.But directly can be produced by the host cell of restructuring These raw fragments.For example, antibody fragment can be isolated from antibody phage storehouse.Or, F(ab')2- SH fragments can be directly from big Reclaimed in enterobacteria and nationality chemical mode is coupled to form F (ab ')2Fragment (Carter et al., Bio/Technology 10:163 (1992).According to another method, F(ab’)2Fragment can be directly isolated from the host cell cultures of restructuring.Produce antibody Other technologies of fragment will be readily apparent to one having ordinary skill.In other embodiments, the antibody of selection is single Chain FvFragment (Fv)(WO 93/16185)。
For some purposes in human body using antibody and vitro detection including being determined, preferably using be fitted together to, people Source or human antibody.The method dawn known in the art of chimeric antibody is produced, for example, see Morrison, Science 229: 1202(1985)；Oi et al., BioTechniques 4:214(1986)；Gillies et al., J Immunol Methods 125:191(1989)；With the US patent No.s 5,807,715；4,816,567 and 4,816,397.
Humanized antibody is derived from the antibody molecule with reference to IL-4 and/or IL-13 generated in non-human species' body, wherein One or more CDRs from it are inserted into the FR areas from human immunoglobulin molecule.Known using many this areas Multiple technologies such as CDR transplants (EPO 239,400；WO 91/09967；With the US patent No.s 5,225,539；5,530,101；With And 5,585,089), veneer or surface remodeling (EPO 592,106；EPO 519,596；Padlan,Molecular Immunology 28:489(1991)；Studnicka et al., Protein Engineering 7:805(1994)；With Roguska et al., Proc Natl Acad Sci USA 91:969 (1994)), and chain reorganization (the US patent No.s 5,565, 332) can humanized antibody.
Humanized antibody has one or more amino acid residues from non-people source.These inhuman amino acid residues Commonly referred to as " importing " residue, they are typically derived from the variable domains of " importing ".According to Winter and its colleague et al. Method (Jones et al., Nature 321:522(1986)；Riechmann et al., Nature 332:323 (1988) and Verhoeyen et al., Science 239:1534 (1988)) by anti-with the partial replacement people of inhuman CDR or CDRs sequences The corresponding sequence of body, can be basically carried out humanization.Therefore, these " humanization " antibody be chimeric antibody (the US patent No.s 4, 816,567), wherein essentially less than the sequence of intact human variable domain is replaced by the corresponding sequence from non-human species. In practice, humanized antibody is usually human antibody, and some of CDRs residues and some possible FR residues are by rodent The similar site of antibody is replaced.Heavy chain constant region and hinged region may be from any classification or subclass to obtain the effect of needs, Such as a specific effector function.
Generally, the Framework residues of people's framework region can be replaced by the corresponding residue from CDR donor antibodies, so as to change and have Antigen binding may be improved.Framework substitution can nationality this area aware method identified, be for example set up CDR and Framework residues phase The model of interaction compares to identify specific location to identify the important Framework residues for antigen binding, and through sequence Abnormal Framework residues, such as refering to the US patent No.s 5,585,089 and Riechmann et al., Nature 332:323(1988).
It is highly preferred that humanized antibody retains the high-affinity to IL-4 and/or IL-13, and retain or obtain other Favourable biological property.Therefore, using parental sequences and the threedimensional model of humanized sequence, by analyzing parental sequences and a variety of The method of conceptual humanized products, is prepared into humanized antibody.Three dimensional immunoglobulin model generally can be art technology Personnel utilize and known.Can be illustrated and show selected candidate immunoglobulin sequences sequence possibility three-dimensional conformation structure meter Calculation machine program.Check that this displaying allows to analyze possibility effect of some residues in candidate immunoglobulin sequences sequence function, That is analyzing influence candidate immunoglobulin sequences combination IL-4 and/or the residue of IL-13 abilities.Take this kind of a mode, can be from receiving and lead Enter sequence selection and merge FR residues so that required antibody characteristic is maximized, such as the increased affinity to target antigen, Despite CDR residues, directly and most substantially influence IL-4 and/or IL-13 is combined.CDR region domain can be also modified, contains it It is one or more from derived from the different amino acid of parental generation antibody (CDR derive from the parental generation antibody) amino acid, to provide enhancing or not With purpose property, such as the combination of the affinity (avidity) of bigger affinity or bigger.
Some parts of antibody constant region can be manipulated and changed, there is difference and or better than observation in parental generation antibody to provide Antibody homologue, derivative, fragment to property etc..Thus, for example many IgG4 antibody are two near hinge area formation chain Sulfide linkage.Chain internal key can make parental generation bivalent molecular change obtain unstable, form containing heavy chain and be attached thereto the monovalent molecule of light chain.This Quasi-molecule can be recombined, but be random incorporation.
It is observed that the amino acid in modification IgG4 molecular hinges area can reduce the probability of chain internal key formation, so that stable IgG4 Molecule, this will minimize the probability of bispecific molecule formation.If treatment is IgG4 molecules with antibody, this modification is then favourable , because the Dissociation probability that stability enhancing can be by minimum chemoattractant molecule in production and preparation process and in vivo.It is single Valency antibody may not with bivalent parent molecule identical validity.For example, when bivalent IgG4 is applied into patient, bivalent IgG4 Percentage in two weeks decay be about 30%.The 49-Phe ,82-Ser,115-Arg,144-Met,145-Asn ,161-Arg,169-Met Human Connective tissue growth factor of 228 enhances IgG4 stability.Positioned at the silk of 228 Propylhomoserin can be one kind in another amino acid substitution, such as remaining 19 kinds of amino acid.Especially can recombinant antibodies be made with this change Move, wherein the mutated amino acid substitution that can obtain at 228 of nucleic acid coding sequence.Such as S can be replaced by proline.
Another group of amino acid for being adapted to modification includes the amino acid of hinge area, and these amino acids contain point of heavy chain Son and FcCombination between acceptor and the internalization for being combined antibody.This amino acid is included in IgG1 molecules from about 233 to about 237 Residue (Glu-Leu-Leu-Gly-Gly) (SEQ ID NO:49) in；From the residue (Met-Ile-Ser- of about 252 to about 256 Arg-Thr)(SEQ ID NO:50) residue of (Pro) and from about 318 (Glu) to about 331, such as including Lys320、Lys322With Pro329。
Fully human antibodies are that the therapeutic treatment of people patient is particularlyd hope.Can the method system that knows of many this areas of nationality Standby human antibody, including the above-mentioned phage display side carried out using the antibody library from human immunoglobulin sequence Method, refering to the US patent No.s 4,444,887 and 4,716,111；With WO 98/46645, WO 98/50433, WO 98/24893, WO 98/16654, WO 96/34096, WO 96/33735 and WO 91/10741.Also using Cole's et al. and Boerder et al. Technology prepares human monoclonal antibodies (Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R.Liss(1985)；With Boerner et al., J Immunol 147:86(1991)).
Transgenic mice production human antibody is it is also possible to use, these mouse can not express functional endogenous immunoglobulin, But also express some human immunoglobulin genes.For example, can nationality random fashion or homologous recombination ball is immunized in people's heavy chain and light chain GFP compound is incorporated into the embryonic stem cell of mouse.Or, in addition to people's heavy chain and light chain gene, can be by people can Become area, constant region and variable region to be incorporated into mouse embryo stem cell.Human immunoglobulin gene's seat is introduced by homologous recombination, Murine heavy chain and light chain immunoglobulins gene can be made separately or concurrently to lose function.Specifically, the homozygous deletion in JH areas can Prevent endogenous antibody tormation.The embryonic stem cell being modified is expanded and is microinjected into blastocyst, forms gomphosis mouse.With After breed gomphosis mouse, produce the homozygosis offspring of expression human antibody, such as refering to Jakobovitis et al., Proc Natl Acad Sci USA 90:2551(1993)；Jakobovitis et al., Nature 362:255(1993)；Bruggermann etc. People, Year in Immunol 7:33(1993)；With Duchosal et al., Nature 355:258(1992)).
Transgenic mice entering in whole or in part with IL-4 or IL-13 cell factors such as IL-4 or IL-13 by normal mode Row is immune.Anti- IL-4 and IL-13 monoclonal antibody can be obtained from immune transgenic mice using conventional hybridoma technology.Turn Human immunoglobulin(HIg) transgenosis entrained by DNA murine is reset in B cell atomization, is then subjected to class switch And somatic mutation.Therefore, it is possible to produce IgG, IgA, IgM and IgE antibody for the treatment of using this technology.If being intended to understand Overview, see Lonberg et al., Int Rev Immunol 13:65-93(1995).For single to production human antibody and people Clonal antibody and produce this antibody-like scheme discussion, see such as WO 98/24893；WO 92/01047；WO 96/ 34096；With WO 96/33735；EPO No.0598 877；With the US patent No.s 5,413,923；5,625,126；5,633,425； 5,569,825；5,661,016；5,545,806；5,814,318；5,885,793；5,916,771 and 5,939,598. this Outside, such as Amgen (Fremont, CA), Genpharm (San Jose, CA) and Medarex, Inc. (Princeton, NJ) etc. Company can be engaged in the offer of anti-IL-4 and/or IL-13 human antibodies using technology similar to the above.
Equally, can immunosuppressive have human peripheral leucocytes, splenocyte or marrow (such as Israel XTL The three-source hybridoma technology of Biopharmaceuticals companies) mouse, prepare people mAbs.Using being referred to as, " guiding is selected Select " the selected epitope of technology generation identification fully human antibodies.In the method, using chosen non-human monoclonal antibodies Selection (Jespers et al., the Bio/technology 12 of the fully human antibodies of identification same epitope is guided such as mouse antibodies: 899(1988))。
During using recombinant technique, antibody variants why can be produced in the cell, in periplasmic space, or directly be secreted into culture In base.If antibody variants why is produced in the cell, the first step for example removes minute fragments by centrifugation or ultrafiltration, Its host cell or the fragment being cleaved.Carter et al., Bio/Technology 10:163 (1992) describe one Plant the method that separation is secreted into the antibody in colibacillus periplasm space.In brief, cytoplasm and sodium acetate (pH 3.5) and EDTA is contacted.Cell fragment can be removed by centrifugation.When antibody variants why is secreted into culture medium, typically first with city The ultrafiltration module concentration for selling protein compression filter such as Amicon or Millipore Pellicon comes from these expression systems Supernatant.Protease inhibitors such as PMSF can be added with protease inhibition solution, can also add antibiotic to prevent external dirt Contaminate the growth of thing.
The antibodyome that for example hydroxyapatite, gel electrophoresis, dialysis and affinitive layer purification are prepared from cell can be used Compound.A-protein or protein G depend on any IgF on antibody variants why if appropriate for as affinity ligandcKnot The species and isotype in structure domain.Protein A purified antibody (the Lindmark based on human IgG1, IgG2 or IgG4 heavy chains can be used Et al., J Immunol Meth 62:1(1983)).Can be used protein G be used for mouse isotypes and human IgG 3 (Guss et al., EMBO J 5:1567(1986)).The most common matrix that affinity ligand is combined is agarose, but other matrix can also be used.Machine The stable for example controllable hole glass of matrix of tool or poly- (styrene divinyl) benzene can allow the faster stream realized than agarose Fast and shorter processing time.When antibody variants why includes CH3During domain, Bakerbond ABXTM resins (JT can be used Baker；Phillipsburg, NJ) purified.Also using other oroteins purification technique, for example ion exchange column is classified Separation, ethanol precipitation, reversed-phase HPLC, the chromatography on silica, the chromatography on heparin-agarose, anion or cation exchange Chromatography (such as many poly-aspartate posts), chromatofocusing, SDS-PAGE and ammonium sulfate precipitation on resin, this depends on to be recycled Antibody or variant.
Carry out after any any preliminary purification step, the mixture containing purposeful antibody or purpose variant and pollutant can be carried out Low pH hydrophobic interaction chromatographies, wherein using pH about 2.5-4.5 elution buffer, preferably in low salt concn (e.g., from about 0- 0.25M salt) under carry out.
The antibody of the present invention can be bispecific antibody.Bispecific antibody can be monoclonal antibody, it is however preferred to have extremely The people of few two kinds of different antigen-binding specificities or humanized antibody.In a preferred embodiment, bispecific antibody, its Fragment etc. has binding specificity to IL-4 and IL-13.
The method for producing bispecific antibody is well-known.Traditionally, the recombinant production of bispecific antibody is base In the coexpression of two heavy chain immunoglobulin/light chains pair, two of which heavy chain has different specificity (Milstein etc. People, Nature 305:537(1983)).Due to being randomly assigned for heavy chain immunoglobulin and light chain, hybridoma (quadroma (quadroma) potential mixture of 10 kinds of different antibodies molecules) is produced, wherein only a kind of have correct bispecific knot Structure.The purifying of correct molecule is generally carried out by affinity chromatography step.Similar approach is disclosed in the Hes of WO 93/08829 Traunecker et al., EMBO J 10:3655(1991).Such as Kufer et al., Trends Biotech 22:238-244, 2004 provide other methods of production bispecific antibody.
Constant region for immunoglobulin sequence with required binding specificity can be fused to the constant domain sequence of immunoglobulin On row.It is preferred that yu includes at least part hinge area, CH2And CH3The heavy chain immunoglobulin constant domain in area is merged.It There can be first heavy chain constant region (CH1), it contains at least combines required site in a light chain occurred in merging.It will compile The DNAs of code heavy chain immunoglobulin corresponding circle of sensation and light chain immunoglobulin (if desired) is inserted into different expression vectors, and altogether It is transformed into suitable host organism body.More details for producing bispecific antibody, see such as Suresh et al., Meth Enzym 121:210(1986)。
Present invention contemplates that different conjugate antibody.The antibody that different conjugate antibody is connected by two covalent bonds is constituted. Through suggestion for example with this kind of antibody target immune system cell to undesired cell (the US patent No.s 4,676,980).Consider, should Antibody can in vitro be prepared with the known method of synthetic proteins chemistry, including be related to those methods of crosslinking agent.For example, immune poison Element can be reacted with disulfide exchange or form the mode of thioester bond to build.Being suitable for the example of the reagent of the purpose includes Iminothiolate) and methyl -4-mercaptobutyrimidate, and such as the US patent No.s 4, disclosed in 676,980 Those.
Furthermore, it is possible to produce IL-4 and/or IL-13 single domain antibody.Some examples of this technology, exist WO9425591 has been described when referring to the antibody from Camelidae heavy chain Ig, and is referred in US20030130496 from bacteriophage Library has also been described when separating single domain human antibody.
Alternatively, some technology (US patent No.s 4,946,778 described for producing single-chain antibody；Bird,Science 242:423(1988)；Huston et al., Proc Natl Acad Sci USA 85:5879(1988)；And Ward, et al., Nature 334:544 (1989)) it is also adapted to produce single-chain antibody.Single-chain antibody is by by FvThe heavy chain and light chain in domain Fragment is delivered a child into formed by single chain polypeptide with amino acid bridging.Function F in Escherichia colivThe package technique of fragment can also Utilize (Skerra et al., Science 242:1038(1988)).
Present invention comprises resisting with recombination form and peptide fusion or chemically conjugated (including covalent and non-covalent conjugated) Body.The antibody of fusion or the conjunction that stops of the present invention, which can be used for simplifying, to be purified, refering to such as WO 93/21232；EP 439,095； Naramura et al., Immunol Lett 39:91(1994)；The US patent No.s 5,474,981；Gillies et al., Proc Natl Acad Sci USA 89:1428(1992)；And Fell et al., J Immunol 146:2446(1991).Labeled amino acid sequence Row can be six histidine peptides, the label (QIAGEN, Inc., Chatsworth, CA) that such as pQE carriers are provided, in addition, wherein being permitted It can also be obtained more through commercial channel, Gentz et al., Proc Natl Acad Sci USA 86:821(1989).It is other to can be used for The peptide tag of purifying includes but is not limited to " HA " label, and it corresponds to an epitope (Wilson for being derived from influenza hemagglutinin protein Et al., Cell 37:767 (1984)) and " flag " label.
Single chain polypeptide binding molecule, wherein heavy chain and light chain F can also be createdvRegion is connected.Single-chain antibody (" scFv") and they Construction method described in such as US patent No.s 4,946,778.Or, FabIt can build and express in a similar manner.With Complete murine monoclonal antibody is compared, and all human antibodies fully and partially can have a less immunogenicity, fragment and Single-chain antibody can also have less immunogenicity.
Antibody or antibody fragment, can be from McCafferty et al., Nature 348:552 (1990) technology is produced Antibody phage libraries separation.Clarkson et al., Nature 352:624 (1991) and Marks et al., J Mol Biol 222:581 (1991) are described respectively separates muroid and human antibody using phage library.Subsequent publication is described with chain Reorganization production high-affinity (in the range of nM) human antibody (Marks et al., Bio/Technology 10:779 (1992)), And to combine infection and In vivo recombination as strategy (Waterhouse et al., the Nucl for building very big phage library Acids Res 21:2265(1993)).Therefore, these technologies are the conventional monoclonal antibody hybridomas for separating monoclonal antibody The feasible alternative of technology.
The anti-IL-4 and/or IL-13 antibody of candidate is exempted from enzyme linked immunosorbent assay (ELISA) (ELISA), FACS, Western What epidemic disease engram technology or other immunochemical techniques known in the art were detected.
In order to determine whether specific antibody homologue is combined with people IL-4 and/or IL-13, any traditional combination mensuration It can apply.Useful IL-4 and IL-13 combination mensurations include facs analysis, ELISA measure, surface plasmon resonance (Biacore), radiommunoassay etc., these methods detect the combination of antibody and people IL-4 and/or IL-13 and thus produced Raw function.Total length teaching herein and the people IL-4 and IL-13 of soluble form are useful in this kind of measure.Antibody or The combination of homologue and IL-4 and/or IL-13 or its soluble fragments, can be easily by using the immune ball to the species There is albumen specific second of antibody to detect, the antibody or homologue detected is derived from above-mentioned species.
It is any suitable in order to determine whether specific antibody or homologue significantly block IL-4 and/or IL-13 combination Competition assay can be used.Useful measure is included such as ELISA measure, FACS measure, radiommunoassay, and they determine The competitiveness that amount antibody or homologue are combined with IL-4 and/or IL-13.Preferably, part block mark people IL-4 and/or The ability that IL-13 is combined with immobilized antibody or homologue is measured.
The antibody of the present invention can be in terms of antibody identification or the IL-4 specifically bound and/or IL-13 epitope or part To describe or provide.The epitope or polypeptide portion can be provided as described herein, such as by the position of N-terminal and C-terminal, pass through neighbour Size, comformational epitope of nearly amino acid residue etc..
The antibody of the present invention also can be described or provided in terms of cross reactivity.With reference to IL-4 and/or IL-13 have to Few 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 65%, at least 60%, extremely Few 55%, and at least 50% homogeneity (being calculated using known in the art and method described herein) IL-4 and/ Or the antibody of IL-13 polypeptides, it is also included in the present invention.
The antibody of the present invention can also be described or provided in terms of with IL-4 and/or IL-13 binding affinity.It is anti- IL-4 and/or IL-13 antibody can be below about 10-7M, below about 10-6M, or below about 10-5M KDWith reference to.Purpose antibody Can be beneficial compared with high binding affinity, such as with about 10-8To about 10-15M, about 10-8To about 10-12M, about 10-9To about 10-11M, or about 10-8To about 10-10M equilibrium dissociation constants or KDThose antibody.Present invention also offers some antibody, such as originally Any of method immunoassays as described herein for determining competitive binding are determined that these antibody are competing in technical field Suppress to striving property the combination of antibody and the epitope of the present invention.In some preferred embodiments, suppress antibody competition with The combination of epitope reaches at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 60%, Or at least 50%.
Present invention additionally comprises the compound that stops containing purposeful antibody.The compound that stops includes two key components, purpose antibody and Can be second component of a kind of cell binding agent, cytotoxic agent etc..
Term " cell binding agent " used herein refers to a kind of molecule of energy specific recognition cell surface and tied with it The activating agent of conjunction.Therefore, cell binding agent can be T cell differentiation antigen, pathogen antigen such as viral antigen, and differentiation antigen, cancer resists Original, cell-specific antigens, tissure specific antigen, Ig or Ig sample molecules etc..
Cell binding agent can be currently known or just known any types, including peptide, non-peptide, carbohydrate, nucleic acid, Part, acceptor etc., or its combination.The cell binding agent can be any compound that can be combined with cell, either with special Property or non specific manner combine.In general, cell binding agent can be antibody (especially monoclonal antibody), lymph because Son, hormone, growth factor, vitamin, nutrient delivery molecule (such as transferrins), or other any cell-binding molecules or thing Matter.
Other examples of available cell binding agent include：Polyclonal antibody；Monoclonal antibody；And antibody fragment, such as Fab、Fab'、F(ab')2And Fv(Parham,J.Immunol.131:2895-2902(1983)；Spring et al., J.Immunol.113:470-478(1974)；And Nisonoff et al., Arch.Biochem.Biophys.89：230-244 (1960))。
Second component can also be a kind of cytotoxic agent.Term " cytotoxic agent " used herein refers to reduce Or function or the growth of cell are blocked, and/or cause the material of cytoclasis.Therefore, cytotoxic agent can be a kind of Japanese yew Alcohol, maytansine (maytansinoids), such as DM1 or DM4, CC-1065 or CC-1065 analogs, ricin, mitogen are mould Plain C etc..In certain embodiments, as the present invention the compound that stops any bonding agent, cytotoxic agent be with covalent bond with Purpose antibody is connected directly or by a cleavable or not cleavable connector.
The example of suitable maytansine includes maytansinol (maytansinol) and maytansinol analog.Maytansine can suppress The formation of micro-pipe simultaneously has very strong toxicity to mammalian cell.
The example of suitable maytansinol analog is included containing through modifying those of aromatic ring and having modification in other positions Those maytansine alcohol analogs.This kind of suitable maytansine is disclosed in following US patents：4,424,219；4,256,746； 4,294,757；4,307,016；4,313,946；4,315,929；4,331,598；4,361,650；4,362,663；4,364, 866；4,450,254；4,322,348；4,371,533；6,333,410；5,475,092；5,585,499；And 5,846, 545。
The suitable example containing a maytansinol analog through modifying aromatic ring includes：(1) C-19- dechlorinations (US patents Number 4,256,746) (for example reduced and prepared by ansamytocin P2 LAH)；(2) C-20- hydroxyls (or C-20- piptonychias Base) +/- C-19- dechlorinations (the US patent No.s 4,361,650 and 4,307,016) (such as with streptomyces (Stretomyces) or put Line Pseudomonas (Actinomyces) demethylation is prepared with lithium aluminium hydride (LAH) dechlorination)；And (3) C-20- demethoxylations, C- 20- acyloxy (- OCOR), +/- dechlorination (the US patent No.s 4,294,757) (be acylated and prepared with acid chloride).
The suitable example for having the maytansinol analog of modification in other positions includes：(1) C-9-SH (the US patent No.s 4, 424,219) (maytansinol and H are passed through2S or P2S5Reaction and prepare)；(2) C-14 alkoxy methyls (demethoxylation/CH2OR) (the US patent No.s 4,331,598)；(3) C-14- methylols or acyloxy methyl (CH2OH or CH2OAc) (the US patent No.s 4,450, 254) (prepared from Nocardia (Nocardia))；(4) C-15- hydroxyls/acyloxy (the US patent No.s 4,364,866) is (logical Crossing streptomycete makes maytansinol convert and prepare)；(5) C-15- methoxyl groups (US4,313,946 and 4,315,929) are (from Trewia Nudiflora is separated)；(6) C-18-N- demethylations (the US patent No.s 4,362,663 and 4,322,348) (make U.S. by streptomycete Step on alcohol demethylation and prepare)；And (7) 4,5- deoxies (the US patent No.s 4,371,533) (pass through the tri-chlorination of maytansinol Titanium/LAH is reduced and prepared).
The cytotoxicity compound that stops can be prepared with in-vitro method.In order to which cytotoxic agent, medicine or prodrug are connected with antibody, Usually using a linker.Suitable linker is known in the art, including disulfide group, thioether group, acid is unstable Determine base, photo-labile base (photolabile group), the unstable base of peptase and the unstable base of esterase.For example, utilizing two sulphur Compound exchange reaction, or form thioether bond between purpose antibody and medicine or precursor medicine, you can build the compound that stops.
As discussed above, the invention provides the separation for encoding antibody described herein or its function fragment or variant variant Nucleotide sequence, containing coding the present invention antibody or its function fragment IL-4 and/or IL-13 bound fractions nucleotides sequence The recombinant technique of the vector construct of row, the host cell containing this carrier, and production polypeptide.
The carrier generally comprises component known in the art, and generally comprise but be not limited to it is one or more under Row：Signal sequence, replication orgin, one or more marks or Select gene promote and/or strengthened the sequence of translation, enhancer Element etc..Therefore, expression vector include with suitable transcription or translation regulatory nucleotide sequence, for example those are dynamic from lactation Thing, microorganism, the nucleotide sequence of virus or insect genes, the nucleotide sequence effectively connected.The example of other regulating and controlling sequences Attached bag includes operator, mRNA ribosome bind sites, and/or other control transcription and translations (such as its starting and terminate) is suitable Suitable sequence.When regulating and controlling sequence is related to the nucleotide sequence function of appropriate polypeptide, nucleotide sequence is exactly " effectively connecting ". Therefore, if promoter nucleotide sequence controls the transcription of the nucleotide sequence, then the promoter nucleotide sequence be exactly with For example antibody heavy chain sequence is effectively connected.
In addition, the sequence for the proper signal peptide that coding is connected with heavy chain of antibody and/or sequence of light chain non-natural, can include table Up to carrier.For example, the nucleotide sequence of signal peptide (secretion is leading) can be merged with meeting frame with peptide sequence so that the antibody It is secreted into periplasmic space or culture medium.The signal peptide worked in desired host cell, enhance appropriate antibody or The cell exocrine of its part.The signal peptide can be cut in cell secretory antibody from polypeptide.This kind of secretion signal Example be well-known and including for example in the US patent No.s 5,698,435,5,698,417, and 6, described in 204,023 Those secretion signals.
Carrier can be plasmid, single-stranded or double-stranded viral vector, single-stranded or double-stranded RNA or DNA phage vectors, phagocytosis The carrier of grain, sticking grain or any other purpose transgenosis., can be by using the well-known technology that DNA and RNA are imported to cell Examples of such carriers imports cell as polynucleotides.In the case of bacteriophage and viral vector, well-known sense can be also used Dye and transduction techniques, cell is imported using the virus of carrier as packaging or packing.Viral vector can be replication competent type or duplication Deficiency.In the latter case, viral breeding typically can only be sent out in supplement type (complementing) host cell It is raw, and need to use be loaded with produce particle necessary to a variety of virus compositions variety carrier.Using from existing DNA construct RNA, it is (special refering to such as WO 86/05807 and WO 89/01036, and US that cell free translation system can also be used for production albumen Profit number is 5,122,464).
The antibody of the present invention can be from any suitable host cell expression.Example bag available for the host cell of the present invention Prokaryotic, yeast or higher eukaryotic are included, and including but not limited to microorganism is as with containing purposeful antibody coding sequence Bacterium (such as Escherichia coli, bacillus subtilis that recombinant phage dna, DNA or the sticking grain DNA expression vectors of row are converted (B.subtilis), Enterobacter (Enterobacter), Erwinia (Erwinia), Klebsiella (Klebsiella), Proteus (Proteus), Salmonella (Salmonella), Serratia (Serratia) and Shigella (Shigella), and bacillus (Bacilli), pseudomonas (Pseudomonas) and streptomyces)；With containing There are yeast (such as saccharomyces (Saccharomyces), the Pichia pastoris of the recombinant yeast expression vector conversion of antibody coding sequence Belong to (Pichia), actinomyces (Actinomycetes), Kluyveromyces (Kluyveromyces), Schizosaccharomyces (Schizosaccharomyces), Mycotoruloides (Candida), trichoderma (Trichoderma), neurospora (Neurospora), and filamentous fungi, such as neurospora (Neurospora), Penicillium (Penicillium), Tolypocladium and aspergillus (Aspergillus))；With recombinant virus expression vector (such as bar containing antibody coding sequence Shape virus) infection insect cell system；With recombinant virus expression vector (such as cauliflower mosaic virus, CaMV；Or Tobacco mosaic Virus, TMV) infection, or the plant converted with the recombinant plasmid expression vector (such as Ti-plasmids) containing antibody coding sequence Cell system；Or (such as COS, CHO, BHK, 293 or 3T3 are thin for the mammalian cell system comprising recombinant expression construct body Born of the same parents).The construct contains promoter (such as metallothionein promoter) from mammalian cell gene group or from the food in one's mouth Promoter (such as adenoviral late promoter of newborn animal virus；Or vaccinia virus 7.5K promoters).
For the expression vector of prokaryotic host cell, one or more phenotypic selection markers genes are typically contained.Phenotype is selected Selecting marker gene is, such as coding assigns antibiotic resistance or provides the gene of the albumen of autotrophy requirement.Useful prokaryotic hosts The example of the expression vector of cell is included from commercially available plasmid such as pKK223-3 (Pharmacia Fine Chemicals,Uppsala,Sweden)、pGEM1(Promega Biotec,Madison,WI)、pET(Novagen, Madison, WI) and pRSET (Invitrogen, Carlsbad, CA) serial carrier (Studier, J Mol Biol 219: 37(1991)；And Schoepfer, Gene 124:83 (1993)) those carriers for being originated.It is generally used for restructuring protokaryon place The promoter sequence of chief cell expression vector includes T7, (Rosenberg et al., Gene 56:125 (1987)), beta-lactamase (penicillase), lactose promoter system (Chang et al., Nature 275:615(1978)；And Goeddel et al., Nature 281:544 (1979)), tryptophan (trp) promoter systems (Goeddel et al., Nucl Acids Res 8:4057 (1980)), and tac promoters (Sambrook et al., Molecular Cloning, A Laboratory Manual, 2 editions, Cold Spring Harbor Laboratory(1990))。
Yeast vector often contains replication orgin sequence, such as from 2 μ yeast plasmids, autonomously replicating sequence (ARS), opens Sub-area, poly-adenosine sequence, transcription terminator and selectable marker gene.The suitable promoter of yeast vector Sequence includes following promoters：Metallothionein, 3-phosphoglycerate kinases (Hitzeman et al., J Biol Chem 255:2073 (1980)) or other glycolytic ferments (Holland et al., Biochem 17:4900 (1978)) such as enolase, sweet Oily aldehyde -3- phosphate dehydrogenases, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3- phosphoric acid Monoglyceride mutase, pyruvate kinase, triose-phosphate isomerase, phosphogvlucoisomerase and glucokinase, etc..It is other For the appropriate carrier and promoter of Yeast expression, in Fleer et al., Gene 107:Further illustrated in 285 (1991).Its Its yeast and the appropriate promoters and carrier of yeast conversion scheme are well known in the art.Yeast conversion scheme It is well-known.Hinnen et al., Proc Natl Acad Sci 75:1929 (1978) describe such a scheme, It selects Trp in selective medium+Transformant.
Any eukaryotic cell culture is all feasible, the either culture from vertebrate or invertebrate Thing.The example of invertebral zooblast, including plant and insect cell (Luckow et al., Bio/Technology 6:47 (1988)；Miller et al., Genetic Engineering, Setlow et al., eds., vol.8, pp.277-9, Plenum Publishing(1986)；And Maeda et al., Nature 315:592(1985)).For example, rhabdovirus system can be used for Produce heterologous protein.In insect system, autogra-phacalifornica nuclear polyhedrosis virus (Autographa californica Nuclear polyhedrosis virus, AcNPV) carrier is can be used as to express alien gene.The virus is greedy on meadow Grown in noctuid (Spodoptera frugiperda) cell.Antibody coding sequence can be in AcNPV promoters (such as polyhedral body Protein promoter) control under be cloned.Other identified hosts include yellow-fever mosquito (Aedes), Drosophila melanogaster (Drosophila melanogaster) and silkworm (Bombyx mori).The transfected virus strain of a variety of various kinds is that the public can obtain , the Bm-5 strains of such as AcNPV L-1 variants and BmSNPV.In addition, as in the art it is well known that cotton, corn, Potato, soybean, morning glory (petunia), the plant cell cultures of tomato and tobacco also are used as host.
The breeding of vertebrate cells, vertebrate cells in culture medium (tissue culture medium (TCM)), can be a kind of conventional Step, although overcritical cell line is implicitly present in, it is needed such as the proprietary culture medium with unique factor, trophocyte, ginseng Read Tissue Culture, Kruse et al., eds., Academic Press (1973).Useful mammalian host cell line Example be monkey kidney；Human embryonic kidney cell line；Baby hamster kidney cell；Chinese hamster ovary cell/- DHFR (CHO, Urlaub et al., Proc Natl Acad Sci USA 77:4216(1980))；Mouse Sertoli cell；Human cervical carcinoma cell (such as HeLa)；Dog kidney Cell；Human pneumonocyte；Human liver cell；Mouse mammary tumor；And NS0 cells.
The conversion of host cell carrier is cultivated with producing antibody in conventional nutrient culture, and the culture medium contains Growth factor, vitamin, mineral matter etc., and it is suitable for the inducer of cell used and carrier.Conventional promoter sequence and Enhancer sequence is derived from the cytomegalovirus (CMV) of polyomavirus, adenovirus 2, simian virus 40 (SV40) and people.It is derived from The virus genomic DNA sequence dnas of SV40 can be used for providing other genetic elements (such as SV40 starting points, early and late promoter, increasing Hadron, montage and poly-adenosine site), with the expression structure gene order in mammalian host cell.Viral early stage and Late promoter is particularly useful, because being both easy to obtain as fragment from viral genome, the fragment also may be used Virus origin of replication can be contained.Exemplary expression vectors for mammalian host cell can obtain from commercial channel.
The culture medium that can be obtained from commercial channel such as Ham's F10, minimum essential medium (MEM), RPMI-1640 and The Eagle culture mediums (DMEM) of Dulbecco improvement are adapted to cultivate host cell.In addition, Ham et al., Meth Enzymol 58:44 (1979) and Barnes et al., Anal Biochem 102:255 (1980), and the US patent No.s 4,767,704；4, 657,866；4,560,655；5,122,469；5,712,163；Or any culture medium described in 6,048,728 can also be used as place The culture medium of chief cell is used.It is any in these culture mediums, if necessary all can hormone supplemented and/or other growth factors (such as insulin, transferrins or EGF), salt (such as chloride, such as sodium chloride, calcium chloride or magnesium chloride；And phosphorus Hydrochlorate), buffer solution (such as HEPES), nucleotides (such as adenosine and thymidine), antibiotic, trace element (be defined as inorganic compound, The ultimate density being typically present is in micromolar scope), and glucose or suitable energy source.Any other necessity Supplement, can appropriate concentration be included, be used as a design alternative.Condition of culture, such as temperature, pH value, be all It is known being suitable for cell in the art, and render transgenic can ideal express.
Pass through any of method in the art, so that it may obtain polynucleotide of interest, and determine the polynucleotides Nucleotide sequence.If for example, the nucleotide sequence of antibody is known, so that it may which the oligonucleotides assembling chemically synthesized is compiled Polynucleotides (such as Kutmeier et al., the Bio/Techniques 17 of code antibody:What 242 (1994) were described), Ran Houkuo Increase the oligonucleotides of connection, for example, pass through PCR.
Alternatively, the polynucleotides of encoding antibody can be produced from the nucleic acid for the cell for expressing the antibody.If containing coding The clone of the nucleic acid of certain specific antibodies be it is unavailable, but antibody molecule sequence be it is known, then can from appropriate sources as text Storehouse obtains the nucleic acid of encoding immune globulin, and the nucleic acid may is that has specific nucleic acid, institute to the cell for producing antibody The hybridoma for the antibody that cell is stated as selected to express the present invention.The suitable primer of configuration can be expanded for PCR.Then, make With any method well known in the art, the amplification of nucleic acid produced by PCR can be cloned into reproducible clone and carried In body.
Once nucleotide sequence and corresponding antibody amino acids sequence are determined, so that it may using known in the art The method for manipulating nucleotide sequence, such as DNA recombinant techniques, direct mutagenesis, PCR etc. (refer to, for example Sambrook et al., Molecular Cloning, A Laboratory Manual, 2 editions, Cold Spring Harbor Laboratory (1990)；And Ausubel et al., eds., Current Protocols in Molecular Biology, John Wiley＆Sons (1998), manipulates the nucleotide sequence of the antibody to obtain purpose equivalent as described herein, produces containing not With the antibody of amino acid sequence, for example, causing 49-Phe ,82-Ser,115-Arg,144-Met,145-Asn ,161-Arg,169-Met Human Connective tissue growth factor, missing and/or inserting.
The amino acid sequence of heavy chain and/or light variable domains can be checked in a well known manner, to identify CDR sequences Row, for example, by the comparison with other heavy chains and the known amino acid sequence of light chain variable region to determine the high changeability of sequence Region.Using conventional DNA recombinant techniques, can by one or more CDR insert framework region, for example insert people framework region make it is non- Human antibody humanization, as described above.The many nucleosides of purpose produced by the framework region and one or more CDR combination Antibody or at least encode its ED domain that acid, codified and IL-4 and/or IL-13 are specifically bound.For example, this method can For produce it is one or more participation intrachain disulfide bonds Variable Area cysteine residues amino acid substitution or missing, with Produce the antibody molecule for lacking one or more intrachain disulfide bonds.
The antibody or antibody fragment of the present invention can be used to detect IL-4 and/or IL- in biological sample in vitro or in vivo 13, therefore also can just detect expression IL-4 and/or IL-13 cell.In one embodiment, anti-IL-4 of the invention And/or IL-13 antibody is used to determine in tissue or IL-4 and/or IL-13 presence and level in the cell from the tissue. For example, in the immunoassays with the antibody of the present invention or antibody fragment, IL-4 and/or IL-13 can be determined in the tissue or work Level in sample product.Tissue or its biopsy samples can be freezed or fixed.Same Way or other methods can be used for determining IL-4 And/or IL-13 other properties, such as its level, cellular localization, mRNA level in-site, its mutation.
The above method can be used for for example diagnosing cancer in cancered subject in known will or doubt, wherein by the patient IL-4 the and/or IL-13 levels of middle measurement are compared with normal reference subject or standard.The measure of the present invention can also be used for diagnosis Arthritis or other autoimmune diseases being characterized with the infiltration and enrichment of B cell and differentiation GALT development.
Present invention also offers in order to study or diagnostic application and further mark monoclonal antibody, humanized antibody and Its epitope binding fragments.In certain embodiments, the mark is radiolabeled, fluorogen, chromophore, developer, or Metal ion.
A kind of diagnostic method is additionally provided, suffers from cancer wherein the labelled antibody or its epitope binding fragments are administered to doubt Disease, arthritis, autoimmune disease or other IL-4 and/or the disease of IL-13 mediations subject, and by the mark Distribution in subject's body is measured or monitored.
The antibody and its fragment of the present invention can be used as affinity purification agent.In the process, using the art The method known, antibody is fixed in solid phase, on such as glucan or agarose resin or filter paper.By fixed antibody with containing IL-4 and/or IL-13 sample or the cells contacting for being loaded with the IL-4 and/or IL-13 to be purified, then with suitable molten Agent wash holder, the solvent will remove sample in addition to IL-4 and/or IL-13 or to be purified cells almost all of thing Matter, IL-4 and/or IL-13 or to be purified cell are then combined on by the antibody of the fixed present invention.Finally, with another suitable Solvent (such as glycine buffer, pH 5.0) washing holder, this will discharge IL-4 and/or IL-13 or cell from antibody.
For diagnostic application, purpose antibody would generally be marked with detectable part.There are many marks to be available for utilizing, It is commonly divided into following a few classes：(a) radio isotope, such as36S、14C、125I、3H and131(antibody can use radio isotope mark to I Note, such as using Current Protocols in Immunology, vol.12, Coligen et al., editor, Wiley- Technology described in Interscience, New York (1991), and radioactivity can measure with scinticounting)；(b) fluorescence mark Note, such as Rare Earth Chelate (Europium chelate), fluorescein and its derivative, rhodamine and its derivative, red sulphonyl, Liz amine, algae Lactoferrin and Texas are red；Fluorescence labeling can use such as CurrentProtocols in Immunology (ibid) to disclose Technology be conjugated on antibody, wherein fluorescence can use fluorometric quantification；And (c) has a variety of zymolyte marks to be available for utilizing (US The patent No. 4,275,149 provide summary), enzyme can generally be catalyzed the chemical modification of chromogenic substrate, this can using multiple technologies come Measurement, for example enzyme can be catalyzed the change of substrate colors, and this can be weighed with spectrophotometric；Or, enzyme can change the glimmering of substrate Light or chemiluminescence.The technology of quantitative fluorescence change is that it is well known that for example using luminometer, or the mark can be to fluorescence Acceptor provides energy.The example of enzyme mark includes luciferase (for example, firefly luciferase and bacterial luciferase；US The patent No. 4,737,456), luciferin (luciferin), 2,3-dihydrophthalazinedione, malic dehydrogenase, Urease, peroxidase such as horseradish peroxidase (HRPO), alkaline phosphatase are beta galactosidase, glucoamylase, molten Bacterium enzyme, carbohydrate oxidase (such as glucose oxidase, galactose oxidase and glucose-6-phosphate dehydrogenase), Heterocyclic oxidases (such as uric acid Enzyme and xanthine oxidase), lactoperoxidase (lactoperoxiase), microperoxisome (microperoxiase) Deng.Make the technology of enzyme and antibody conjugate in O'Sullivan et al., Meth Enz, ed.Langone＆Van Vunakis, Described in Academic Press, New York, 73 (1981).
When being marked using these, there is suitable substrate to be available for utilization, for example：(i) it is available for horseradish peroxidase Hydroperoxidase (hydrogen peroxiase) is (such as adjacent as substrate, wherein hydroperoxidase oxidation dye precursors Phenylenediamine (OPD) or 3,3', 5,5'- tetramethyl benzidine hydrochloride (TMB))；(ii) it is available for alkaline phosphatase (AP) P-nitrophenyl phosphate is used as chromogenic substrate；And (iii) beta-D-galactosidase (β-D-Gal) can use chromogenic substrate (example Such as p-nitrophenyl-beta-D-galactosidase), or fluorogenic substrate such as 4- methylumbelliferyls base keto acyl-beta-D-galactosidase.
Other enzyme-substrate combinations are available for the art professional to utilize.For generality commentary, US patents are see Numbers 4,275,149 and 4,318,980.
Sometimes, mark is indirectly conjugated with antibody.For example, antibody can be with biotin-conjugated, any of the above described report is all Can be conjugated with avidin, vice versa.Biotin is optionally combined with avidin, therefore, and mark can be with Antibody is conjugated with the indirect mode.Or, in order to realize the indirect conjugation of mark, antibody is sewed with small haptens (such as digoxin) Close, one of above-mentioned different types of mark or report is conjugated with anti digoxin antibody.Therefore, can be real using second of antibody Now mark the indirect conjugation with antibody or mutain.
In another embodiment of the present invention, antibody need not be marked, and its presence can be used (another with antibody The secondary antibody of kind of form) labelled antibody that combines detects.
The antibody of the present invention can be used for any of assay method, such as competitive binding assay, directly or indirectly sandwich Determine and immune precipitation determination.Zola,Monoclonal Antibodies：A Manual of Techniques(CRC Press,Inc.1987)。
Competitive binding assay depend on reference material and the test specimen of tape label with it is competing in finite quantity antibody binding Strive ability.The amount of antigen and the amount of the reference material with antibody binding are inversely proportional in test specimen.For ease of determining the standard combined The amount of thing, antibody is typically insoluble before or after competition.As a result, can be with the reference material and test specimen of antibody binding Uncombined reference material and test specimen is conveniently separated.
Sandwich assay is directed to use with two kinds of antibody, and each all has the ability immunogen portions different from target to be detected (certainly Stator or epitope) combine.In sandwich assay, test specimen to be analyzed and be directly or indirectly fixed on solid support the A kind of antibody binding, second of the antibody then directly or indirectly marked is combined with combined test specimen, from And insoluble three moiety complex is formed, refering to such as US patent No.s 4,376,110.Second of antibody can use detectable in itself Part is marked (direct sandwich assay), or the combination that can be marked with anti-immunoglobulin antibody or with detectable part (indirect sandwich measure) is measured to other Suitable members of (such as antibody/antigen, receptor/ligand, enzyme/substrate).For example, a kind of The sandwich assay of type is that ELISA is determined, and in this case, the detectable part is enzyme.
Present invention additionally comprises Reagent Kit, such as it includes antibody, its fragment, homologue, its derivative, such as band Mark or have the cytotoxic compound that stops, and antibody operation instructions, the compound etc. that stops for killing specific cell type.Should Specification may include in vitro, the guidance of in vivo or in vitro use antibody, the compound that stops etc..Antibody can be liquid form or solid Body, typically lyophilized.The kit can be comprising other suitable reagents, such as buffer solution, reconstituted solutions and in order to make a reservation for use Other neccessary compositions on way.Consider with the packaged agent combination of scheduled volume and the specification for its purposes, the purposes For example for therapeutical uses or for carrying out diagnostic assay.When antibody is tape label, for example, marked with enzyme, then the examination Agent box may include the co-factor (substrate precursor for for example providing detectable chromophore or fluorogen) needed for substrate and enzyme.In addition, Including other additives, such as stabilizer, buffer solution (such as Block buffer or lysis buffer) may also comprise.Plurality of reagents Relative quantity can change and provide the concentrate of reagent solution, which provides customer flexibility, save space, save reagent Deng.These reagents can also dry powder form provide, typically lyophilized form, including excipient, it can provide and have in dissolving The reagent solution of debita spissitudo.
The antibody of the present invention can be used for treatment mammal.In one embodiment, for example, for the preclinical number of acquisition According to purpose, purpose antibody or equivalent are administered to non-human mammal.Exemplary non-human mammal to be treated, including Non-human primate, dog, cat, rodent and other mammals, wherein having carried out preclinical study.This lactation Animal can be need to use the animal model of the foundation of the disease of Antybody therapy, or the toxicity available for research purpose antibody.Each In such embodiment, dose escalation study can be carried out in mammal.
No matter antibody, whether there is second component (such as therapeutic agent portion conjugated therewith), either independent or and cell toxicant Sex factor is administered in combination, and can be used as therapeutic agent.The present invention relates to the therapy based on antibody, wherein being reserved to dynamic Thing, mammal or people apply the antibody of the present invention, to treat disease, obstacle or the situation of IL-4 and/or IL-13 mediations.
Term " treatment " used in the present invention refers to therapeutic treatment and preventative or precautionary measures.It refers to pre- It is anti-, cure, reverse, weaken, improve, minimize, suppress or stop morbid state, disease process, disease pathogenic factor (such as bacterium Or virus) or other unusual conditions ill-effect.
Therefore, the present invention also includes multivalent antibody, including double special anti-IL-4/IL-13 antibody, and it has what is be attached thereto Diagnose or control the effector molecule, atom or other materials for the treatment of functions.For example, antibody can have radiodiagnosis label or radioactivity Cytotoxicity atom or metal or cytotoxic substance such as ricin chain, be attached thereto for cancer in-vivo diagnostic or control Treat.
In addition, the present invention antibody can be additionally used in immunoassays, purification process and it is other use immunoglobulin or its The method of fragment.Such purposes is known from this area.
Correspondingly, the present invention also provides the anti-il-13 comprising the present invention and/or anti-IL-4 antibody or the combination of its fragment Thing, the antibody easily with pharmaceutically useful carrier, diluent or excipient composition, this is the Normal practice of this area.
Term " pharmaceutical composition " used in the present invention means the preparation of a variety of prepared products.Contain many of therapeutically effective amount The preparation of valency antibody is sterile aqueous solutions, liquid suspension or lyophilized form, optionally comprising stabilizer or excipient.
Term " obstacle " used in the present invention, which means, any can have benefited from the situation of Antybody therapy of the present invention.This includes Chronic and acute disorder or disease, including those tend to the pathological condition that makes mammal, especially people catch the obstacle. The nonrestrictive example for having obstacle to be treated includes cancer, inflammation, autoimmune disease, infection, cardiovascular disease herein Disease, respiratory disorder, sacred disease and metabolic disease.
The antibody of the present invention can be used to treat, suppress or prevention disease, such as the disease of allergic disease, Th2 mediation, IL- Disease, the disease of IL-4 mediations and/or the disease of IL-4/IL-13 mediations of 13 mediations.The example of such disease includes Huo Qijin Disease, asthma, allergic asthma, atopic dermatitis, atopic allergology, ulcerative colitis, chorionitis, allergic rhinitis, COPD3 idiopathic pulmonary fibrosis, chronic transplanting rejection, the pulmonary fibrosis of bleomycin induction, radiation-induced pulmonary fibrosis, lung Portion's granuloma, progressive systemic sclerosis, snail fever, liver fibrosis, kidney, Burkitt lymphoma, Hodgkin's disease, non-are suddenly Strange gold disease, Sezary syndrome, asthma, dense toxicity arthritis, dermatitis herpetiformis, chronic idiopathic urticaria, ulcerative colitis Pulmonary disorders that inflammation, chorionitis, Hypertrophic scar, Whipple diseases, benign prostatic hyperplasis, IL-4 acceptors work, IL-4 by The epithelial barrier of body mediation destroys the situation worked, the digestive system obstacle that IL-4 acceptors work, the allergia to medicine Reaction, Kawasaki disease, drepanocytosis, Churg-Strauss syndromes, Grave's diseases, pre-eclampsia, Sjogren's are integrated Levy, LADA lymphoproliferative syndrome, autoimmune hemolytic anemia, Barrett's oesophaguses, LADA Uveitis, pulmonary tuberculosis, cystic fibrosis, allergia broncho-pulmonary nosomycosis, chronic obstructive pulmonary disease, bleomycin are induced Tuberculosis and fibrosis, pulmonary alveolar proteinosis (pulmonary alveolar proteinosis), adult respiratory distress syndrome integrate Levy, sarcoidosis, hyper-IgE syndrome, idiopathic eosinophilia syndrome (idiopathic hypereosinophil Syndrome), LADA hair blister sick (autoimmune blistering disease), pemphigus vulgaris, epidermolysis Pemphigoid, myasthenia gravis, chronic fatigue syndrome, nephrosis.
Term " allergic disease " means pathological condition, and wherein patient is to a kind of material of non-immunogenic under normal circumstances It is super quick and make immune response.The general features of allergic disease is that IgE activates mast cell and causes inflammatory reaction (such as part Reaction, general reaction), this kind of reaction can cause the benign symptom as rhinorrhea, it is also possible to the anaphylaxis of threat to life Shock and death.The example of allergic disease includes but is not limited to allergic rhinitis (such as pollinosis), asthma, and (such as allergia is roared Breathe heavily), allergic dermatitis (such as eczema), contact dermatitis, food hypersenstivity and nettle rash (nettle rash (hive)).
" disease of Th2 mediations " as used herein means a kind of disease, and its pathology is (in whole or in part) by CD4+ The immune response (immune response of Th2 types) of Th2T lymphoid cells regulation and control is caused, and its feature terrain is into IL-4, IL-5, IL-9 And IL-13.The immune response of Th2 types and the production of some cell factors (such as IL-4, IL-13) and the antibody (such as IgE) of some classifications Raw and humoral immunity is relevant.The disease of Th2- mediations is characterized in Th2 cell factors (such as IL-4, IL-13) and/or some classes The elevated levels of presence of other antibody (such as IgE), including such as allergic disease (such as allergic rhinitis, atopic dermatitis, heavy breathing Breathe heavily (such as essential asthma), allergia airway disorders (AAD), anaphylactic shock, conjunctivitis), with IL-4 and/or IL-13 levels Increase relevant autoimmune disorders (such as rheumatoid arthritis, host vs grafts disease, nephrosis (such as nephrotic syndrome, wolf Sore ephritis)), and (such as virus, parasite, fungi, (such as white is read for the infection relevant with IL-4 and/or IL-13 level rises Pearl bacterium (C.albicans)) infection).Some cancers are relevant with IL-4 and/or IL-13 elevated levels, or induced with IL-4 And/or the cancer cell multiplication of IL-13 inductions it is relevant (such as B cell lymphoma, t cell lymphoma, Huppert's disease, head and neck cancer, Breast cancer and oophoroma).These cancers can be treated, suppress or prevented with the Ii gaud of the present invention.
Term " cancer " used in the present invention means or described the physiological status of mammal especially people, its typical case Feature is that cell grows without regulation and control.The example of cancer includes but is not limited to cancer (carcinoma), lymthoma, blastoma, meat Knurl and leukaemia.
Term " autoimmune disease " used in the present invention is meant due to individual autologous tissue and for autologous tissue Nonmalignant disease or obstacle.The example of autoimmune disease or obstacle includes but is not limited to inflammatory reaction such as inflammatory skin Disease, including psoriasis and dermatitis；Allergia situation such as eczema and asthma；It is other to be related to T cell infiltration and chronic inflammatory reaction Symptom；Atherosclerosis, diabetes (such as type i diabetes or insulin-dependent diabetes mellitus)；Multiple sclerosis and maincenter god Through system inflammation sexual dysfunction.
The antibody of the present invention can be used as the composition being administered alone, or can be used in combination with other activating agents.It is anti- Body can be with existing IL-13 therapies (such as existing IL-13 activating agents such as anti-il-13 R α l, IL-4/13Trap, anti-IL- 13) anti-IL-4 antibody, and existing IL-4 activating agents (such as anti-IL-4R, IL-4 mutein, IL-4/13Trap) is added to add Anti-il-13 antibody and IL-4 antibody (such as WO05/0076990 (CAT), WO03/092610 (Regeneron), WO00/64944 (Genetic Inst.) and WO2005/062967 (Tanox)) it is used for together in combination treatment.
The antibody of the present invention can be applied and/or prepared together with one or more other treatments or activating agent.When one When individual part is applied together with other therapeutic agent, part can be before other therapeutic agent be applied, while or being applied after administration.One As for, part and other activating agent are generally to provide the overlapping mode of therapeutic effect and applied.Can be with part of the invention Apply together or the other activating agent prepared together include such as panimmunity medicine, such as cyclosporine, methotrexate (MTX), Ah Mycin or cis-platinum, antibiotic, antifungal agent, antivirotic and immunotoxin.For example, when apply antagonist preventing, suppress or When treating lung inflammation or respiratory disorder (such as asthma), antagonist can be administered in combination with following：Phosphodiesterase inhibitors (such as phosphorus The inhibitor of acid diesters enzyme 4), bronchodilators (such as β2agonists, anticholinergic drug, theophylline), short acting beta-agonists are (such as husky fourth It is amine alcohol (albuterol), albuterol (salbuiamol), bambuterol, fenoterol [sigmal] l, isoetherine, different Third adrenaline, Levalbuterol (leva [iota] buterol), Australia's Cynarine, pirbuterol, Terbutaline and Tornlate), long-acting beta-agonist (such as Formoterol and salmeterol), short-acting anticholinergic drug (such as Ipratropium Bromide and oxygen support Bromine ammonium), long-acting anticholinergic (such as Tiotropium Bromide), theophylline (such as short acting formulation, durative action preparation), suction-type steroids (as times Chlorine rice pine, beclomethasone, budesonide, flunisolide, fluticasone propionate and fluoxyprednisolone), oral steroid (the bold and vigorous Buddhist nun of such as first Dragon, prednisolone, prednisolon and metacortandracin), short acting beta-agonists combined with anticholinergic drug (such as salbutamol/relax breathe heavily Spirit/Ipratropium Bromide and fenoterol/Ipratropium Bromide), long-acting beta activator and suction-type steroid combination be (as husky beautiful Special sieve/fluticasone and formoterol/budesonide), and mucolytic agent (such as Erdosteine, acetylcysteine, bromine Oneself new, carbocyslcine, guiiafencsin and organidin.
It is other to be co-administered to prevent, suppress or treat the conjunction of asthma (such as allergic asthma) with the antibody of the present invention Suitable co-therapeutic agent includes corticosteroid (such as beclomethasone, budesonide, fluticasone), color thuja acid salt, nedocromil, β Activator (such as albuterol, Terbutaline, bambuterol, fenoterol, reproterol, tolubuterol, salmeterol, Fomtero), zafirlukast, salmeterol, metacortandracin, prednisolone, theophylline, zileutron, montelukast and leukotriene Modifying agent.The part of the present invention can be adapted to treatment disease (disease of such as Th-2 mediations, the disease of YL-A mediations, IL- with a lot Diseases, the disease and cancer of IL-4 mediations of 13 mediations) co-therapeutic agent be co-administered, including cell factor, antalgesic/solution The medicine of a warm nature, antemetic and chemotherapeutics.
Such as well-known or described herein in the art, the antibody of the present invention can be carried with pharmaceutically useful composition forms For.The terms such as " physiologically acceptable ", " pharmacologically acceptable " mean the regulator batch of federal or state government Standard, or it has been included in American Pharmacopeia or other universally recognized pharmacopeia for animal especially people.
Anti- IL-4, anti-il-13 and double special anti-can be applied to mammal, especially people in any acceptable mode IL-4/IL-13 antibody.Input method is including but not limited to parenteral, subcutaneous, intraperitoneal, intrapulmonary, intranasal, Epidural cavity, suction and Oral route；If (intralesional) is applied in immunosuppressive therapy to be carried out, focus.Parenteral infusions include it is intramuscular, Intracutaneous, intravenous, intra-arterial or intraperitoneal are applied.Antibody or composition can facilitate approach to apply with any, for example, pass through infusion Or fast injection, absorbed by epithelium or mucous membrane lining (such as oral mucosa, rectum and intestinal mucosa), and can be with other lifes Thing activating agent is applied together.Using can be systemic or locality.In addition, perhaps needing the present invention with any appropriate approach Treatment antibody or composition introduce central nervous system, including intra-ventricle and intrathecal injection；Intraventricular injection is by means of wholeheartedly Intraventricular catheter, the conduit being for example connected with a storage such as Ao Moye storages (Ommaya reservoir).In addition, the antibody is suitable It is administered together in pulse infusion mode, especially in the way of antibody dosage successively decreases.Preferably, it is administered with injection system, preferably Ground is injected intravenously or is subcutaneously injected, and it is short-term or long-term to be partly dependent on administration.
A variety of other delivery systems are it is well known that the administration of the antibody available for the present invention, including to be for example packaged in Liposome, particulate, microcapsules (refer to Langer, Science 249:1527(1990)；Treat et al., in Liposomes in the Therapy of Infectious Disease and Cancer；Lopez-Berestein et al., editor, p.353-365(1989)；And Lopez-Berestein, ibid., p.317-327) and can express the restructuring of the compound Cell；Receptor-mediated endocytosis is (refering to Wu et al., J Biol Chem 262:4429(1987))；Nucleic acid is used as retrovirus Or the structure of the part of other carriers etc..
Active component can be also encapsulated in the microcapsules for example prepared with coascervation technologies or interface multimerization, For example respectively in colloid drug delivery systems (such as liposome, albumin microsphere, microemulsion, nano-particle and Nano capsule) or Hydroxymethyl cellulose or gelatin-microcapsule and poly- (methyl methacylate) microcapsules in microemulsion.Remington's Pharmaceutical Sciences (Lei Shi pharmacy is complete works of), 16 editions, A.Osal is edited in (1980) and is disclosed these technologies.
Also transpulmonary administration can be applied, such as using inhalator or sprayer, and the preparation with Alevaire.Antibody also may be used Apply patient lungs in the form of dry powder composite, refering to such as US patent No.s 6,514,496.
In a specific embodiment, it may desire to the treatment antibody in the region local application present invention for needing to treat Or composition；This may be accomplished by：Such as, but not limited to, local infusion, topical application, injection, via conduit, with Suppository or the mode of implantation；The implant be porous, non-porous or spawn, including film such as sialastic films or Fiber.Preferably, when applying the antibody of the present invention, it should be noted that do not absorbed or non-adsorbable material using albumen.
In another embodiment, the antibody can be delivered via controlled release durg delivery system.In one embodiment, it can be used Pump (refers to Langer, Science 249:1527(1990)；Sefton,CRC Crit Ref Biomed Eng 14:201 (1987)；Buchwald et al., Surgery 88:507(1980)；And Saudek et al., N Engl J Med 321:574 (1989)).In another embodiment, polymeric material can be used (to refer to Medical Applications of Controlled Release, Langer et al., editor, CRC Press (1974)；Controlled Drug Bioavailability, Drug Product Design and Performance, Smolen et al., eds., Wiley (1984)；Ranger et al., J Macromol Sci Rev Macromol Chem 23:61(1983)；Referring further to Levy etc. People, Science 228:190(1985)；During et al., Ann Neurol 25:351(1989)；And Howard et al., J Neurosurg 71:105(1989)).In yet another embodiment, controlled release durg delivery system can be placed on the vicinity of therapeutic target.
By mixing the polypeptide with required purity and optional " pharmaceutically useful " carrier, diluent, excipient or conventional In the art stabilizer (i.e. buffer, stabilizer, preservative, isotonic agent, non-ionic detergent, antioxidant with And other multiple additives), refering to Remington's Pharmaceutical Sciences (Lei Shi pharmacy is complete works of), 16th Version, Osol, ed. (1980), polypeptide or Antybody therapy preparation can be prepared into lyophilized formulations or aqueous solution storage.These additives exist Under dosage used and concentration, to recipient typically all without toxicity, therefore, excipient, diluent, carrier etc. are pharmaceutically useful.
" separation " or " purifying " antibody is originated or derived protein substantially free of cellular material, or from cell or tissue Other contaminating proteins of culture medium, or substantially free of precursor or other compounds in the case of chemical synthesis.It is " basic It is upper to be free of cellular material that " this word includes antibody preparation, and the cellular component of wherein polypeptide/albumen and cell is separated, described thin The antibody can be produced with separation or reorganization in the cellular component of born of the same parents.Therefore, the antibody substantially free of cellular material includes dirt Contaminate the antibody preparation that albumen is below about 30%, 20%, 10%, 5%, 2.5% or 1% (dry weight).When antibody is with recombination form During generation, it is also preferred that substantially free of culture medium, i.e., with protein product stereometer, culture medium content is below about 20%, 10%, 5%th, 2.5% or 1%.When antibody is produced in chemical synthesis mode, preferably substantially free from precursor or other chemistry Product and reagent, i.e. purpose antibody are and precursor or are related to other chemicals that albumen synthesizes and separate.Therefore, these antibody Product contains other chemical combination beyond precursor or purpose antibody below about 30%, 20%, 10%, 5% or 1% (dry weight) Thing.In yet other embodiments, antibody is isolated or purified.
Term " as little as undetectable aggregation level " used herein, refers in sample contain no more than 5%, is no more than 4%th, no more than 3%, no more than 2%, no more than 1% and be often no more than 0.5% aggregation (based on protein by weight), for example with Efficient size exclusion chromatography method (HPSEC) measurement.
Term " as little as undetectable fragmentation levels " used herein, refers to for example at one determined by HPSEC Contain in unimodal place, or such as two (2) peak (heavy chain and light chain) places, sample determined by reduction capillary gel electrophoresis (rCGE) Have equal to or higher than 80%, 85%, 90%, 95%, 98% or 99% total protein, and without respectively higher than 5%, higher than 4%, height In 3%, higher than 2%, higher than 1%, or it is other unimodal higher than 0.5% total protein.RCGE used herein refers to reducing condition Under capillary gel electrophoresis, the reducing condition is enough to make the disulfide bond in antibody or Antibody types molecule or antibody derived molecules It is reduced.
In the liquid preparation containing IL-4 and/or IL-13 antibody or its binding fragment, term used herein is " steady Fixed " and " stable " refer to the antibody or its antigen-binding fragment in preparation, in given manufacture, preparation, transport and storage bar Under part, for the resistance of thermally and chemically unfolding, aggregation, degraded or fragmentation." stabilization " preparation of the present invention is given Manufacture, preparation, transport and condition of storage under, can be held equal to or higher than 80%, 85%, 90%, 95%, 98%, 99% or 99.5% bioactivity.The stability of the antibody preparation, can be assessed according to the degree of aggregation, degraded or fragmentation, and It is compared with reference；The method of use is known for professionals in the art, including but not limited to rCGE, dodecane Base sodium sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and HPSEC.
Term " carrier " refers to diluent, adjuvant, excipient or the carrier applied together with therapeutic agent.This kind of physiology is carried Body can be sterile liquid, such as water and oil, including oil, animal, the oil of plant or synthesis source, such as peanut oil, soybean Oil, mineral oil, sesame oil etc..When pharmaceutical composition is intravenous administration, water is suitable carrier.Saline solution and grape The aqueous solution of sugar and glycerine can also be used as liquid-carrier, in particular for Injectable solution.Suitable drug excipient bag Include starch, glucose, lactose, sucrose, gelatin, malt, rice (rice), flour, chalk, silica gel, odium stearate, monostearate sweet Grease, talcum, sodium chloride, skimmed milk power, glycerine, propane diols, water, ethanol etc..If desired, said composition also can be containing few The wetting agent or emulsifying agent of amount, or pH buffer.Said composition can take solution, supensoid agent, emulsion, tablet, pill, capsule The forms such as agent, powder, sustained release preparation, reservoir (depot).Said composition can be matched somebody with somebody with traditional binder and carrier such as triglycerides Suppository is made.Oral formulations can contain standard vector, mannitol, lactose, starch, magnesium stearate, the saccharin sodium of such as pharmaceutical grade (sodium saccharine), cellulose, magnesium carbonate etc..The example of appropriate carrier is in " Remington's It is described in Pharmaceutical Sciences, Martin ".This based composition is preferably pure by the antibody containing effective dose Change form antibody, and appropriate carrier is in the form of providing and be adapted to apply to patient.As in the art known, said preparation is by structure Build to be suitable for the mode applied.
Buffer solution, which helps to maintain pH value, to be similar in the range of physiological condition.The concentration model that preferred buffer is present It is about 2mM to about 50mM to enclose.Being suitable for the buffer solution of the present invention includes organic acid and inorganic acid and its salt, such as lemon Phthalate buffer (such as monosodium citrate-disodium citrate mixture, citric acid-trisodium citrate mixture, citric acid-lemon Single sodium mixture of lemon acid etc.), Succinate Buffer (such as butanedioic acid-mono succinate sodium mixture, butanedioic acid-sodium hydroxide Mixture, butanedioic acid-disodium succinate mixture etc.), tartrate buffer (such as tartaric acid-sodium tartrate mixture, wine Stone acid-potassium tartrate mixture, tartaric acid-sodium hydroxide mixture etc.), fumarate buffer (such as fumaric acid-fumaric acid Single sodium mixture, fumaric acid-Disodium fumarate mixture, monosodium fumarate-Disodium fumarate mixture etc.), gluconate delay Fliud flushing (such as gluconic acid-gluconic acid sodium salt mixture, gluconic acid-sodium hydroxide mixture, gluconic acid-potassium gluconate mixture Deng), oxalic acid salt buffer (such as oxalic acid-sodium oxalate mixture, oxalic acid-sodium hydroxide mixture, oxalic acid-potassium oxalate mixture Deng), lactate buffer (such as lactic acid-sodium lactate mixture, lactic acid-sodium hydroxide mixture, lactic acid-potassium lactate mixture Deng) and acetate buffer (such as acetic acid-sodium acetate mixture, acetic acid-sodium hydroxide mixture).Phosphate-buffered Liquid, carbonate buffer solution, histidine buffering liquid, triethylamine salt such as Tris, HEPES and other known such buffer solution are equal It can use.
Preservative can be added to postpone microorganism growth, addition scope can be 0.2%-1% (w/v).Suitable for this hair Bright preservative includes phenol, phenmethylol, metacresol, methyl p-hydroxybenzoate, propylparaben, octadecyl two Methyl-benzyl ammonium chloride, benzyaconium halide (such as chloride, bromide and iodide), the own diamine of chlorine, to hydroxyl Benzoic acid alkyl base ester such as methyl p-hydroxybenzoate or propyl ester, catechol, resorcinol, cyclohexanol and 3- amylalcohols.
The presence of isotonic agent (isotonicifier) can ensure that the physiology isotonicity of the fluid composition of the present invention, and it is wrapped Include sugar alcohol more than multi-sugar alcohol, preferably ternary or ternary, such as glycerine, erythrite, arabitol, xylitol, sorbierite with And mannitol.In view of the relative quantity of other compositions, polyalcohol can the amount of about 0.1% to about 25% (weight) exist, preferably Ground 1% to 5%.
Stabilizer refers to the extensive excipient of species, and its envelop of function can dissolve or contribute to from filler to by therapeutic agent Prevention denaturation or viscous additive on the wall.Typical stabilizer can be multi-sugar alcohol；Amino acid, such as arginine, rely Propylhomoserin, glycine, glutamine, asparagine, histidine, alanine, ornithine, L-Leu, 2- phenylalanines, paddy ammonia Acid, threonine etc.；Organic sugar or sugar alcohol, such as lactose, trehalose, stachyose, arabitol, erythrite, mannitol, sorbierite, wood Sugar alcohol, ribitol, myo-inositol (myoinisitol), galactitol, glycerine etc., including cyclitol such as inositol；Polyethylene glycol；Ammonia Base acid polymer；Sulfur-bearing reducing agent, such as urea, glutathione, lipoic acid, sodium thioglycolate, thioglycerol, α-MTG And sodium thiosulfate；Low molecular weight polypeptide is (i.e.<10 residues)；It is protein, such as human serum albumins, fetal bovine serum albumin, bright Glue or immunoglobulin；Hydrophilic polymer, such as polyvinylpyrrolidone, carbohydrate, monose, such as xylose, mannose, fructose, grape Sugar；Disaccharides, such as lactose, maltose and sucrose；Trisaccharide, such as gossypose；Polysaccharide, such as glucan.Stabilizer scope is often to live The 0.1 to 10,000w/w of property protein part.
Other a variety of excipient include filler (such as starch), chelating agent (such as EDTA), antioxidant (such as ascorbic acid, Methionine or vitamin E) and cosolvent.
The need for institute's fixture body idicatio, this paper preparation can also include more than one reactive compounds, preferably Those have the compound that complementary activity adversely influences each other.For example, may desire to further provide for immunodepressant.This Class compound molecule exists to effectively realize the combination of expected purpose amount.
Term " surfactant " used herein refers to the organic matter with amphiphilic structure, the base being inclined to by opposing solubility Group, typically one oil-soluble hydrocarbon chain and a water soluble ion group composition.Surfactant can be according to surfactant moiety Electric charge and be divided into anionic, cationic and nonionic surface active agent.Surfactant pass through frequently as wetting agent, Emulsifying agent, solubilizer and dispersant, pharmaceutical composition and biologic material products for a variety of various kinds.
Nonionic surface active agent or detergent (also known as " wetting agent ") can be added to help the dissolving of therapeutic agent, and Treatment albumen is protected to avoid vibrating caused aggregation, also make it that preparation stress (shear surface exposed to shearing force surface Stress) without causing the denaturation of albumen.Suitable nonionic surface active agent include polysorbate (20,80 etc.), Polyoxamer (184,188 etc.),Polyalcohol and polyoxyethylene sorbitan monoether ( Deng).Nonionic surface active agent existence range can be about 0.05mg/ml extremely About 1.0mg/ml, preferably about 0.07mg/ml are to about 0.2mg/ml.
Term " inorganic salts " used herein refer to it is any because in sour hydrogen or acid it is part or all of by metal or rise metal The group displacement of effect and the not carbon compound generated, and be commonly used as in pharmaceutical composition and biomaterial preparation for Power modulating compound.Most common inorganic salts are NaCl, KCl, NaH2PO4Deng.
Present invention resides in the commercial refrigerator and freezer temperature in Doctor's office or laboratory (such as from about -20 DEG C to about 5 DEG C) There is down the liquid preparation of stability, aforementioned stable is assessed with for example efficient size exclusion chromatography method (HPSEC), is used In storage purpose, e.g., from about 60 days, about 120 days, about 180 days, about 1 year, about 2 years or more.The liquid preparation of the present invention is in room The stability of at least multiple hours is also show under temperature, for example, is assessed according to HSPEC, such as before the use 1 hour, 2 small When or about 3 hours.
Term " small molecule " and similar terms include but is not limited to peptide, plain peptidomimetic (peptidomimetics), amino acid, Amino acid analogue, polynucleotides, polynucleotides analog, nucleotides, nucleotide analog, molecular weight are every mole and are less than about 10,000 grams organic or inorganic compound (i.e. including it is miscellaneous it is organic and/organo-metallic compound), molecular weight be every mole be less than About 5,000 grams of organic or inorganic compound, molecular weight be every mole be less than about 1,000 grams organic or inorganic compound, point Son amount is less than about 500 grams of organic or inorganic compound for every mole, and the salt of this kind of compound, ester and other pharmaceutically useful Form.
Therefore, in the case of cancer, antibody of the invention can be administered alone, also can be with other types for the treatment of of cancer It is administered in combination, including traditional chemotherapeutics (taxol (paclitaxel), carboplatin (carboplatin), cis-platinum (cisplatin) and Doxorubicin (doxorubicin)), anti-EGFR agent (Gefitinib (gefitinib), Erlotinib (erlotinib) and Cetuximab (cetuximab)), anti-angiogenic agent (bevacizumab (bevacizumab) and easypro Buddhist nun For Buddhist nun (sunitinib)), and immunomodulator such as interferon-' alpha ' and Thalidomide (thalidomide).
Term " therapeutic agent " used herein refers to can be used for being metabolized to abnormal IL-4 and/or IL-13 and activity is related Treatment, management or the improved any activating agent of disease, obstacle, illness etc..
In addition, the antibody of the present invention can be conjugated with wide variety of effector molecules, such as heterologous polypeptide, medicine, radioactive nucleus Thuja acid or toxin, refering to such as WO 92/08495；WO 91/14438；WO 89/12624；The US patent No.s 5,314,995；And EPO 396,387.Antibody and its fragment can be conjugated with treatment part, and for example cytotoxin (for example cytostatics or kills cell Agent), (for example alpha emitter is such as therapeutic agent or radioactive metal ion213Bi).Cytotoxin or cytotoxic agent include any damage The activating agent of evil cell.Example includes taxol (paclitaxol), Cytochalasin B (cytochalasin B), Gramicidin D (gramicidin D), Ethidium Bromide (ethidium bromide), emetine (emetine), mitomycin (mitomycin), Etoposide (etoposide), Teniposide (tenoposide), vincristine (vincristine), vincaleukoblastinum (vinblastine), colchicin (colchicine), Doxorubicin (doxorubicin), daunorubicin (daunorubicin), dihydroxy anthraquinone (dihydroxy anthracindione), mitoxantrone (mitoxantrone), rice Draw mycin (mithramycin), D actinomycin D (actinomycin D), 1- boldenones (1- Dehydrotestosterone), glucocorticoid (glucocorticoids), procaine (procaine), totokaine (tetracaine), lidocaine (lidocaine), Propranolol (propranolol) and puromycin (puromycin) and Its analog or homologue.Therapeutic agent includes but is not limited to antimetabolite (such as methotrexate (MTX) (methotrexate), 6- sulfydryls Purine (6-mercaptopurine), 6-thioguanine (6-thioguanine), cytarabine (cytarabine), 5- fluorine Urea pyrimidine (5-fluorouracil) and dacarbazine (decarbazine)), alkylating agent (such as mustargen (mechlorethamine), Chlorambucil (chlorambucil), melphalan (melphalan), BCNU (carmustine (BSNU)) and lomustine (lomustine (CCNU)), endoxan (cyclophosphamide), disappear in vain Pacify (busulfan), dibromannitol (dibromomannitol), streptozotocin (streptozotocin), mitomycin C (mitomycin C) and along dichlorodiamine platinum (II) (DDP) cis-platinum (cisplatin)), anthracycline (anthracyclines) (such as daunorubicin (daunorubicin), daunomycin (daunomycin) and Doxorubicin (doxorubicin)), antibiosis Element (such as dactinomycin D (dactinomycin), D actinomycin D (actinomycin), bleomycin (bleomycin), meter La Mycin (mithramycin) and anthramycin (anthramycin (AMC))), and antimitotic agent (such as vincristine (vincristine) and vincaleukoblastinum (vinblastine)).
Such treatment part and the technology of antibody conjugate is set to be it is well known that refering to such as Arnon et al., in Monoclonal Antibodies and Cancer Therapy, Reisfeld et al. (eds.), p.243-56Alan R.Liss(1985)；Hellstrom et al., in Controlled Drug Delivery, 2nd ed., Robinson et al., eds.,p.623-53,Marcel Dekker(1987)；Thorpe,in Monoclonal Antibodies'84: Biological And Clinical Applications, Pinchera et al., eds., p.475-506 (1985)； Monoclonal Antibodies For Cancer Detection and Therapy, Baldwin et al., eds., p.303-16,Academic Press(1985)；With Thorpe et al., Immunol Rev 62:119(1982).Alternatively, resist Body can with second of antibody conjugate, to form the different conjugate of antibody, such as bifunctional antibody, refering to such as US patent No.s 4,676, 980。
The conjugate of the present invention can be used for changing given biological respinse, and therapeutic agent or drug moiety are understood not to only It is limited to traditional chemotherapeutant.For example, the drug moiety can be albumen or polypeptide with required bioactivity.This kind of egg It may include in vain, for example toxin, such as abrin, ricin A, Pseudomonas exotoxin, or diphtheria toxin；Albumen, Such as TNF, alpha-interferon, beta-interferon, nerve growth factor, platelet derived growth factor, tissue plasmin Activator；Apoptosis agent, such as TNF-α, TNF-β, AIM I (WO 97/33899), AIM II (WO 97/34911), FasL (Takahashi et al., Int Immunol, 6:1567(1994)),VEGF(WO 99/23105)；Thrombosis；It is anti-angiogenic Generating agent, such as angiostatin or endostatin；Or biological respinse modifying agent, such as lymphokine, interleukin 1 (IL- 1), interleukin 2 (IL-2), interleukin-6 (IL-6), granulocyte macrophage colony stimulating factor (GM-CSF), Granulocyte colony stimulating factor (GCSF) or other growth factors.
Preparation for applying in vivo must be sterile.This can be realized for example, by aseptic filtration membrane filtration.For example, The liquid preparation of the present invention can be filtered and sterilized by using 0.2 μm or 0.22 μm of filter.
Spacetabs type product can be prepared.The Suitable examples of spacetabs type product include the solid hydrophobic polymers containing antibody Semi-permeable matrix, the matrix is in the form of formed article, such as film or matrix.The example of spacetabs type matrix includes polyester, water Gel (such as poly- (HEMA), poly- (vinyl alcohol), polylactide (the US patent No.s 3,773,919), L- paddy The copolymer of propylhomoserin and ethyl-L-glutamate ester, nondegradable ethylene-vinyl acetate, degradable lactic acid-ethanol are total to Polymers (Injectable microspheres being for example made up of lactic acid-ethanol copolymer) and poly- D- (-) -3-hydroxybutyrate.Such as second The polymer of alkene-vinylacetate and lactic acid-ethanol etc. can discharge molecule up to more than 100 days, but some hydrogels are released The time for putting albumen is then shorter.Depending on involved mechanism, it can work up for stable rational strategy.If for example, It was found that aggregation of multiple is to be exchanged by thio-disulfide and form intermolecular S -- S, then residual by modifying sulfydryl Base, it is freeze-dried from acid solution, control water capacity, uses appropriate additive, 49-Phe ,82-Ser,115-Arg,144-Met,145-Asn ,161-Arg,169-Met Human Connective tissue growth factor and the special polymerization of exploitation Thing base composition can just reach stabilization.
Antibody or variant compositions will be prepared in the way of meeting good medical practice, quantitative and administration.This respect is examined The factor of worry includes the specific obstacle to be controlled, the specific mammal to be controlled or people, the clinical condition of individual patient, original of causing a disease Other factorses known to cause, delivering activating agent position, medication, dosage regimen and medical worker.What is be administered is anti- " therapeutically effective amount " of body or variant will depend on these consideration, it is possible to be in order to prevent, improve or treat certain IL-4 and/ Or minimum flow necessary to the diseases of IL-13 mediations, situation or obstacle.
Optionally, antibody or variant currently used for prevention or treatment together with discussing one or more activating agents of obstacle Prepare.The effective dose of such other activating agents depends on amount, obstacle or the type for the treatment of of antibody present in preparation, Yi Jishang The other factorses that face is discussed.These are used generally as dosage used before this and by same method of administration, or are this The pact of preceding dosage used is from 1 to 99%.
Term used herein " effective dose " means the amount of following therapies (such as prevention or therapeutically active agent), the amount It is enough to reduce the seriousness of the disease of IL-4 and/or IL-13 mediations and/or shortens its duration, improves one or more Symptom, prevents advancing of disease that IL-4 and/or IL-13 are mediated or the degeneration for causing disease, or be enough to prevent IL-4 and/or Development, recurrence, breaking-out or the progress of the disease or one or more symptom of IL-13 mediations, or strengthen or improve another right The prevention of the useful therapy (such as another therapeutically active agent) of disease for the treatment of IL-4 and/or IL-13 mediations and/or control curative effect Really.
The amount of effective treatment antibody or its fragment will depend on the disease in the use or treatment of specified disease or situation The property of disease or situation, and can be determined by the clinical technology of standard.When it is possible, it can first show that dose-response is bent in vitro The pharmaceutical composition of line and the present invention.If suitable animal model system can use, dose-response curve can be equally obtained, And utilize its extrapolated suitable people's dosage for putting into practice methods known in the art.But, the general knowledge based on this area has Effect ground promote reduction inflammatory effect pharmaceutical composition, for example, available local treatment agent concentration be about 5 to 20ng/ml it Between, preferably about 10 between 20ng/ml.
In preferred embodiments, administration can be subcutaneously injected in the aqueous solution for the treatment of polypeptide, antibody or its fragment.Often The scope of secondary dosage can be about 0.5mg to about 50mg by every kilopond gauge, or it is highly preferred that be calculated as about by every kg body weight 3mg to about 30mg.For specific disease, PATIENT POPULATION, method of application etc., the dosage can be empirically determined, to put into practice this skill Known method of pharmacy in art field.
Depending on many clinical factors, include the susceptibility of disease type, disease severity and patient for treatment's agent, Hypodermic dosage arrangement can change once in a week in the range of once a day.
The invention provides the method for the liquid preparation for preparing antibody or itself IL-4 and/or IL-13 binding fragment, it includes The fraction of antibody purification is concentrated into about 15mg/ml, about 20mg/ml, about 30mg/ml, about 40mg/ml, about 50mg/ml, about 60mg/ml, about 70mg/ml, about 80mg/ml, about 90mg/ml, about 100mg/ml, about 200mg/ml, about 250mg/ml, about 300mg/ml or higher ultimate density, for example using with appropriate molecular weight (mw) cutoff value (cutoff) (such as it F(ab')2The cutoff value of fragment is 30KD；For FabThe cutoff value of fragment be 10KD) semipermeable membrane.
In addition, the present invention also includes liquid preparation stable, with the purpose product for improving Half-life in vivo.Cause This, purpose antibody subject (preferably people) internal half-life period be more than 3 days, more than 7 days, more than 10 days, more than 15 days, More than 25 days, more than 30 days, more than 35 days, more than 40 days, more than 45 days, more than 2 months, more than March, more than April, more than May Or it is longer.
In order to extend the serum circulation of antibody in vivo, the technology of a variety of various kinds can be used.For example, inert polymer molecule Such as high molecular weight polyethylene glycol (PEG), the N-terminal or C-terminal of antibody can be conjugated to by PEG locus specificity or by relying ammonia ε amino is connected on antibody present on sour residue, wherein can be with or without multifunctional linker.Can use causes biology The minimum linear or branch polymer of loss of activity derives.Conjugation can closely be monitored by SDS-PAGE and mass spectrum, with true Protect PEG molecules and the appropriate of antibody is conjugated.Unreacted PEG can be sewed by size exclusion or ion-exchange chromatography with antibody-PEG Compound is separated.Using method known to those skilled in the art, such as immunoassay as described herein can determine PEG and spread out The binding activity and in vivo efficacy of raw antibody.
There is the antibody of increased half-life period in vivo, also can be by will one or more amino acid modified (i.e. substitutions, slotting Enter or lack) introduce IgG constant domains or its FcR binding fragments (such as FeOr hinge FeDomain fragment) produce, refering to example Such as WO 98/23289；WO 97/34631；And the US patent No.s 6,277,375.
In addition, antibody can be conjugated with albumin make it that antibody is more stable in vivo, or there is longer half-life period in vivo. These technologies are well known in the art, refering to such as WO 93/15199, WO 93/15200 and WO 01/77137；With And EPO 413,622.Antibody also can for example, by glycosylation, acetylation, phosphorylation, amidatioon, with known protection group/blocking group Derivatization, proteolysis cutting, it is connected with cell ligand or other albumen etc. to modify.
In an embodiment, it is formulated as being suitable for the medicine of people's intravenous administration according to conventional steps Composition.Generally, the composition of intravenous administration is the solution in sterile isotonic aqueous buffer solution., should in necessary situation Composition can also include solubilizer and local anesthetic such as lidocaine or other " cacaine " class anesthetic, to mitigate injection site Pain.Generally, Multiple components are individually to be supplied or mixed supply in the form of unit dose, such as in sealing Drying freeze-dried powder or without the form of aqueous concentrate in container, the sealing container such as ampoule bottle or capsule, and the amount of lined out activity composition. When composition is administered with infusion, it can be dispersed in the infusion bottle containing sterile pharmaceutical grade water or salt solution.Work as combination When thing is administered with injection system, it is possible to provide the ampoule bottle of sterile water for injection or salt solution, for example, provide in a kit form so that Composition can be mixed first before administration.
The present invention is also provided, and liquid preparation of the invention is installed in sealing container, in such as ampoule bottle or capsule (sachet), The amount of purpose product is indicated thereon.The liquid preparation of the present invention can hold in the sealing for indicating the amount of antibody or antibody fragment and concentration In device.For example, the liquid preparation of the present invention can be supplied in sealing container, its IL-4 and/or IL-13 antibody having is at least 15mg/ml、20mg/ml、30mg/ml、40mg/ml、50mg/ml、60mg/ml、70mg/ml、80mg/ml、90mg/ml、 100mg/ml, 150mg/ml, 200mg/ml, 250mg/ml, or 300mg/ml, with 1ml, 2ml, 3ml, 4ml, 5ml, 6ml, 7ml, 8ml, 9ml, 10ml, 15ml or 20ml amount.
There is provided containing preparing article to above-mentioned treating dysfunction utility.This, which prepares article, includes container and label. Suitable container includes such as bottle, bottle, syringe and test tube.Container can be formed from multiple material, such as glass or plastics. Container accommodates the composition of the situation or disease that can effectively diagnose, prevent or treat IL-4 and/or IL-13 mediations, and can have Having sterile access port, (such as container can be intravenous solution bag or bottle, and it has the plug that can be punctured by hypodermic needle Son).Label or subsidiary label on container indicate that said composition is for treating selected situation.This prepares article and can also wrapped Second container is included, it contains pharmaceutically useful buffer solution, such as phosphate buffered saline solution, Ringer's solution and glucose solution. It may also include the required other materials of position from business and user, including buffer solution, diluent, filter, syringe needle, The package insert of syringe and operation instruction.
In order to which technical staff is favourable, the present invention will be illustrated with following non-limiting examples, and the example describes one A little present invention can embodiment of the nationality to implement or the present invention can be implemented wherein.
Embodiment
Embodiment 1:The sequencing of mouse anti human IL-13 monoclonal antibody clones B-B13 Fv domains
Reagent used in following method is purchased from Cell Sciences, Inc. (Canton, MA, USA) mouse Anti-il-13 monoclonal antibody clone B-B13.Cell Sciences for antibody B-B13 preparation business Diaclone (France retail trader of the U.S.).
Anti-il-13 monoclonal antibody clone B-B13 amino acid sequence is to utilize Edman N-terminals sequencing technologies and mass spectrum point The combine measured of analysis.Antibody passes through the processing of following distinct methods, to produce polypeptide or fragments of peptides, these fragments and then use Different method classification separation are sequenced and liquid chromatography/mass spectrometry/mass spectrum (LC- to prepare sample with Edman N-terminals later MS/MS) analyze, this is matched with related protein sequence database peptide.
The SDS-Page of antibody, with or without overfocus paddy aminopeptidase (pyrogluamino) processing with separate heavy chain and Light chain, then trace to Kynoar (PVDF) film and and carry out band Edman N-terminals sequencing.
With the specific proteases limitedly partial hydrolysis of antibody, then simultaneously trace is to pvdf membrane and goes forward side by side by progress SDS-Page The Edman N-terminals sequencing of row band.
Finite part chemical cleavage is carried out to whole antibody or heavy chain and light chain SDS-Page gel-tapes, then carried out SDS-Page and trace are to pvdf membrane and and carry out the Edman N-terminals of band and be sequenced.
The SDS-Page gel-tapes of whole antibody or heavy chain and light chain are gone forward side by side with specific proteases progress proteolysis Row LC/MS/MS is analyzed.
The SDS-Page gel-tapes of heavy chain and light chain are subjected to proteolysis with specific proteases, high back voltage is then used Chromatographic fractionation separates (rp-hplc), then carries out the sequencing of Edman N-terminals and LC/MS/MS analyses of each fraction.
Make limited proteolysis to antibody with papain, pass through SDS-Page classification separation Fd (heavy chain of antibody VH- CH1 fragments) gel-tape, with specific proteases proteolysis, reverse high performance liquid chromatography (rp-hplc), then carry out each fraction Edman N-terminals sequencing and LC/MS/MS analysis.
Embodiment 2:Mouse anti human IL-4 monoclonal antibody clones 8D4-8 Fv domains sequencing
The anti-IL-4 monoclonal antibody clones 8D4-8 of reagent mouse is purchased from Biozol diagnostica Vertrieb GmbH (Eching, Germany).Biozol is the BioLegend (San Diego, CA, USA) of production 8D4-8 antibody retail trader of Germany.
The amino acid sequence of the anti-IL-4 monoclonal antibodies of mouse (clone 8D4-8) is to utilize Edman sequencings and mass spectral analysis (Pham et al., 2006, Anal.Biochem.352 of combine measured:77-86；Roberts et al., 2005, Anal.Chem.67:3613-25).In short, antibody is first separated into light chain and heavy chain, then each chain sequence specific Protease or chemical method cutting.Obtained peptide is separated with reverse chromatograms and uses substance assistant laser desorpted/MALDI-MS (MALDI) and/or LC-MS/MS analysis.Unique peptide and complete heavy chain and light chain and then progress Edman sequencings, with accurate Ground determines the sequence of protein.
Embodiment 3:The humanization of mouse anti human IL-13 monoclonal antibody clones B-B13 Fv domains
Humanization code described herein is used to realize the humanization of B-B13 clones.It is recommended that the shape of six humanizations To solve problematic residue, (deacylation amine site, the methionine exposed to solvent, acid are unstable for mutation in formula, including CDR Position).
B-B13 VL＆VH sequences and Protein Data Bank (PDB) version in July, 2007 carry out blast.Retrieve big Most similar light chains and heavy chain amino acid sequence.It was found that most homologous for 1EGJ in variable light.It was found that in variable heavy chain most It is homologous for 1FNS.1EGJ＆1FNS structures are used to build the Homology model of variable domains, then utilize molecule manipulation ring The standardization program implemented in border (MOE) carries out energy minimization to it.MOE is provided by Chemical Computing group A set of comprehensive Computer-Aided Drug Design software.Thereafter it is implicit in broad sense Bonn to B-B13 3D Homology models The molecular dynamics (MD) for carrying out for 1.7 nanoseconds in solvent (Generalized Born implicit solvent) is calculated.So Afterwards to each B-B13 amino acid, using 1 obtained, 700 MD tracks snapshots compared with reference to medoid positions, are calculated The distribution of its root-mean-square deviation (rmsd).Root-mean-square deviation distribution and the overall situation finally with a statistical test to each amino acid is square Root difference cloth is compared, to determine the amino acid from the point of view of MD calculating, if is had enough flexibilities and is possible to be considered as and B Cell receptor interacts, so that the reason for being activated as immune response.By the flexible location of mouse B-B13 variable regions with downloading to The corresponding position of human antibody sequence is compared in local in January, 2007 version ImMunoGeneTics databases.Only that A little flexible residues for being more than average value three times and some flanking residues for saving these flexible residues 3D structures are just retained For searching for.The human antibody variable region for selecting residue containing same flexibility most, especially considers positioned at CDR'sIn the range of Position, to replace the flexible residue of mouse B-B13 antibody variable regions.Some mutation in CDR are also included within the form of proposal To avoid problematic residue.It has studied following sequence motifs：Asp-Pro (acid instability key), Asn-X-Ser/Thr (glycosylation), Asn-Gly/Ser/Thr (desamidization site of exposed areas), Met (oxidation of exposed areas).By generation Humanized sequence blast in UniProtKB/Swiss-Prot databases with regard to sequence similarity, has drawn and has had been made closing Manage the confidence level assumed.As a result find, all sequences, which are all shown with human antibody number, very high degree of similarity.In addition, institute Some sequences are all without any known B- or T- cells being listed in immune epitope database and analysis resource (IEDB databases) Epitope.
Three kinds of forms (H1, H2, H3) are proposed to heavy chain and three kinds of forms (L1, L2 and L3) are proposed to light chain.Light chain Three kinds of forms derive from CAA83271.1 (Genebank accession number CAA83271).L1 forms include 4 mutation.L2 forms include one Individual other mutation is to remove the DP sites (Pro99) in CDR3.Compared with L2, L3 added in CDRs two it is other prominent Become, they are the deacylation amine sites (N34Q, N96A) of 2 hypothesis.H1, H2 and the H3 form of heavy chain derive from CAC39364.1 (Genebank accession number CAC39364).The template is not the template of highest scoring, but it is not include and known immunogene sequence Row display high homology (>70%) template of highest scoring.H1 forms include 6 mutation, and H2 sequences add two in addition Mutation solve three deacylation amine sites (N60A, N73T and N83T).The sequence number of amino acid reflect its albumen it In natural order (N-terminal to C-terminal).H3 includes two other mutation (Y100R＆D106K) for being believed to improve effect. It is recommended that the VL and VH of 6 combinations variant are to produce humanized antibody：VL1xVH1,VL2xVH2,VL1xVH3,VL3xVH1, VL3xVH2 and VL3xVH3.As shown in table 1, it is detailed using this specification to the amino acid in B-B13VL the and VH variants of humanization The resurfacing technology provided in a bright section is described in detail to be changed.The column of the left side one represent original amino acid and they in mouse Position in B-B13mAb.
Table 1
Embodiment 4:The humanization of mouse anti human IL-4 monoclonal antibody clones 8D4-8 Fv domains
The humanization of 8D4-8 clones is realized using herein above described humanization (surface reforming) technology.It is prepared for Two kinds of humanization forms.A kind of form includes one in the CDR of heavy chain and is considered to solve the problematic residue (acid exposed to the open air The unstable position of property) mutation.
8D4-8 VL＆VH sequences and the PDB versions in July, 2007 carry out blast.Retrieve most of similar light chains And heavy chain amino acid sequence.It was found that most homologous for 1YDJ in variable light.It was found that most homologous for 1IQW in variable heavy chain. 1YDG＆1IQW structures are used to build the Homology model of variable domains, then using the standardization program implemented in MOE to it Carry out energy minimization.Thereafter solvent (Generalized Born are implied in broad sense Bonn to 8D4-8 3D Homology models Implicit solvent) in carried out 1.7 nanoseconds molecular dynamics (MD) calculate.Then to each 8D4 amino acid, profit With 1 obtained, 700 MD tracks snapshots compared with reference to medoid positions, calculate the distribution of its root-mean-square deviation (rmsd). Finally the root-mean-square deviation distribution of each amino acid is compared with global root-mean-square deviation distribution with a statistical test, to determine The amino acid is from the point of view of MD calculating, if has enough flexibilities and is possible to be considered as to interact with B-cell receptor, from into The reason for being activated for immune response.By the flexible location of mouse 8D4-8 variable regions and locally downloading in January, 2007 version The corresponding position of human antibody sequence is compared in ImMunoGeneTics databases.Only those flexibilities are more than average value three Residue and some flanking residues for saving these flexible residues 3D structures again is just preserved for search.Selection is containing identical The most human antibody variable region of flexible residue, especially considers positioned at CDR'sIn the range of position, to replace mouse 8D4- The flexible residue of 8 antibody variable regions.Some other mutation is finally prepared to avoid problem residue.It has studied following sequence base Sequence：Asp-Pro (acid instability key), Asn-X-Ser/Thr (glycosylation), the Asn-Gly/Ser/Thr (deacylations of exposed areas Amination site), Met (oxidation of exposed areas).It was found that unique problematic residue be heavy chain CDR2 in DP sites.Will production Raw humanized sequence carries out blast with regard to sequence similarity in UniProtKB/Swiss-Prot databases, has drawn Through the confidence level for making reasonable assumption.Full sequence all shows the high similarity with numerous human antibodies.In addition, all sequences Any known B cell or t cell epitope listed by not containing in IEDB databases.
Prompting obtains two kinds of forms (H1, H2) to heavy chain and a kind of form (L1) is obtained to light chain.The L1 of light chain Form derives from BAC01676.1 (Genebank accession number BAC01676).L1 forms include 3 mutation.H1 the and H2 forms of heavy chain Derived from BAC02418.1 (Genebank accession number BAC02418).H1 forms include 9 mutation, and H2 forms are extra comprising one It is mutated to remove the DP sites (Pro53) in CDR2.It is prepared for two combinations, VL1xVH1 and VL1xVH2.
The display of table 2 is using humanization (surface reforming) technology to the amino acid institute in 8D4-8VL the and VH variants of humanization The change of work.The column of the left side one represents original amino acid and their positions in mouse 8D4-8mAb.
Table 2
Embodiment 5:Inosculating antibody IL-13 clone B-B13 monoclonal antibodies, inosculating antibody IL-4 clone's 8D4-8 monoclonal antibodies And clone and the generation of humanization variants
Anti-il-13 clones B-B13 and anti-IL-4 clones 8D4-8 variable heavy chain and the amino acid sequence of light chain is reversed and translated For nucleotide sequence, and with Young L. and Dong Q. (Nucl.Acids Res. (2004), 32 (7), e59) describe it is overlapping Extension PCR (OE-PCR) modification code is generated respectively.PCR primer Invitrogen TOPO TA Cloning Kit (catalog number (Cat.No.)s： 45-0641) it is cloned intoIn 4-TOPO, and it is sequenced with M13 is positive with M13 reverse primers.Variable domains are distinguished It is fused to constant heavy chain (IGHG1, Genebank accession number Q569F4) or light chain (IGKC) Genebank accession number Q502W4) In, digested with NheI and HindIII, each domain is connected to Durocher et al. (2002), Nucl.Acids Res.30 (2), analog (analogon) the sequestered expression vector pXL of the pTT carriers of E9 descriptions NheI/HindIII sites, so that Generate the Mammalian expression plasmid of chimeric B-B13 heavy chains and light chain and chimeric 8D4-8 heavy chains and light chain.
The anti-il-13 clone B-B13 and anti-IL-4 clones 8D4-8 expression cloning of humanization variants is encoded also through overlapping Extension PCR (OE-PCR), the original series amino acid based on proposal exchanges synthetically produced.
The expression plasmid for encoding the heavy chain of antibody and light chain is bred in escherichia coli DH5a.Plasmid for transfection is profit Prepared with Qiagen EndoFree Plasmid Mega kits from Escherichia coli.
To transfect, in the serum-free FreeStyle culture mediums (Invitrogen) of the 100mL volumes in 500mL shaking flasks By 3x 105Cell/mL inoculation HEK293FreeStyle cells (Invitrogen).Cell one 37 DEG C, contain 8%CO2Plus Cultivated in the incubator of humid air, on the orbital shaker platform rotated with 110rpm.
Inoculation three days after, using a CASY electronic cell counter (System GmbH) determine survival Cell number and total cell number.The cell that survival rate is more than 90% is used to transfect, and cell density is 1-1.5x106Cell/mL. 100mL cells have heavy chain and light chain expression plasmid mixture (5x10 at one-7μ gDNA/ cells) 500mL shaking flasks in utilize FugeneHD (Roche) is transfected under conditions of business's explanation is prepared, wherein DNA:FugeneHD ratios are 2:7.After transfection Cell in 37 DEG C of incubator (8%CO on the orbital shaker platform rotated with 110rpm2) in culture 7 days.
Goat anti human IgG (Fc is special) [NatuTec is coated with a Nunc F96-MaxiSorp-Immuno plate A80-104A].The antibody is diluted to 10ug/ml in carbonate coating buffer solution (50mM sodium carbonate pH 9.6), the distribution per hole 50uL.Flat board rubber belt sealing, stores at 4 DEG C and stays overnight.Washed with lavation buffer solution (PBS pH 7.4,0.1%Tween20) Flat board three times.It is assigned 150uL lock solutions (1%BSA/PBS) to cover flat board per hole.At room temperature after 1 hour, with washing Buffer solution is washed to wash three times.100uL samples or standard (scope is 1500ng/ml to 120ng/ml) are added, and places 1 at room temperature Hour.Flat board is washed with lavation buffer solution three times.Add with incubation solution (0.1%BSA, PBS pH 7.4,0.05%Tween20) By 1:The 100uL Goat anti human IgG-FC-HRP conjugates [NatuTec A80-104P-60] of 10.000 dilutions.Pass through at room temperature After 1 hour is incubated, three flat boards are washed with lavation buffer solution.100uL ABTS substrate (10mg ABTS pieces are distributed into every hole (Pierce 34026) is dissolved in ml 0.1M Na2HPO4, 0.05M citric acid solutions, pH 5.0.Use preceding addition 10uL 30% H2O2/ 10ml substrate buffer solutions), and make it develop the color.After colour developing (about 10 to 15 minutes), add 50uL 1%SDS solution with Terminating reaction.Flat board is in A405 readings.
Protein albumin A (HiTrapTM Protein AHP Columns, GE Life Sciences) on affine color Spectrum purifying.After the acetate buffer pH3.5 elutions for containing 100mM NaCl with 100mM, monoclonal antibody is prepared in PBS solution In and by 0.22 μm filtering.Protein concentration is determined by measuring in 280nm absorbance.Protein is used per a collection of 200Plus LabChip kits are analyzed on the biological analysers of Agilent 2100 under reduction and non reducing conditions, To determine the purity and molecular weight of each subunit and monomer.
Embodiment 6:Humanization anti-il-13 clones B-B13 variants and the anti-IL-4 of humanization clones the table of 8D4-8 variants Levy
Recombined human IL-13 and IL-4 reagent are purchased from Chemicon (USA).Biacore dynamics has been carried out as follows Analysis.
The antibody of purifying is entered on a Biacore 3000 (GE Healthcare) using surface plasmon technology Detailed Kinetic Characterization is gone.A kind of catch assay is employed, (such as people-Fc is special using a kind of species specific antibody of thing for it Different in nature MAB 1302, Chemicon) antibody interested is captured and oriented.Capture antibody standardization program passes through primary amine (10000RU) is fixed on research grade CM5 chips (GE Life Science).The analyzed antibody of capture simultaneously adjusts RU values, leads The 30RU analytes for obtaining maximum when flow velocity is 10 μ l/min are caused to combine.0 to the HBS EP concentration ranges between 50nM (10mM HEPES pH 7.4,150mM NaCl, 3mM EDTA, 0.005% surfactant P20), flow velocity is 30 μ l/min When, measure the binding kineticses relative to restructuring IL-4 and IL-13.With 10mM glycine pH2.5 regeneration chips surface.Using not having There is the flow cell of antibody of capture as reference, kinetic parameter is analyzed and calculated in BIA assessment plan bags.For The addition of two antigens of research is combined, and the co-injection method of (wizard-driven) is driven using a guide, one of them After antigen injection, IL-13/IL-4 antigen mixture is injected immediately.
The suppression that nationality is bred by the cell for measuring IL-4 or IL-13 mediations in TF-1 cells, measures antibody of the present invention Bioactivity.In brief, applicant stimulates the growth of TF-1 cells with IL-4 or IL-13.TF-1 is a growth dependence There is the cell line of reaction in cell factor and to many cell factors, including IL-4 and IL-13.Induction growth (with the absence of Base line condition during cell factor is compared) then represent IL-4 or IL-13 bioactivity.Anti- IL-4, anti-il-13 and double spies Different anti-IL-4/IL-13 antibody is asserted the TF-1 cell growths for blocking IL-4 or IL-13 inductions.In addition, double special resists IL-4/IL-13 antibody has been asserted to block stimulates induced TF-1 cells to breed by the IL-4 and IL-13 combined.Block effect Should according to dosage rely on mode measure using produce IC50 while suppressing (50% antibody concentration) as antibody to its target, i.e. IL-4 or IL-13 neutralising capacity.The method details that place of matchmakers uses in more detail below.
TF-1 cells (ATCC, CRL-2003) are maintained at adds hGM-CSF's (ultimate density is 4ng/ml) containing new Complete medium (contains high glucose, 25mM Hepes buffer solutions and glutamine, 10%FBS, 1x P/S, 1mM Sodium Pyruvate DMEM) in.IL-13 (15ng/ml) or IL-4 (1ng/ml) before processing 24 hours.Cell presses 0.05x106/ on 96 orifice plates Ml is seeded in the complete medium without hGM-CSF.Before cell is added to, in having that 37 DEG C of precincubation are serially diluted The antibody of correspondence cell factor 30 minutes.Cell culture 72 hours (37 DEG C, 5%CO2).Add cellTiter 96Aqueous MTS/PMS solution.Then incubated cell 3 hours.After the stage, a culture plate reader is utilized in 490nm Record absorbance.IC50 values are calculated with Speed softwares.
The binding kineticses and neutralization activity of humanization B-B13 variants are shown in Table 3 (nt, do not survey).
Table 3
Compared with original mouse B-B13 (13 times) and chimeric B-B13 (6 times), a kind of B-B13 variants of humanization, HuB-B13VL3xVH2, with significantly higher affinity.When the anti-il-13 antibody of these humanizations is used to treat asthmatic patient When, improved affinity can cause the raising of efficiency and effect.In addition, when being used for people, compared with mouse antibody or chimeric antibody, people Source antibody can have the immunogenicity of reduction.
The binding kineticses and neutralization activity of humanization 8D4-8 variants are shown in Table 4.
Table 4
Compared with original mouse 8D4-8 (11 times) and chimeric 8D4-8 (2 times), the 8D4-8 variants of a humanization, Hu8D4-8VL1xVH1, with significantly higher affinity.When the anti-IL-4 antibody of this humanization is used to treat asthmatic patient When, improved affinity can cause the raising of efficiency and effect.In addition, when being used for people, compared with mouse antibody or chimeric antibody, people Source antibody can have the immunogenicity of reduction.
Embodiment 7：The clone of the anti-IL-4/IL-13 bispecific antibodies of humanization and generation
Form for expressing bispecific antibody (BsAb) is the bi-domain double end form of US5,989,830 descriptions IgG variants.In this form, IgG molecules its corresponding heavy chain and light chain N-terminal by second antibody another is variable Domain extends.Therefore, the IgG molecules obtained are a different tetramers being made up of two heavy chains and two light chains.Heavy chain is by two Individual variable weight structure domain (VH1-VH2) composition, comes two different antibody that free connector links together, the connection Body is by ten amino acid (G4S)2Composition, and it is fused to IgG4 constant domains.Light chain is by two variable light domain (VL1- VL2) constitute, carry out free connector and link together two different antibodies, the connector is by ten amino acid (G4S)2Composition, And it is fused to constant κ regions.
The Weight variable domain of 8D4-8 variants and the sequence of light domain are produced by PCR, in its respective coding (G4S)2-(GGA TCC) -8D4-8 some 5 '-end introduce BamHI restriction sites (GGA TCC).8D4-8 humanizations Variant VH 3 ' sequences are terminated with ApaI restriction sites first amino acid of CH1 domains (coding), with merging later To IGHG4 sequences (having lacked end Lys and with the Q569F4 of the double mutation of S241P and L248E).The 3 ' of VL8D4-8-end is to compile The BsiWI restriction sites of the first two amino acid of the constant κ chains of code terminate, with being fused to IGKC (Genebank accession number later Q502W4)。
The Weight variable domain of B-B13 variants and the sequence of light domain are produced by PCR, in its respective coding (G4S)2-(B-B13)-(GGA GGC GGA GGG TCC GGA GGC GGA GGA TCC(SEQ ID NO:7) some) 3 '-end introduce BamHI restriction sites.VH the and VL sequences of B-B13 variants are respective at its by NheI restriction sites What 5 '-end was produced, followed by ATG initiation codon and the leader peptide of coded sequence.
B-B13 and 8D4-8 VH is through their BamHI sites at (G4S)2It is fused to together in connector.B-B13 Their BamHI sites are passed through at (G4S) with 8D4-8 VL2Arrived in connector by fusion together.Therefore, the heavy chain of generation and The series connection of light chain has consisting of.
Bispecific antibody heavy chain：NheI- leader peptides-VH-B-B13- (G4S)2-VH 8D4-8-ApaI。
Bispecific antibody light chain：NheI- leader peptides-VL-B-B13- (G4S)2-VL 8D4-8-BsiWI。
All PCR intermediate segments Invitrogen TOPO TA Cloning Kit (catalog number (Cat.No.)s：45-0641) it is cloned intoIn 4-TOPO, and it is sequenced with M13 is positive with M13 reverse primers.
After sequence confirms, heavy chain is connected in series through its ApaI site and is fused to IGHG4 sequences, and variable light chain series connection passes through it BsiWI sites are fused to IGKC.The bi-domain heavy chain and light chain of generation are digested with NheI and HindIII, are each connected to In sequestered expression vector pXL NheI/HindIII sites, generate respectively dynamic for TBTI heavy chains and light chain lactation The plasmid of thing expression.
The combination of humanization VH and the VL form of B-B13 and 8D4-8 according to table 5 below, generates four people sources Change double special anti-IL-4/ anti-il-13s constructs.
Table 5
Double special anti-IL-4/ anti-il-13s Ab Anti-il-13 Fv Anti- IL-4Fv
huTBTI3_1_1 B-B13VL3xVH2 8D4-8VL1xVH2
huTBTI3_2_1 B-B13VL3xVH2 8D4-8VL1xVH1
huTBTI3_1_2 B-B13VL2xVH2 8D4-8VL1xVH2
huTBTI3_2_2 B-B13VL2xVH2 8D4-8VL1xVH1
Embodiment 8：The sign of humanization bispecific antibody
Carried out with reference to the explanation pressed with middle determination of activity in above example.
Table 6 gives the binding kineticses of the anti-IL-4/IL-13 antibody variants whies of four humanizations.All four are double special Xenoantibody construct is attached to IL-4 and IL-13 with high-affinity.
Table 6
The neutralization activity of the anti-IL-4/IL-13 bispecific antibodies variant of humanization is summarized in table 7.HuTBTI3-1_1 and HuTBTI3-2_1 has neutralized the TF-1 cells propagation of IL-13 or IL-4 inductions completely, and IC50 is as follows.
Table 7
It is well known that mutation IL-13 allele it is high-frequency it is associated with asthma (Heinzmann A. et al., 2000, Hum Mol Genet 9,4, the 549-559 pages).Therefore, it have studied IL-13 protein of the bispecific antibody to mutation The binding kineticses of (huIL-13 R112Q variants, PeproTech, Rocky Hill, NJ, USA).As a result show, huTBTI3- The combination of 1_1 and huTBTI3-2_1 and IL-13 variants and and wild type IL-13 combination it is similar.
Table 8 shows the binding kineticses of the anti-IL-4/IL-13 molecules of humanization and the IL-13 protein of mutation.
Table 8
Sequence table
<110>Sanofi Aventis Deutschland (sanofi-aventis US Inc)
E labor (Rao, Ercole)
V meters of Coles (Mikol, Vincent)
Lee D (Li, Danxi)
J Crewes Yi Pu (Kruip, Jochen)
M Dai Weisen (Davison, Matthew)
<120>With IL-4 and/or the IL-13 antibody combined and application thereof
<130> US2008/020
<160> 7
<170>PatentIn version 3s .5
<210> 1
<211> 111
<212> PRT
<213>Artificial sequence
<220>
<223>Humanization mouse/mouse VL3 regions
<400> 1
Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly
1 5 10 15
Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Asp Ser Tyr
20 25 30
Gly Gln Ser Tyr Met His Trp Tyr Gln Gln Lys Ala Gly Gln Pro Pro
35 40 45
Lys Leu Leu Ile Tyr Leu Ala Ser Asn Leu Glu Ser Gly Val Pro Ala
50 55 60
Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asp
65 70 75 80
Pro Val Gln Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Asn Ala
85 90 95
Glu Asp Ser Arg Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105 110
<210> 2
<211> 118
<212> PRT
<213>Artificial sequence
<220>
<223>Humanization mouse/mouse VH2 regions
<400> 2
Glu Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Ala Pro Gly Gly
1 5 10 15
Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Asp Ser
20 25 30
Ser Ile Asn Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu
35 40 45
Gly Met Ile Trp Gly Asp Gly Arg Ile Asp Tyr Ala Asp Ala Leu Lys
50 55 60
Ser Arg Leu Ser Ile Ser Lys Asp Ser Ser Lys Ser Gln Val Phe Leu
65 70 75 80
Glu Met Thr Ser Leu Arg Thr Asp Asp Thr Ala Thr Tyr Tyr Cys Ala
85 90 95
Arg Asp Gly Tyr Phe Pro Tyr Ala Met Asp Phe Trp Gly Gln Gly Thr
100 105 110
Ser Val Thr Val Ser Ser
115
<210> 3
<211> 108
<212> PRT
<213>Artificial sequence
<220>
<223>Humanization mouse/mouse VL1 regions
<400> 3
Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Val Ser Val Gly
1 5 10 15
Asp Thr Ile Thr Leu Thr Cys His Ala Ser Gln Asn Ile Asp Val Trp
20 25 30
Leu Ser Trp Phe Gln Gln Lys Pro Gly Asn Ile Pro Lys Leu Leu Ile
35 40 45
Tyr Lys Ala Ser Asn Leu His Thr Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Ala His Ser Tyr Pro Phe
85 90 95
Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg
100 105
<210> 4
<211> 124
<212> PRT
<213>Artificial sequence
<220>
<223>Humanization mouse/mouse VH1 regions
<400> 4
Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr
20 25 30
Trp Ile His Trp Ile Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
35 40 45
Gly Met Ile Asp Pro Ser Asp Gly Glu Thr Arg Leu Asn Gln Arg Phe
50 55 60
Gln Gly Arg Ala Thr Leu Thr Val Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Gln Leu Arg Ser Pro Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
85 90 95
Thr Arg Leu Lys Glu Tyr Gly Asn Tyr Asp Ser Phe Tyr Phe Asp Val
100 105 110
Trp Gly Ala Gly Thr Leu Val Thr Val Ser Ser Ala
115 120
<210> 5
<211> 124
<212> PRT
<213>Artificial sequence
<220>
<223>Humanization mouse/mouse VH2 regions
<400> 5
Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr
20 25 30
Trp Ile His Trp Ile Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
35 40 45
Gly Met Ile Asp Ala Ser Asp Gly Glu Thr Arg Leu Asn Gln Arg Phe
50 55 60
Gln Gly Arg Ala Thr Leu Thr Val Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Gln Leu Arg Ser Pro Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
85 90 95
Thr Arg Leu Lys Glu Tyr Gly Asn Tyr Asp Ser Phe Tyr Phe Asp Val
100 105 110
Trp Gly Ala Gly Thr Leu Val Thr Val Ser Ser Ala
115 120
<210> 6
<211> 10
<212> PRT
<213>Artificial sequence
<220>
<223>Connector
<400> 6
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
1 5 10
<210> 7
<211> 30
<212> DNA
<213>Artificial sequence
<220>
<223>Primer
<400> 7
ggaggcggag ggtccggagg cggaggatcc 30

Claims (47)

1. specific bond IL-4 humanized antibody.
2. the antibody of claim 1, it is included by SEQ ID NO:The variable light chain domain of 3 compositions.
3. the antibody of claim 1, it, which is included, is selected from SEQ ID NO:4 and SEQ ID NO:5 variable heavy chain domain.
4. any one of claim 1-3 optional antibody, wherein the antibody is antibody fragment.
5. the antibody of claim 1, it includes the C of constant regionH1、CH2And CH3Domain.
6. polypeptide as claimed in claim 5, IgG antibody therein is IgG4 antibody.
7. the nucleic acid of coding polypeptide as claimed in claim 1.
8. the carrier containing nucleic acid as claimed in claim 7.
9. the cell containing carrier as claimed in claim 8.
10. specific bond IL-13 humanized antibody.
11. the antibody of claim 10, it is included by SEQ ID NO:The variable light chain domain of 1 composition.
12. the antibody of claim 11, it is included by SEQ ID NO:The variable heavy chain domain of 2 compositions.
13. any one of claim 10-12 optional antibody, wherein the antibody is antibody fragment.
14. any one of claim 10-12 antibody, it includes the C of constant regionH1、CH2And CH3Domain.
15. such as the polypeptide of claim 14, wherein IgG antibody is IgG4 antibody.
16. the nucleic acid of the coding such as polypeptide of claim 15.
17. the carrier containing the nucleic acid such as claim 16.
18. the cell containing the carrier such as claim 17.
19. specific bond IL-13 and IL-4 bispecific antibody or bispecific antibody fragment.
20. the bispecific antibody or antibody fragment of claim 19, it further includes variable light chain and variable heavy chain.
21. the bispecific antibody or antibody fragment of claim 20, wherein the variable light includes amino acid sequence SEQ ID NO:1 and SEQ ID NO:3.
22. the bispecific antibody or antibody fragment of claim 20, wherein the variable heavy chain includes amino acid sequence SEQ ID NO:2 and SEQ ID NO:5.
23. the bispecific antibody or antibody fragment of claim 20, wherein the variable heavy chain includes amino acid sequence SEQ ID NO:2 and SEQ ID NO:4.
24. the bispecific antibody or antibody fragment of claim 20, wherein the variable light includes amino acid sequence SEQ ID NO:1 and SEQ ID NO:3, and the variable heavy chain includes amino acid sequence SEQ ID NO:2 and SEQ ID NO:4.
25. the bispecific antibody or antibody fragment of claim 24, wherein the SEQ ID NO:1 and SEQ ID NO:3 by peptide Connector links together, the SEQ ID NO:2 and SEQ ID NO:4 are linked together by peptide connector.
26. the bispecific antibody or antibody fragment of claim 25, wherein the peptide connector is by SEQ ID NO:6 compositions.
27. IL-13 and IL-13 bispecific antibody is specifically combined, wherein variable light chain includes SEQ ID NO:1 and SEQ ID NO:3, variable heavy chain includes SEQ ID NO:2 and SEQ ID NO:4, and also include constant region domain.
28. the bispecific antibody of claim 27, wherein the constant region domain is made up of CH1, CH2, CH3 and CL.
29. humanized antibody and the pharmaceutical composition of pharmaceutical acceptable carrier comprising claim 1 or claim 8.
30. included in the optional bispecific antibody or the medicine group of antibody fragment and pharmaceutically useful carrier of claim 19-28 Compound.
31. the humanized antibody of claim 1 or claim 10, it is further conjugated with effector molecule.
32. the humanized antibody of claim 31, wherein the effector molecule is selected from：Heterologous polypeptide, medicine, radioactive nucleotides And toxin.
33. the optional bispecific antibody or antibody fragment of any one of claim 19-28, it further sews with effector molecule Close.
34. the bispecific antibody or fragment of claim 33, wherein the effector molecule is selected from：Heterologous polypeptide, medicine, radioactivity Nucleotides and toxin.
35. treating the method for allergic disease in mammal, it comprises the steps：Have to the mammal using treatment The optional bispecific antibody or antibody fragment according to claim 19-28 of effect amount.
36. treating the method for allergic disease in mammal, it comprises the steps：Have to the mammal using treatment The humanized antibody according to claim 1 or 10 of effect amount.
37. the method for the treatment of cancer, it comprises the steps：Being wanted according to right for therapeutically effective amount is applied to the mammal Seek 19-28 optional bispecific antibody or antibody fragment.
38. the method for the treatment of cancer, it comprises the steps：Being wanted according to right for therapeutically effective amount is applied to the mammal Ask 1 or 10 humanized antibody.
39. treating the method for asthma in mammal, it comprises the steps：Therapeutically effective amount is applied to the mammal According to claim 19-28 optional bispecific antibody or antibody fragment.
40. treating the method for asthma in mammal, it comprises the steps：Therapeutically effective amount is applied to the mammal According to the humanized antibody of claim 1 or 10.
41. treating the method for disease relevant with the abnormal generations of IL-4 and/or IL-13 in mammal, it comprises the steps： The optional bispecific antibody or antibody fragment according to claim 19-28 of therapeutically effective amount are applied to the mammal.
42. treating the method for disease relevant with the abnormal generations of IL-4 and/or IL-13 in mammal, it comprises the steps： The humanized antibody according to claim 1 or 10 of therapeutically effective amount is applied to the mammal.
43. suppressing the method for the reaction that TH-2 is mediated in mammal, it comprises the steps：Apply and control to the mammal Treat the optional bispecific antibody or antibody fragment according to claim 19-28 of effective dose.
44. suppressing the method for the reaction that TH-2 is mediated in mammal, it comprises the steps：Apply and control to the mammal Treat the humanized antibody according to claim 1 or 10 of effective dose.
45. the nucleic acid of the coding such as bispecific antibody of claim 27.
46. the carrier containing the nucleic acid such as claim 45.
47. the cell containing the carrier such as claim 46.
CN201710131539.4A 2007-10-15 2008-10-14 Antibodies that bind to IL-4 and/or IL-13 and uses thereof Active CN106986938B (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP07291259.5 2007-10-15
EP07291259A EP2050764A1 (en) 2007-10-15 2007-10-15 Novel polyvalent bispecific antibody format and uses thereof
US3712808P 2008-03-17 2008-03-17
US61/037,128 2008-03-17
CN200880111668.6A CN101827863B (en) 2007-10-15 2008-10-14 Antibodies that bind IL-4 and/or IL-13 and their uses

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN200880111668.6A Division CN101827863B (en) 2007-10-15 2008-10-14 Antibodies that bind IL-4 and/or IL-13 and their uses

Publications (2)

Publication Number Publication Date
CN106986938A true CN106986938A (en) 2017-07-28
CN106986938B CN106986938B (en) 2021-07-09

Family

ID=39313041

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201710131539.4A Active CN106986938B (en) 2007-10-15 2008-10-14 Antibodies that bind to IL-4 and/or IL-13 and uses thereof
CN202110668094.XA Pending CN113480647A (en) 2007-10-15 2008-10-14 Antibodies that bind to IL-4 and/or IL-13 and uses thereof
CN200880111668.6A Active CN101827863B (en) 2007-10-15 2008-10-14 Antibodies that bind IL-4 and/or IL-13 and their uses

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202110668094.XA Pending CN113480647A (en) 2007-10-15 2008-10-14 Antibodies that bind to IL-4 and/or IL-13 and uses thereof
CN200880111668.6A Active CN101827863B (en) 2007-10-15 2008-10-14 Antibodies that bind IL-4 and/or IL-13 and their uses

Country Status (43)

Country Link
US (17) US8388965B2 (en)
EP (12) EP2050764A1 (en)
JP (5) JP5858616B2 (en)
KR (5) KR20190022928A (en)
CN (3) CN106986938B (en)
AR (3) AR068861A1 (en)
AU (5) AU2008312655B2 (en)
BR (1) BRPI0818677B8 (en)
CA (3) CA3015470C (en)
CL (4) CL2008003037A1 (en)
CR (5) CR11337A (en)
CY (5) CY1114987T1 (en)
DK (5) DK2574630T3 (en)
DO (3) DOP2010000109A (en)
ES (5) ES2447915T3 (en)
GT (1) GT201000067A (en)
HN (1) HN2010000710A (en)
HR (5) HRP20140150T1 (en)
HU (4) HUE038556T2 (en)
IL (2) IL205005A (en)
LT (4) LT2574630T (en)
MA (1) MA31838B1 (en)
MX (6) MX354150B (en)
MY (1) MY171214A (en)
NI (7) NI201000040A (en)
NO (2) NO2574629T3 (en)
NZ (3) NZ584658A (en)
PA (1) PA8799001A1 (en)
PE (1) PE20091382A1 (en)
PH (2) PH12013501032B1 (en)
PL (5) PL2574630T3 (en)
PT (5) PT2573121T (en)
RS (5) RS57060B1 (en)
RU (4) RU2488595C2 (en)
SG (4) SG185303A1 (en)
SI (5) SI2574629T1 (en)
TN (1) TN2010000126A1 (en)
TR (2) TR201810005T4 (en)
TW (4) TWI616206B (en)
UA (2) UA118949C2 (en)
UY (1) UY31394A1 (en)
WO (1) WO2009052081A2 (en)
ZA (1) ZA201002069B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109705217A (en) * 2017-10-25 2019-05-03 北京智仁美博生物科技有限公司 Anti-il-13 antibody and application thereof

Families Citing this family (175)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2009040562A1 (en) 2007-09-26 2009-04-02 Ucb Pharma S.A. Dual specificity antibody fusions
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
MX2010005927A (en) * 2007-11-30 2010-06-15 Glaxo Group Ltd Antigen-binding constructs.
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
JP5529869B2 (en) * 2008-08-14 2014-06-25 メルク・シャープ・アンド・ドーム・コーポレーション Antibody purification method using protein A affinity chromatography
CA2737241C (en) 2008-09-26 2017-08-29 Ucb Pharma S.A. Multivalent antibody fusion proteins
KR101431318B1 (en) 2009-04-02 2014-08-20 로슈 글리카트 아게 Multispecific antibodies comprising full length antibodies and single chain fab fragments
SG175077A1 (en) 2009-04-07 2011-11-28 Roche Glycart Ag Trivalent, bispecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
EP2475682B1 (en) * 2009-09-10 2018-01-31 UCB Biopharma SPRL Multivalent antibodies
WO2011034605A2 (en) 2009-09-16 2011-03-24 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
GB201000467D0 (en) * 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
FR2958936A1 (en) 2010-04-14 2011-10-21 Sanofi Aventis ROBO1-FC FUSION PROTEIN AND ITS USE IN THE TREATMENT OF TUMORS
US20130115215A1 (en) * 2010-07-14 2013-05-09 Hongxing Zhou Domain insertion immunoglobulin
KR102306967B1 (en) 2010-08-02 2021-10-01 리제너론 파아마슈티컬스, 인크. Mice that make binding proteins comprising vl domains
UY33543A (en) 2010-08-03 2012-02-29 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
BR112013001847A2 (en) 2010-08-24 2016-05-31 Hoffmann La Roche bispecific antibody, method of preparation of bispecific antibody, trivalent bispecific antibody, methods and pharmaceutical composition
CA2807269A1 (en) 2010-08-24 2012-03-01 Roche Glycart Ag Activatable bispecific antibodies
WO2012085111A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
CN102675460B (en) * 2011-02-28 2015-08-19 珠海市丽珠单抗生物技术有限公司 The humanized antibody of Tumor necrosis factorα
MX342034B (en) 2011-02-28 2016-09-12 Hoffmann La Roche Monovalent antigen binding proteins.
AR085404A1 (en) 2011-02-28 2013-09-25 Hoffmann La Roche PROTEINS OF UNION TO ANTIGEN
US20130344074A1 (en) 2011-03-16 2013-12-26 Sanofi Uses of a dual v region antibody-like protein
HUE053139T2 (en) * 2011-03-28 2021-06-28 Sanofi Sa Dual variable region antibody-like binding proteins having cross-over binding region orientation
TWI622597B (en) * 2011-03-28 2018-05-01 賽諾菲公司 Dual variable region antibody-like binding proteins having cross-over binding region orientation
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
EP2710042A2 (en) 2011-05-16 2014-03-26 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
UY34105A (en) 2011-06-03 2012-07-31 Lg Life Sciences Ltd STABLE LIQUID FORMULATION OF ETANERCEPT
SI3572517T1 (en) 2011-08-05 2021-09-30 Regeneron Pharmaceuticals, Inc. Humanized universal light chain mice
UY34317A (en) 2011-09-12 2013-02-28 Genzyme Corp T cell antireceptor antibody (alpha) / ß
WO2013076580A2 (en) 2011-11-23 2013-05-30 Bioven 3 Limited Recombinant proteins and their therapeutic uses
WO2013103783A1 (en) * 2012-01-04 2013-07-11 Sanofi Us Murine il-13 antibodies
CN104105711B (en) 2012-02-10 2018-11-30 弗·哈夫曼-拉罗切有限公司 Single-chain antibody and other heteromultimerics
CA2864884A1 (en) * 2012-03-27 2013-10-03 Genentech, Inc. Methods of prognosing, diagnosing and treating idiopathic pulmonary fibrosis
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
CN104411718B (en) 2012-06-27 2018-04-24 弗·哈夫曼-拉罗切有限公司 It is used to prepare method of antibody Fc district conjugate of at least one binding entity comprising specific binding target and application thereof
CA2871880A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
EP4324479A3 (en) 2012-08-21 2024-04-24 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4r antagonist
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
CN104797601B (en) 2012-09-12 2019-08-30 建新公司 The polypeptide comprising FC of glycosylation and reduced effector function with change
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
AR093311A1 (en) 2012-11-01 2015-05-27 Abbvie Inc DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AGAINST THE VASCULAR ENDOTELIAL GROWTH FACTOR (VEGF) AND THE BINDING INVOLVED IN THE CELL TO CELL SIGNALING THROUGH THE NOTCH RECEIVER (DLL4)
MX2015005495A (en) 2012-11-01 2016-01-22 Abbvie Inc Stable dual variable domain immunoglobulin protein formulations.
PL2922875T3 (en) 2012-11-20 2017-08-31 Sanofi Anti-ceacam5 antibodies and uses thereof
WO2014102299A2 (en) 2012-12-27 2014-07-03 Sanofi Anti-lamp1 antibodies and antibody drug conjugates, and uses thereof
MX370679B (en) 2013-03-11 2019-12-19 Genzyme Corp Hyperglycosylated binding polypeptides.
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US20140302037A1 (en) * 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
US11634502B2 (en) 2013-03-15 2023-04-25 Amgen Inc. Heterodimeric bispecific antibodies
JP6480907B2 (en) * 2013-03-15 2019-03-13 メモリアル スローン ケタリング キャンサー センター Multimerization technology
EP2981286A4 (en) * 2013-04-05 2016-08-24 Hoffmann La Roche Anti-il-4 antibodies and bispecific antibodies and uses thereof
TWI679019B (en) * 2013-04-29 2019-12-11 法商賽諾菲公司 Anti-il-4/anti-il-13 bispecific antibody formulations
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
MX2016003593A (en) 2013-10-11 2016-06-02 Hoffmann La Roche Multispecific domain exchanged common variable light chain antibodies.
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
CN105849124B (en) 2013-12-20 2022-04-12 豪夫迈·罗氏有限公司 Dual specificity antibodies
EP2893939A1 (en) 2014-01-10 2015-07-15 Netris Pharma Anti-netrin-1 antibody
WO2015121318A1 (en) * 2014-02-12 2015-08-20 Sanofi Anti-il-4/anti-il-13 bispecific antibody/polyglutamate formulations
IL315136A (en) * 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
CA2937556A1 (en) * 2014-02-21 2015-08-27 Genentech, Inc. Anti-il-13/il-17 bispecific antibodies and uses thereof
CN116333148A (en) * 2014-03-19 2023-06-27 建新公司 Site-specific glycoengineering of targeting modules
AU2015230938C1 (en) 2014-03-21 2021-10-14 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
WO2015143406A2 (en) 2014-03-21 2015-09-24 Regeneron Pharmaceuticals, Inc. Vl antigen binding proteins exhibiting distinct binding characteristics
TW201628647A (en) 2014-06-27 2016-08-16 賽諾菲公司 Anti-IL4-IL13 bispecific antibodies
LT3169706T (en) 2014-07-11 2020-03-25 Genmab A/S Antibodies binding axl
MA39070A1 (en) 2014-07-31 2017-11-30 Sanofi Sa Anti-cd38 antibodies specific for the treatment of human cancers
EP3194446B1 (en) 2014-09-18 2022-10-26 Cedars-Sinai Medical Center Compositions and methods for treating fibrosis
US10064952B2 (en) 2014-10-09 2018-09-04 Genzyme Corporation Glycoengineered antibody drug conjugates
EP3218412A1 (en) 2014-11-14 2017-09-20 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
EP3222637A4 (en) * 2014-11-21 2018-10-31 Astellas Pharma Inc. Novel bispecific antibody format
ES2764111T3 (en) 2014-12-03 2020-06-02 Hoffmann La Roche Multispecific antibodies
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
CN107428835B (en) 2015-01-23 2021-11-26 赛诺菲 anti-CD 3 antibodies, anti-CD 123 antibodies, and bispecific antibodies that specifically bind to CD3 and/or CD123
MA41414A (en) 2015-01-28 2017-12-05 Centre Nat Rech Scient ICOS AGONIST BINDING PROTEINS
EP3067062A1 (en) 2015-03-13 2016-09-14 Ipsen Pharma S.A.S. Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament
EP3271723A1 (en) * 2015-03-16 2018-01-24 F. Hoffmann-La Roche AG Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases
US11111314B2 (en) 2015-03-19 2021-09-07 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
TW201710286A (en) 2015-06-15 2017-03-16 艾伯維有限公司 Binding proteins against VEGF, PDGF, and/or their receptors
US20180326084A1 (en) 2015-07-10 2018-11-15 Genmab A/S Axl-specific antibody-drug conjugates for cancer treatment
HRP20211528T1 (en) 2015-10-25 2021-12-24 Sanofi Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection
TW201720459A (en) 2015-11-02 2017-06-16 妮翠斯製藥公司 Combination therapy of NTN1 neutralizing agent with drugs inhibiting epigenetic control
TW201736399A (en) 2015-12-31 2017-10-16 財團法人生物技術開發中心 Anti-VEGFR antibody and uses thereof
CA3010601A1 (en) * 2016-01-08 2017-07-13 Bioalliance C.V. Tetravalent anti-psgl-1 antibodies and uses thereof
US10870701B2 (en) 2016-03-15 2020-12-22 Generon (Shanghai) Corporation Ltd. Multispecific fab fusion proteins and use thereof
SI3443006T1 (en) 2016-04-13 2024-01-31 Sanofi Trispecific and/or trivalent binding proteins
IL262241B2 (en) * 2016-04-13 2024-05-01 Sanofi Sa Trispecific and/or trivalent binding proteins with a crossover dual variable domain arm and a traditional antibody fab arm, pharmaceutical composition comprising said binding proteins and their uses in preventing and/or treating cancer or inflammatory diseases
LT3448391T (en) 2016-04-27 2024-06-25 AbbVie Manufacturing Management Unlimited Company Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
WO2017194568A1 (en) 2016-05-11 2017-11-16 Sanofi Treatment regimen using anti-muc1 maytansinoid immunoconjugate antibody for the treatment of tumors
WO2018011421A1 (en) 2016-07-14 2018-01-18 Genmab A/S Multispecific antibodies against cd40 and cd137
TWI790206B (en) 2016-07-18 2023-01-21 法商賽諾菲公司 Bispecific antibody-like binding proteins specifically binding to cd3 and cd123
WO2018037092A1 (en) 2016-08-26 2018-03-01 Sanofi Multispecific antibodies facilitating selective light chain pairing
TW202300515A (en) 2016-10-20 2023-01-01 法商賽諾菲公司 Anti-chikv antibodies and uses thereof
KR20190070977A (en) 2016-11-01 2019-06-21 젠맵 비. 브이 Polypeptide variants and uses thereof
WO2018106931A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
CA3048347A1 (en) 2017-01-05 2018-07-12 Institut National De La Sante Et De La Recherche Medicale Combined treatment with netrin-1 interfering drug and immune checkpoint inhibitors drugs
KR20240049621A (en) 2017-02-17 2024-04-16 사노피 Multispecific binding molecules having specificity to dystroglycan and laminin-2
WO2018151841A1 (en) 2017-02-17 2018-08-23 Sanofi Multispecific binding molecules having specificity to dystroglycan and laminin-2
KR101961871B1 (en) * 2017-02-20 2019-07-17 주식회사 와이바이오로직스 Novel Multi-Specific Binding Proteins
WO2018183932A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor
EP3635005A1 (en) 2017-06-07 2020-04-15 Genmab B.V. Therapeutic antibodies based on mutated igg hexamers
CN111108120A (en) * 2017-07-03 2020-05-05 财团法人生物技术开发中心 Antibody against human vascular endothelial growth factor receptor and application thereof
US11053309B2 (en) 2017-08-04 2021-07-06 Regeneron Pharmaceuticals, Inc. Methods for treating active eosinophilic esophagitis
US10849960B2 (en) 2017-09-08 2020-12-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synergistic combination of IL-4, interferon gamma, and interferon alpha in treating ovarian cancer
JP7036909B2 (en) 2017-10-10 2022-03-15 サノフイ Anti-CD38 antibody and usage
HUE064655T2 (en) 2017-10-30 2024-04-28 Sanofi Biotechnology Il-4r antagonist for use in a method for treating or preventing asthma
WO2019140320A1 (en) 2018-01-12 2019-07-18 Genzyme Corporation Methods for the quantitation of polypeptides
MA51666A (en) 2018-01-24 2020-12-02 Genmab Bv POLYPEPTIDIC VARIANTS AND THEIR USES
BR112020015006A2 (en) 2018-01-26 2020-12-29 Genzyme Corporation FC VARIANTS WITH ENHANCED CONNECTION TO FCRN AND EXTENDED HALF-LIFE
AU2019232523A1 (en) * 2018-03-05 2020-09-03 Etablissement Francais Du Sang Recombinant single chain immunoglobulins
US20210324067A9 (en) * 2018-03-09 2021-10-21 The Brigham And Women's Hospital, Inc. Combination therapy for cardiovascular diseases
KR20210008380A (en) 2018-05-03 2021-01-21 젠맵 비. 브이 Antibody variant combinations and uses thereof
EP3574915A1 (en) 2018-05-29 2019-12-04 Neovacs Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity
WO2019243636A1 (en) 2018-06-22 2019-12-26 Genmab Holding B.V. Anti-cd37 antibodies and anti-cd20 antibodies, compositions and methods of use thereof
CA3106146A1 (en) 2018-07-13 2020-01-16 Genmab A/S Variants of cd38 antibody and uses thereof
US20240254252A1 (en) 2018-07-13 2024-08-01 Genmab A/S Trogocytosis-mediated therapy using cd38 antibodies
SG11202103100SA (en) 2018-10-04 2021-04-29 Genmab Holding B V Pharmaceutical compositions comprising bispecific anti-cd37 antibodies
SG11202103478RA (en) 2018-10-09 2021-05-28 Sanofi Sa Trispecific anti-cd38, anti-cd28, and anti-cd3 binding proteins and methods of use for treating viral infection
KR102330596B1 (en) * 2018-11-09 2021-11-26 아주대학교산학협력단 High Affinity Human Antibodies Against Human Interleukin-4 Receptor alpha and Uses Thereof
WO2020106754A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
CA3124408A1 (en) 2018-12-21 2020-06-25 Aim Immunotech Inc. Compositions and methods for cancer therapy
CN111518211B (en) * 2018-12-25 2022-06-21 江苏荃信生物医药股份有限公司 Pharmaceutical application of human interleukin 4receptor alpha monoclonal antibody
SG11202109003QA (en) 2019-03-06 2021-09-29 Regeneron Pharma Il-4/il-13 pathway inhibitors for enhanced efficacy in treating cancer
BR112021018627A2 (en) 2019-03-21 2021-11-23 Regeneron Pharma Combination of IL-4/IL-13 pathway inhibitors and plasma cell ablation for the treatment of allergy
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
US11827671B2 (en) 2019-05-24 2023-11-28 Sanofi Methods for treating systemic sclerosis
EP3753954A1 (en) 2019-06-21 2020-12-23 Université de Franche-Comté Anti-cd123 antibodies, anti-cd123 chimeric antigen receptors and anti-cd123 chimeric antigen receptors t cells
CN115175932A (en) 2019-07-16 2022-10-11 赛诺菲 Neutralizing anti-amyloid beta antibodies for the treatment of alzheimer's disease
CA3148764A1 (en) 2019-07-25 2021-01-28 Genzyme Corporation Methods of treating antibody-mediated disorders with fcrn antagonists
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
US20230132241A1 (en) 2020-01-15 2023-04-27 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
EP4096625A1 (en) 2020-01-31 2022-12-07 Sanofi Biotechnology Pulmonary delivery of antibodies
IL295590A (en) 2020-02-28 2022-10-01 Genzyme Corp Modified binding polypeptides for optimized drug conjugation
WO2021175924A1 (en) 2020-03-03 2021-09-10 Active Biotech Ab Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy
TW202146463A (en) 2020-03-05 2021-12-16 法商賽諾菲公司 Protease-processed molecules
EP4121456A1 (en) 2020-03-18 2023-01-25 Genmab A/S Antibodies binding to b7h4
EP4138925A1 (en) 2020-04-24 2023-03-01 Sanofi Antitumor combinations containing anti-ceacam5 antibody conjugates, trifluridine and tipiracil
MX2022013405A (en) 2020-04-24 2022-11-14 Sanofi Sa Antitumor combinations containing anti-ceacam5 antibody conjugates and folfox.
AU2021261553A1 (en) 2020-04-24 2023-01-05 Sanofi Antitumor combinations containing anti-CEACAM5 antibody conjugates and FOLFIFI
WO2021214227A1 (en) 2020-04-24 2021-10-28 Sanofi Antitumor combinations containing anti-ceacam5 antibody conjugates and cetuximab
CN114957472B (en) * 2020-06-22 2023-10-31 南京融捷康生物科技有限公司 Single-domain antibody for resisting IL-4 Ralpha, application and medicine
US20230340067A1 (en) * 2020-06-26 2023-10-26 St. Jude Children's Research Hospital, Inc. Methods of generating an activation inducible expression system in immune cells
EP4185388A1 (en) 2020-07-23 2023-05-31 Genmab B.V. A combination of anti-dr5 antibodies and an immunomodulatory imide drug for use in treating multiple myeloma
IL300835A (en) 2020-09-02 2023-04-01 Genmab As Antibody therapy
IL301004A (en) 2020-09-04 2023-04-01 Merck Patent Gmbh Anti-ceacam5 antibodies and conjugates and uses thereof
MX2023006650A (en) * 2020-12-07 2023-06-21 UCB Biopharma SRL Multi-specific antibodies and antibody combinations.
WO2022184805A1 (en) 2021-03-03 2022-09-09 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding sars-cov-2 antigenic peptides in complex with a major histocompatibility complex protein
JP2024519212A (en) 2021-05-07 2024-05-09 ジェンマブ エー／エス Pharmaceutical compositions comprising bispecific antibodies that bind to B7H4 and CD3 - Patent Application 20070123333
AU2022282666A1 (en) 2021-05-27 2024-01-18 Sanofi Fc VARIANT WITH ENHANCED AFFINITY TO Fc RECEPTORS AND IMPROVED THERMAL STABILITY
MX2024000002A (en) 2021-07-02 2024-07-09 Merck Patent Gmbh Anti-protac antibodies and complexes.
CA3229324A1 (en) * 2021-08-20 2023-02-23 Beatrice DROUET Mrna vaccines comprising il-4 and/or il-13 rna and uses thereof
CA3237142A1 (en) 2021-11-05 2023-05-11 Sanofi Antitumor combinations containing anti-ceacam5 antibody-drug conjugates and anti-vegfr-2 antibodies
MX2024006053A (en) 2021-12-30 2024-07-29 Regeneron Pharma Methods for attenuating atopic march by administering an il-4/il-13 antagonist.
AU2023227442A1 (en) * 2022-03-03 2024-09-12 Pfizer Inc. Multispecific antibodies and uses thereof
WO2023170240A1 (en) 2022-03-09 2023-09-14 Merck Patent Gmbh Anti-ceacam5 antibodies and conjugates and uses thereof
EP4245772A1 (en) 2022-03-18 2023-09-20 Netris Pharma Anti-netrin-1 antibody to treat liver inflammation
EP4249509A1 (en) 2022-03-22 2023-09-27 Netris Pharma Anti-netrin-1 antibody against arthritis-associated pain
TW202413419A (en) 2022-05-27 2024-04-01 法商賽諾菲公司 Natural killer (nk) cell engagers binding to nkp46 and bcma variants with fc-engineering
TW202432574A (en) 2022-10-25 2024-08-16 比利時商艾伯霖克斯公司 GLYCOENGINEERED Fc VARIANT POLYPEPTIDES WITH ENHANCED EFFECTOR FUNCTION
WO2024141496A1 (en) 2022-12-27 2024-07-04 Merck Patent Gmbh Vhh anti-protac antibodies and complexes
EP4413995A1 (en) 2023-02-07 2024-08-14 Université de Franche-Comté Anti-cd123 chimeric antigen receptors t cells for use in the treatement of autoimmune diseases
WO2024180085A1 (en) 2023-02-27 2024-09-06 Netris Pharma Anti-netrin-1 monoclonal antibody for treating endometriosis and associated pains
WO2024180192A1 (en) 2023-03-01 2024-09-06 Sanofi Use of anti-ceacam5 immunoconjugates for treating neuroendocrine cancers expressing ceacam5
EP4427763A1 (en) 2023-03-06 2024-09-11 Sanofi Antitumor combinations containing anti-ceacam5 antibody-drug conjugates, anti-vegfr-2 antibodies and anti-pd1/pd-l1 antibodies
WO2024194455A1 (en) 2023-03-23 2024-09-26 Sanofi CEACAM5 mRNA ASSAY FOR PATIENT SELECTION IN CANCER THERAPY
EP4434586A1 (en) 2023-03-23 2024-09-25 Xenothera Combination of antibodies, or antigen-binding fragments thereof, for the treatment of cancer and composition thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705154A (en) * 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US5928904A (en) * 1993-09-07 1999-07-27 Smithkline Beecham Corporation DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
CN1886426A (en) * 2003-11-07 2006-12-27 伊姆尼斯公司 Antibodies that bind interleukin-4 receptor
WO2007085815A2 (en) * 2006-01-24 2007-08-02 Domantis Limited Ligands that bind il-4 and/or il-13
WO2007107349A1 (en) * 2006-03-22 2007-09-27 Apogenix Gmbh Antibody specific for human il-4 for the treament of cancer

Family Cites Families (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS6023084B2 (en) 1979-07-11 1985-06-05 味の素株式会社 blood substitute
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
JPS5645485A (en) * 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4640835A (en) * 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
DE3668186D1 (en) 1985-04-01 1990-02-15 Celltech Ltd TRANSFORMED MYELOMA CELL LINE AND METHOD USING THE SAME FOR EXPRESSING A GENE ENCODING AN EUKARYONTIC POLYPEPTIDE.
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
DE3675588D1 (en) 1985-06-19 1990-12-20 Ajinomoto Kk HAEMOGLOBIN TIED TO A POLY (ALKENYLENE OXIDE).
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
EP0272253A4 (en) 1986-03-07 1990-02-05 Massachusetts Inst Technology Method for enhancing glycoprotein stability.
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
IL89489A0 (en) 1988-03-09 1989-09-10 Hybritech Inc Chimeric antibodies directed against human carcinoembryonic antigen
AU631545B2 (en) 1988-04-15 1992-12-03 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
JP3105898B2 (en) 1988-04-16 2000-11-06 セルテック リミテッド Method for producing recombinant DNA protein
AU631802B2 (en) 1988-06-14 1992-12-10 Cetus Oncology Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
US5534617A (en) 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
ES2052027T5 (en) 1988-11-11 2005-04-16 Medical Research Council IMMUNOGLOBULINE VARIABLE DOMAIN SEQUENCE CLONING.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
IL94611A (en) 1989-06-05 1994-12-29 Organogenesis Inc Cell culture medium containing insulin or an insulin-like growth factor, transferrin or ferrous ion and triiodothyronine or thyroxin and a method for its use
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
FR2650598B1 (en) 1989-08-03 1994-06-03 Rhone Poulenc Sante DERIVATIVES OF ALBUMIN WITH THERAPEUTIC FUNCTION
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0463151B1 (en) 1990-01-12 1996-06-12 Cell Genesys, Inc. Generation of xenogeneic antibodies
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
ATE158615T1 (en) 1990-03-20 1997-10-15 Univ Columbia CHIMERIC ANTIBODIES WITH RECEPTOR-BINDING LIGANDS IN PLACE OF THEIR CONSTANT REGION
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ATE158021T1 (en) * 1990-08-29 1997-09-15 Genpharm Int PRODUCTION AND USE OF NON-HUMAN TRANSGENT ANIMALS FOR THE PRODUCTION OF HETEROLOGUE ANTIBODIES
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
EP0574395B1 (en) 1990-11-09 2002-06-12 GILLIES, Stephen D. Cytokine immunoconjugates
DE69233482T2 (en) 1991-05-17 2006-01-12 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
ES2136092T3 (en) 1991-09-23 1999-11-16 Medical Res Council PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES.
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
ES2241710T3 (en) 1991-11-25 2005-11-01 Enzon, Inc. PROCEDURE TO PRODUCE MULTIVALENT PROTEINS FROM UNION TO ANTIGEN.
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
FR2686899B1 (en) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
FR2686901A1 (en) 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa NOVEL ANTITHROMBOTIC POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
EP0625200B1 (en) 1992-02-06 2005-05-11 Chiron Corporation Biosynthetic binding protein for cancer marker
CA2076465C (en) 1992-03-25 2002-11-26 Ravi V. J. Chari Cell binding agent conjugates of analogues and derivatives of cc-1065
WO1993021319A1 (en) 1992-04-08 1993-10-28 Cetus Oncology Corporation HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
DK0598877T3 (en) 1992-06-09 2000-02-21 Hoppe Ag Fall and door lock
CA2141602A1 (en) 1992-08-26 1994-03-03 Philip Leder Use of the cytokine ip-10 as an anti-tumor agent
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
ATE204325T1 (en) 1993-04-29 2001-09-15 Unilever Nv PRODUCTION OF ANTIBODIES OR FUNCTIONAL PARTS THEREOF DERIVED FROM HEAVY CHAINS OF IMMUNOGLOBULINS FROM CAMELIDAE
UA40577C2 (en) * 1993-08-02 2001-08-15 Мерк Патент Гмбх Bispecific antigen molecule for lysis of tumor cells, method for preparing of bispecific antigen molecule, monoclonal antibody (variants), pharmaceutical preparation, pharmaceutical kit for lysis of tumor cells (variants), method of lysis of tumor cells
US20020193575A1 (en) 1993-09-07 2002-12-19 Smithkline Beecham P.L.C. Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
DE69434223T2 (en) 1993-09-07 2005-12-22 Smithkline Beecham P.L.C., Brentford Recombinant IL4 antibodies useful in the treatment of IL4-inducing diseases
RU2162711C2 (en) * 1993-09-07 2001-02-10 Смитклайн Бичам Корпорейшн Recombinant antibody il4 used for treatment of disorders associated with function of il4
WO1995009917A1 (en) * 1993-10-07 1995-04-13 The Regents Of The University Of California Genetically engineered bispecific tetravalent antibodies
US5597710A (en) 1994-03-10 1997-01-28 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US6165463A (en) 1997-10-16 2000-12-26 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5989830A (en) 1995-10-16 1999-11-23 Unilever Patent Holdings Bv Bifunctional or bivalent antibody fragment analogue
US6664227B1 (en) 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
WO1997033899A1 (en) 1996-03-14 1997-09-18 Human Genome Sciences, Inc. Apoptosis inducing molecule i
DE69731289D1 (en) 1996-03-18 2004-11-25 Univ Texas IMMUNGLOBULIN-LIKE DOMAIN WITH INCREASED HALF-VALUE TIMES
CN1107072C (en) 1996-03-22 2003-04-30 人类基因组科学公司 Apoptosis inducing molecule II
CA2250166A1 (en) 1996-03-28 1997-10-02 The Johns Hopkins University Soluble divalent and multivalent heterodimeric analogs of proteins
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
GB9625899D0 (en) * 1996-12-13 1997-01-29 Glaxo Group Ltd Substances and their uses
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
CN100387621C (en) 1997-04-14 2008-05-14 麦可麦脱股份公司 Production of antihuman antigen receptors and use thereof
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
CA2309541C (en) 1997-11-03 2011-01-11 Human Genome Sciences, Inc. Vegi, an inhibitor of angiogenesis and tumor growth
EP1115427B1 (en) * 1998-09-25 2003-12-03 Horst Lindhofer Time-staggered utilization of tumor cells in combination with intact antibodies for immunization
CN101333256A (en) * 1999-03-25 2008-12-31 艾博特股份有限两合公司 Human antibodies that bind human il-12 and methods for producing
ES2528794T3 (en) 2000-04-11 2015-02-12 Genentech, Inc. Multivalent antibodies and uses thereof
DK2236152T3 (en) 2000-04-12 2014-07-07 Novozymes Biopharma Dk As Albumin Fusion Proteins
WO2001090192A2 (en) * 2000-05-24 2001-11-29 Imclone Systems Incorporated Bispecific immunoglobulin-like antigen binding proteins and method of production
JP2004523205A (en) * 2000-07-25 2004-08-05 イムノメディクス， インコーポレイテッド Multivalent target binding protein
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
RU2295537C2 (en) * 2000-10-20 2007-03-20 Тугаи Сейяку Кабусики Кайся Modified antagonistic antibody
US20040023338A1 (en) 2001-10-26 2004-02-05 Heavner George A. IL-4 mutein proteins, antibodies, compositions, methods and uses
JP2005512522A (en) 2001-10-26 2005-05-12 セントカー・インコーポレーテツド IL-13 mutein proteins, antibodies, compositions, methods and uses
AU2003243189B2 (en) 2002-05-01 2008-01-24 Regeneron Pharmaceuticals, Inc. Methods of using cytokine antagonists to treat HIV infection and AIDS
US20070104710A1 (en) * 2002-06-28 2007-05-10 Domants Limited Ligand that has binding specificity for IL-4 and/or IL-13
AU2004232928A1 (en) 2003-04-22 2004-11-04 Ibc Pharmaceuticals Polyvalent protein complex
GB0407315D0 (en) * 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
DK1711528T3 (en) * 2003-12-23 2012-08-20 Genentech Inc TREATMENT OF CANCER WITH UNTIL UNKNOWN ANTI-IL 13 MONOCLONAL ANTIBODIES
US7652146B2 (en) 2004-02-06 2010-01-26 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors
ES2567634T3 (en) 2004-02-09 2016-04-25 Human Genome Sciences, Inc. Albumin Fusion Proteins
EP2026071B1 (en) 2004-02-19 2013-07-31 Yale University Identification of cancer protein biomarkers using proteomic techniques
DE602005006758D1 (en) 2004-02-27 2008-06-26 Regeneron Pharma IL-4 / IL-13-specific polypeptides and their therapeutic use
GB0411186D0 (en) * 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
ES2398221T3 (en) * 2004-05-25 2013-03-14 Tactic Pharma, Llc Inhibitor antibodies that bind to the urokinase plasminogen activator complex (uPA and its receptor (uPAR)
AR049390A1 (en) * 2004-06-09 2006-07-26 Wyeth Corp ANTIBODIES AGAINST HUMAN INTERLEUQUINE-13 AND USES OF THE SAME
GB0414799D0 (en) * 2004-07-01 2004-08-04 Glaxo Group Ltd Immunoglobulins
US20060148009A1 (en) 2004-10-12 2006-07-06 Xencor, Inc. Prediction and assessment of immunogenicity
TW200902555A (en) * 2005-01-03 2009-01-16 Hoffmann La Roche Antibodies against IL-13 receptor alpha 1 and uses thereof
US20090041783A1 (en) * 2005-04-28 2009-02-12 Mochida Pharmaceutical Co., Ltd. Anti-platelet membrane glycoprotein vi monoclonal antibody
GB0514319D0 (en) * 2005-07-13 2006-06-14 Secr Defence Antibodies for anthrax
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
PL1942939T5 (en) 2005-09-30 2021-10-11 Medimmune Limited Interleukin-13 antibody composition
PT2532679T (en) * 2005-10-21 2017-07-18 Novartis Ag Human antibodies against il13 and therapeutic uses
GB0600488D0 (en) * 2006-01-11 2006-02-22 Glaxo Group Ltd Immunoglobulins
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
US20130344074A1 (en) * 2011-03-16 2013-12-26 Sanofi Uses of a dual v region antibody-like protein
TWI679019B (en) * 2013-04-29 2019-12-11 法商賽諾菲公司 Anti-il-4/anti-il-13 bispecific antibody formulations
TW201628647A (en) * 2014-06-27 2016-08-16 賽諾菲公司 Anti-IL4-IL13 bispecific antibodies

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5928904A (en) * 1993-09-07 1999-07-27 Smithkline Beecham Corporation DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US5705154A (en) * 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
CN1886426A (en) * 2003-11-07 2006-12-27 伊姆尼斯公司 Antibodies that bind interleukin-4 receptor
WO2007085815A2 (en) * 2006-01-24 2007-08-02 Domantis Limited Ligands that bind il-4 and/or il-13
WO2007107349A1 (en) * 2006-03-22 2007-09-27 Apogenix Gmbh Antibody specific for human il-4 for the treament of cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIRD C等: "Development of immunoassays for human interleukin 3 and interleukin 4, some of which discriminate between different recombinant DNA-derived molecules", 《CYTOKINE》 *
HART T K等: "Preclinical efficacy and safety of pascolizumab (SB 240683): A humanized anti-interleukin-4 antibody with therapeutic potential in asthma", 《CLINICAL & EXPERIMENTAL IMMUNOLOGY》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109705217A (en) * 2017-10-25 2019-05-03 北京智仁美博生物科技有限公司 Anti-il-13 antibody and application thereof
CN109705217B (en) * 2017-10-25 2020-09-11 北京智仁美博生物科技有限公司 anti-IL-13 antibodies and uses thereof

Also Published As

Publication number Publication date
MY171214A (en) 2019-10-02
PE20091382A1 (en) 2009-10-14
PL2573121T3 (en) 2018-01-31
PH12013501032A1 (en) 2015-05-18
CL2008003037A1 (en) 2009-03-06
JP2011501671A (en) 2011-01-13
RU2015141428A3 (en) 2019-04-30
PL2205640T3 (en) 2014-05-30
JP2018078907A (en) 2018-05-24
TW201536322A (en) 2015-10-01
MX363638B (en) 2019-03-28
HRP20171765T1 (en) 2017-12-29
PL2573119T3 (en) 2018-07-31
PT2574629T (en) 2018-02-23
IL249289A0 (en) 2017-01-31
AU2013203339B9 (en) 2017-02-02
SI2205640T1 (en) 2014-04-30
MX2010003290A (en) 2010-04-30
EP2574629B1 (en) 2017-11-22
AU2013203324A1 (en) 2013-05-02
RS53175B (en) 2014-06-30
CL2013002040A1 (en) 2014-01-24
CL2012003196A1 (en) 2013-01-25
CN101827863A (en) 2010-09-08
JP2015231382A (en) 2015-12-24
MX363634B (en) 2019-03-28
HRP20140150T1 (en) 2014-03-28
AU2013203328B2 (en) 2017-01-05
HRP20181085T1 (en) 2018-09-07
CY1120033T1 (en) 2018-12-12
US20130236461A1 (en) 2013-09-12
HUE037205T2 (en) 2018-08-28
RU2015141428A (en) 2017-04-04
JP6126653B2 (en) 2017-05-10
BRPI0818677B1 (en) 2019-11-12
RS57060B1 (en) 2018-05-31
PT2573121T (en) 2017-11-21
US20180030156A1 (en) 2018-02-01
AR068861A1 (en) 2009-12-09
ES2660152T3 (en) 2018-03-21
CR20150102A (en) 2015-04-30
KR20190022928A (en) 2019-03-06
KR20140112574A (en) 2014-09-23
US20130251717A1 (en) 2013-09-26
EP2205640A2 (en) 2010-07-14
EP2573119A1 (en) 2013-03-27
CR11337A (en) 2010-04-21
DK2574630T3 (en) 2018-07-30
WO2009052081A2 (en) 2009-04-23
MX363901B (en) 2019-04-08
US20230235088A1 (en) 2023-07-27
DOP2010000109A (en) 2010-05-31
AU2013203339A1 (en) 2013-05-02
US20210047437A1 (en) 2021-02-18
DOP2013000302A (en) 2014-02-16
HRP20180320T1 (en) 2018-04-06
US20140023649A1 (en) 2014-01-23
AU2013202389B9 (en) 2017-02-02
UY31394A1 (en) 2009-05-29
HRP20180517T1 (en) 2018-05-04
NI201000403A (en) 2010-09-07
SG10201602770UA (en) 2016-05-30
CY1120887T1 (en) 2019-12-11
DK2205640T3 (en) 2014-02-24
SG10201913836SA (en) 2020-03-30
DOP2013000301A (en) 2014-02-16
SI2574629T1 (en) 2018-03-30
TWI619508B (en) 2018-04-01
US20130236460A1 (en) 2013-09-12
NO2574629T3 (en) 2018-04-21
RU2721236C2 (en) 2020-05-18
ES2447915T3 (en) 2014-03-13
AU2013203324C1 (en) 2017-03-30
KR20180014189A (en) 2018-02-07
US9738728B2 (en) 2017-08-22
US20130236463A1 (en) 2013-09-12
ES2664476T3 (en) 2018-04-19
NO2573121T3 (en) 2018-01-20
US20130243778A1 (en) 2013-09-19
CR20150654A (en) 2016-02-08
HUE038556T2 (en) 2018-10-29
TR201802225T4 (en) 2018-03-21
US20130251718A1 (en) 2013-09-26
EP2573116A1 (en) 2013-03-27
TWI616206B (en) 2018-03-01
AU2013203339B2 (en) 2017-01-05
RU2015141418A3 (en) 2019-05-14
RU2488595C2 (en) 2013-07-27
EP2573119B1 (en) 2018-01-03
EP2573121A1 (en) 2013-03-27
LT2573119T (en) 2018-04-10
NI201000405A (en) 2010-09-07
CN113480647A (en) 2021-10-08
GT201000067A (en) 2012-04-12
LT2573121T (en) 2017-12-11
NI201000040A (en) 2010-09-07
NZ584658A (en) 2012-08-31
HUE036530T2 (en) 2018-07-30
SI2573121T1 (en) 2018-01-31
EP2573118A1 (en) 2013-03-27
RS56914B1 (en) 2018-05-31
US11453727B2 (en) 2022-09-27
TW201536321A (en) 2015-10-01
AU2013202389B2 (en) 2017-01-05
CA3071750A1 (en) 2009-04-23
KR101954596B1 (en) 2019-03-07
PH12013501033B1 (en) 2015-05-25
TWI616205B (en) 2018-03-01
US20130243777A1 (en) 2013-09-19
CL2013002039A1 (en) 2014-03-07
EP2205640B1 (en) 2013-11-20
TR201810005T4 (en) 2018-08-27
NI201000401A (en) 2010-09-07
JP5858616B2 (en) 2016-02-10
US20130259866A1 (en) 2013-10-03
PL2574630T3 (en) 2018-09-28
BRPI0818677A2 (en) 2015-04-14
EP2574630B1 (en) 2018-04-18
DK2573121T3 (en) 2017-12-04
UA104130C2 (en) 2014-01-10
AU2013203328A1 (en) 2013-05-02
NI201000406A (en) 2010-09-07
NI201000404A (en) 2010-09-07
CY1119875T1 (en) 2018-06-27
PT2205640E (en) 2014-02-25
JP6280526B2 (en) 2018-02-14
EP2573115A1 (en) 2013-03-27
SI2573119T1 (en) 2018-05-31
LT2574630T (en) 2018-07-25
EP2574630A1 (en) 2013-04-03
HN2010000710A (en) 2013-07-22
AR122833A2 (en) 2022-10-12
AU2013203328B9 (en) 2017-02-02
CY1120108T1 (en) 2018-12-12
CA2702473A1 (en) 2009-04-23
NZ729148A (en) 2021-12-24
AU2013203324B2 (en) 2017-01-19
RU2013120318A (en) 2014-11-10
CA3071750C (en) 2022-06-14
US8388965B2 (en) 2013-03-05
ZA201002069B (en) 2010-12-29
AR122834A2 (en) 2022-10-12
UA118949C2 (en) 2019-04-10
CA3015470C (en) 2022-01-18
JP2016006086A (en) 2016-01-14
SI2574630T1 (en) 2018-08-31
IL205005A (en) 2016-11-30
US10759871B2 (en) 2020-09-01
DK2574629T3 (en) 2018-02-26
JP2016006087A (en) 2016-01-14
AU2008312655B2 (en) 2013-05-02
CY1114987T1 (en) 2016-12-14
IL205005A0 (en) 2010-11-30
CA3015470A1 (en) 2009-04-23
CR20150103A (en) 2015-04-14
WO2009052081A4 (en) 2009-07-23
NZ709353A (en) 2018-06-29
MA31838B1 (en) 2010-11-01
MX354666B (en) 2018-03-15
NI201000402A (en) 2010-09-07
EP2574626A1 (en) 2013-04-03
PT2573119T (en) 2018-04-04
ES2647872T3 (en) 2017-12-27
KR20100067669A (en) 2010-06-21
RU2705551C2 (en) 2019-11-07
HUE038444T2 (en) 2018-10-29
US20130251716A1 (en) 2013-09-26
US20130236462A1 (en) 2013-09-12
CA2702473C (en) 2018-10-09
TW200932263A (en) 2009-08-01
US20100226923A1 (en) 2010-09-09
AU2013202389A1 (en) 2013-05-02
WO2009052081A3 (en) 2009-06-04
PA8799001A1 (en) 2009-07-23
DK2573119T3 (en) 2018-04-16
EP2574629A1 (en) 2013-04-03
EP2573117A1 (en) 2013-03-27
KR101823859B1 (en) 2018-02-01
CN106986938B (en) 2021-07-09
KR20160142889A (en) 2016-12-13
CN101827863B (en) 2017-03-22
NZ601342A (en) 2014-02-28
RU2010119521A (en) 2011-11-27
AU2008312655A1 (en) 2009-04-23
US9732162B2 (en) 2017-08-15
EP2573121B1 (en) 2017-08-23
TN2010000126A1 (en) 2011-09-26
LT2574629T (en) 2018-03-12
BRPI0818677B8 (en) 2021-05-25
US20130209469A1 (en) 2013-08-15
RU2580049C2 (en) 2016-04-10
CR20150101A (en) 2015-04-14
RS56553B1 (en) 2018-02-28
PL2574629T3 (en) 2018-05-30
RU2015141418A (en) 2017-04-04
PH12013501032B1 (en) 2015-05-18
US20130243776A1 (en) 2013-09-19
KR101682373B1 (en) 2016-12-06
PH12013501033A1 (en) 2015-05-25
EP2050764A1 (en) 2009-04-22
ES2679281T3 (en) 2018-08-23
PT2574630T (en) 2018-07-17
SG185303A1 (en) 2012-11-29
EP3686220A1 (en) 2020-07-29
MX354150B (en) 2018-02-15
KR101681909B1 (en) 2016-12-05
SG10201913838RA (en) 2020-03-30
JP6126652B2 (en) 2017-05-10
RS57396B1 (en) 2018-09-28
TW201825117A (en) 2018-07-16

Similar Documents

Publication Publication Date Title
CN101827863B (en) Antibodies that bind IL-4 and/or IL-13 and their uses

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1241902

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant